<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Immunol</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Immunology</journal-title>
</journal-title-group>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30294322</article-id>
<article-id pub-id-type="pmc">6158389</article-id>
<article-id pub-id-type="doi">10.3389/fimmu.2018.02111</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Genetic Alterations of TRAF Proteins in Human Cancers</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Zhu</surname>
<given-names>Sining</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jin</surname>
<given-names>Juan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gokhale</surname>
<given-names>Samantha</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lu</surname>
<given-names>Angeli M.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shan</surname>
<given-names>Haiyan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Feng</surname>
<given-names>Jianjun</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xie</surname>
<given-names>Ping</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<xref ref-type="corresp" rid="c001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/557999/overview" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Cell Biology and Neuroscience, Rutgers University</institution>, <addr-line>Piscataway, NJ</addr-line>, <country>United States</country></aff>
<aff id="aff2"><sup>2</sup><institution>Graduate Program in Cellular and Molecular Pharmacology, Rutgers University</institution>, <addr-line>Piscataway, NJ</addr-line>, <country>United States</country></aff>
<aff id="aff3"><sup>3</sup><institution>Department of Pharmacology, Anhui Medical University</institution>, <addr-line>Hefei</addr-line>, <country>China</country></aff>
<aff id="aff4"><sup>4</sup><institution>Department of Obstetrics and Gynecology, The Affiliated Suzhou Hospital of Nanjing Medical University</institution>, <addr-line>Suzhou</addr-line>, <country>China</country></aff>
<aff id="aff5"><sup>5</sup><institution>Engineering Research Center of the Modern Technology for Eel Industry, Ministry of Education of the People's Republic of China, Fisheries College of Jimei University</institution>, <addr-line>Xiamen</addr-line>, <country>China</country></aff>
<aff id="aff6"><sup>6</sup><institution>Member, Rutgers Cancer Institute of New Jersey</institution>, <addr-line>New Brunswick, NJ</addr-line>, <country>United States</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Tania H. Watts, University of Toronto, Canada</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Juan M. Zapata, Instituto de Investigaciones Biomédicas Alberto Sols (IIBM), Spain; Shao-Cong Sun, University of Texas MD Anderson Cancer Center, United States</p>
</fn>
<corresp id="c001">*Correspondence: Ping Xie <email>xie@dls.rutgers.edu</email></corresp>
<fn fn-type="other" id="fn001">
<p>This article was submitted to Molecular Innate Immunity, a section of the journal Frontiers in Immunology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>20</day>
<month>9</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>9</volume>
<elocation-id>2111</elocation-id>
<history>
<date date-type="received">
<day>29</day>
<month>7</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>28</day>
<month>8</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2018 Zhu, Jin, Gokhale, Lu, Shan, Feng and Xie.</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>Zhu, Jin, Gokhale, Lu, Shan, Feng and Xie</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>The tumor necrosis factor receptor (TNF-R)-associated factor (TRAF) family of cytoplasmic adaptor proteins regulate the signal transduction pathways of a variety of receptors, including the TNF-R superfamily, Toll-like receptors (TLRs), NOD-like receptors (NLRs), RIG-I-like receptors (RLRs), and cytokine receptors. TRAF-dependent signaling pathways participate in a diverse array of important cellular processes, including the survival, proliferation, differentiation, and activation of different cell types. Many of these TRAF-dependent signaling pathways have been implicated in cancer pathogenesis. Here we analyze the current evidence of genetic alterations of <italic>TRAF</italic> molecules available from The Cancer Genome Atlas (TCGA) and the Catalog of Somatic Mutations in Cancer (COSMIC) as well as the published literature, including copy number variations and mutation landscape of TRAFs in various human cancers. Such analyses reveal that both gain- and loss-of-function genetic alterations of different TRAF proteins are commonly present in a number of human cancers. These include pancreatic cancer, meningioma, breast cancer, prostate cancer, lung cancer, liver cancer, head and neck cancer, stomach cancer, colon cancer, bladder cancer, uterine cancer, melanoma, sarcoma, and B cell malignancies, among others. Furthermore, we summarize the key <italic>in vivo</italic> and <italic>in vitro</italic> evidence that demonstrates the causal roles of genetic alterations of TRAF proteins in tumorigenesis within different cell types and organs. Taken together, the information presented in this review provides a rationale for the development of therapeutic strategies to manipulate TRAF proteins or TRAF-dependent signaling pathways in different human cancers by precision medicine.</p>
</abstract>
<kwd-group>
<kwd>TRAFs</kwd>
<kwd>cancer</kwd>
<kwd>oncogenes</kwd>
<kwd>tumor suppressor genes</kwd>
<kwd>NF-κB</kwd>
<kwd>MAPK</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source id="cn001">National Institutes of Health<named-content content-type="fundref-id">10.13039/100000002</named-content></funding-source>
<award-id rid="cn001">R01 CA158402</award-id>
<award-id rid="cn001">R21 AI128264</award-id>
<award-id rid="cn001">P30CA072720</award-id>
</award-group>
<award-group>
<funding-source id="cn002">U.S. Department of Defense<named-content content-type="fundref-id">10.13039/100000005</named-content></funding-source>
</award-group>
<award-group>
<funding-source id="cn003">Rutgers, The State University of New Jersey<named-content content-type="fundref-id">10.13039/100011132</named-content></funding-source>
</award-group>
</funding-group>
<counts>
<fig-count count="6"></fig-count>
<table-count count="3"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="342"></ref-count>
<page-count count="30"></page-count>
<word-count count="24604"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>The tumor necrosis factor receptor (TNF-R)-associated factor (TRAF 1–7) family of cytoplasmic adaptor proteins regulates the signal transduction pathways of a variety of receptors, including the TNF-R superfamily, Toll-like receptors (TLRs), NOD-like receptors (NLRs), RIG-I-like receptors (RLRs), and cytokine receptors (<xref ref-type="bibr" rid="B1">1</xref>–<xref ref-type="bibr" rid="B4">4</xref>). TRAF proteins function as both adaptor proteins and E3 ubiquitin ligases to regulate receptor signaling, leading to the activation of canonical and noncanonical nuclear factor-κBs (NF-κB1 and NF-κB2), mitogen-activated protein kinases (MAPKs: ERK1/2, JNK1/2, and p38), or interferon-regulatory factors (IRFs: IRF3, IRF5, and IRF7) (<xref ref-type="bibr" rid="B1">1</xref>–<xref ref-type="bibr" rid="B4">4</xref>). The TRAF-dependent signaling pathways participate in a diverse array of important cellular processes, including the survival, proliferation, differentiation, activation, and stress responses of different cell types (<xref ref-type="bibr" rid="B1">1</xref>–<xref ref-type="bibr" rid="B4">4</xref>). Many of these TRAF-dependent signaling pathways have been implicated in cancer pathogenesis.</p>
<p>With the rapid progress made in next-generation deep sequencing technology and the tremendous efforts put forth on whole genome/exome/transcriptome sequencing and copy number variation (CNV) analyses of cancers at the post-genome era, it has become increasingly clear that genetic alterations of TRAF proteins are commonly present in various human cancers. Here we analyze the current evidence of genetic alterations of <italic>TRAF</italic> molecules available from the Cancer Genome Atlas (TCGA) (<xref ref-type="bibr" rid="B5">5</xref>) and the Catalog of Somatic Mutations in Cancer (COSMIC) (<xref ref-type="bibr" rid="B6">6</xref>) as well as the published literature, including the landscape of genetic alterations and the map of recurrent mutations in <italic>TRAF</italic> molecules in different types of human cancers. Moreover, we summarize the key <italic>in vivo</italic> and <italic>in vitro</italic> evidence that demonstrates the causal roles of genetic alterations of <italic>TRAF</italic> proteins in tumorigenesis within different cell types and organs. Collectively, the information presented in this review identifies <italic>TRAF</italic> proteins and TRAF-dependent signaling pathways as important therapeutic targets in specific human cancers.</p>
</sec>
<sec id="s2">
<title>TRAF1</title>
<sec>
<title>Landscape of genetic alterations</title>
<p>According to the TCGA and COSMIC datasets of sample size n &gt; 100, the frequency of genetic alterations of <italic>TRAF1</italic> is generally &lt;4% in human cancers (Figure <xref ref-type="fig" rid="F1">1A</xref>). The eight human cancers with relatively higher genetic alterations of <italic>TRAF1</italic> are pancreatic cancer (3.7%) (<xref ref-type="bibr" rid="B7">7</xref>), skin cutaneous melanoma (2.9%) (TCGA, PanCancer Atlas), esophageal cancer (2.8%) (TCGA, PanCancer Atlas), stomach cancer (2.7%) (<xref ref-type="bibr" rid="B8">8</xref>), sarcoma (2.4%) (<xref ref-type="bibr" rid="B9">9</xref>), ovarian cancer (2.3%) (TCGA, Provisional), lung cancer (2.3%) (<xref ref-type="bibr" rid="B10">10</xref>), and prostate cancer (2%) (TCGA, Provisional). The most common genetic alterations of <italic>TRAF1</italic> are gene amplification (copy gain) and mutation. Deep deletion (copy loss) is less common but also detected in several types of human cancers (Figure <xref ref-type="fig" rid="F1">1</xref>). Truncation is rare for <italic>TRAF1</italic> in human cancers.</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>Landscape of genetic alterations of the <italic>TRAF</italic> family in human cancers. <bold>(A)</bold> Representative results retrieved from TCGA. For each <italic>TRAF</italic> gene, eight cancer types that exhibit relatively higher frequency of genetic alterations were selected and datasets with relatively larger sample size (n &gt; 100) are shown. <bold>(B)</bold> Frequent genetic alterations recognized in the published literature. Genetic alterations shown include deep deletion (copy number loss), mutation (missense mutation, frameshift insertion or deletion, and in frame insertion or deletion), truncation (nonsense mutation), amplification (copy number gain), and fusion. The sample size of each dataset is indicated on top of each bar in the graphs.</p>
</caption>
<graphic xlink:href="fimmu-09-02111-g0001"></graphic>
</fig>
</sec>
<sec>
<title>Overview and map of recurrent mutations</title>
<p>To date, there are 139 different mutations of the <italic>TRAF1</italic> gene detected in human cancers, comprising 80% (111/139) mutations that alter the protein sequence of <italic>TRAF1</italic> and 20% (28/139) coding silent mutations (Table <xref ref-type="table" rid="T1">1</xref>). In the <italic>TRAF</italic> family, <italic>TRAF1</italic> has the lowest count of recurrent mutations. Only 29% (32/111) of the coding-altering mutations of <italic>TRAF1</italic> are recurrent and have been detected in at least two patients with various cancers. Almost all the recurrent mutations of <italic>TRAF1</italic> are missense mutations (94%, 30/32) except one nonsense mutation (truncation) and one fusion (Table <xref ref-type="table" rid="T1">1</xref> and Figure <xref ref-type="fig" rid="F2">2</xref>). These recurrent mutations occurred across 24 different amino acids that are distributed in all the major domains of the TRAF1 protein (Figure <xref ref-type="fig" rid="F3">3</xref>). Interestingly, missense mutations of two specific amino acids are detected in more than three patients: R70C or H in the linker between the Zinc finger and the coiled-coil domain, and M182I of the coiled-coil (also known as TRAF-N) domain of the <italic>TRAF1</italic> protein (Figure <xref ref-type="fig" rid="F3">3</xref>). The R70 mutations are detected in 4 patients with stomach, colon, and colorectal cancers (TCGA) (<xref ref-type="bibr" rid="B11">11</xref>–<xref ref-type="bibr" rid="B13">13</xref>). M182I is documented in 4 patients with melanoma and chronic lymphocytic leukemia (CLL) (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>). The functional significance of R70C/H and M182I mutations of <italic>TRAF1</italic> remains to be determined.</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p>Summary of the number of different types of mutations of TRAF proteins detected in human cancers.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Type of mutation</bold>
</th>
<th align="center" colspan="2" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">
<bold>TRAF1</bold>
</th>
<th align="center" colspan="2" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">
<bold>TRAF2</bold>
</th>
<th align="center" colspan="2" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">
<bold>TRAF3</bold>
</th>
<th align="center" colspan="2" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">
<bold>TRAF4</bold>
</th>
<th align="center" colspan="2" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">
<bold>TRAF5</bold>
</th>
<th align="center" colspan="2" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">
<bold>TRAF6</bold>
</th>
<th align="center" colspan="2" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">
<bold>TRAF7</bold>
</th>
</tr>
<tr>
<th colspan="1" rowspan="1"></th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>All</bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>Recurrent</bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>All</bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>Recurrent</bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>All</bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>Recurrent</bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>All</bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>Recurrent</bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>All</bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>Recurrent</bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>All</bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>Recurrent</bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>All</bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>Recurrent</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="15" rowspan="1" style="background-color:#bcbdc0" valign="top">
<bold>CODING ALTERING</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"> Missense</td>
<td align="center" colspan="1" rowspan="1" valign="top">96</td>
<td align="center" colspan="1" rowspan="1" valign="top">30</td>
<td align="center" colspan="1" rowspan="1" valign="top">168</td>
<td align="center" colspan="1" rowspan="1" valign="top">75</td>
<td align="center" colspan="1" rowspan="1" valign="top">166</td>
<td align="center" colspan="1" rowspan="1" valign="top">75</td>
<td align="center" colspan="1" rowspan="1" valign="top">86</td>
<td align="center" colspan="1" rowspan="1" valign="top">39</td>
<td align="center" colspan="1" rowspan="1" valign="top">137</td>
<td align="center" colspan="1" rowspan="1" valign="top">49</td>
<td align="center" colspan="1" rowspan="1" valign="top">132</td>
<td align="center" colspan="1" rowspan="1" valign="top">38</td>
<td align="center" colspan="1" rowspan="1" valign="top">281</td>
<td align="center" colspan="1" rowspan="1" valign="top">161</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"> Frameshift</td>
<td align="center" colspan="1" rowspan="1" valign="top">7</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="center" colspan="1" rowspan="1" valign="top">13</td>
<td align="center" colspan="1" rowspan="1" valign="top">10</td>
<td align="center" colspan="1" rowspan="1" valign="top">41</td>
<td align="center" colspan="1" rowspan="1" valign="top">21</td>
<td align="center" colspan="1" rowspan="1" valign="top">6</td>
<td align="center" colspan="1" rowspan="1" valign="top">1</td>
<td align="center" colspan="1" rowspan="1" valign="top">8</td>
<td align="center" colspan="1" rowspan="1" valign="top">2</td>
<td align="center" colspan="1" rowspan="1" valign="top">6</td>
<td align="center" colspan="1" rowspan="1" valign="top">1</td>
<td align="center" colspan="1" rowspan="1" valign="top">15</td>
<td align="center" colspan="1" rowspan="1" valign="top">5</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"> Truncation</td>
<td align="center" colspan="1" rowspan="1" valign="top">5</td>
<td align="center" colspan="1" rowspan="1" valign="top">1</td>
<td align="center" colspan="1" rowspan="1" valign="top">9</td>
<td align="center" colspan="1" rowspan="1" valign="top">4</td>
<td align="center" colspan="1" rowspan="1" valign="top">23</td>
<td align="center" colspan="1" rowspan="1" valign="top">9</td>
<td align="center" colspan="1" rowspan="1" valign="top">8</td>
<td align="center" colspan="1" rowspan="1" valign="top">3</td>
<td align="center" colspan="1" rowspan="1" valign="top">9</td>
<td align="center" colspan="1" rowspan="1" valign="top">5</td>
<td align="center" colspan="1" rowspan="1" valign="top">9</td>
<td align="center" colspan="1" rowspan="1" valign="top">2</td>
<td align="center" colspan="1" rowspan="1" valign="top">8</td>
<td align="center" colspan="1" rowspan="1" valign="top">3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"> In frame deletion</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="center" colspan="1" rowspan="1" valign="top">5</td>
<td align="center" colspan="1" rowspan="1" valign="top">2</td>
<td align="center" colspan="1" rowspan="1" valign="top">2</td>
<td align="center" colspan="1" rowspan="1" valign="top">1</td>
<td align="center" colspan="1" rowspan="1" valign="top">2</td>
<td align="center" colspan="1" rowspan="1" valign="top">1</td>
<td align="center" colspan="1" rowspan="1" valign="top">2</td>
<td align="center" colspan="1" rowspan="1" valign="top">1</td>
<td align="center" colspan="1" rowspan="1" valign="top">1</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="center" colspan="1" rowspan="1" valign="top">8</td>
<td align="center" colspan="1" rowspan="1" valign="top">2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"> In frame insertion</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="center" colspan="1" rowspan="1" valign="top">2</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"> Splice mutation</td>
<td align="center" colspan="1" rowspan="1" valign="top">2</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="center" colspan="1" rowspan="1" valign="top">5</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="center" colspan="1" rowspan="1" valign="top">7</td>
<td align="center" colspan="1" rowspan="1" valign="top">1</td>
<td align="center" colspan="1" rowspan="1" valign="top">2</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="center" colspan="1" rowspan="1" valign="top">4</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="center" colspan="1" rowspan="1" valign="top">4</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="center" colspan="1" rowspan="1" valign="top">6</td>
<td align="center" colspan="1" rowspan="1" valign="top">2</td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td align="left" colspan="1" rowspan="1" valign="top"> Fusion</td>
<td align="center" colspan="1" rowspan="1" valign="top">1</td>
<td align="center" colspan="1" rowspan="1" valign="top">1</td>
<td align="center" colspan="1" rowspan="1" valign="top">5</td>
<td align="center" colspan="1" rowspan="1" valign="top">1</td>
<td align="center" colspan="1" rowspan="1" valign="top">14</td>
<td align="center" colspan="1" rowspan="1" valign="top">1</td>
<td align="center" colspan="1" rowspan="1" valign="top">1</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="center" colspan="1" rowspan="1" valign="top">6</td>
<td align="center" colspan="1" rowspan="1" valign="top">1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">  Subtotal</td>
<td align="center" colspan="1" rowspan="1" valign="top">111</td>
<td align="center" colspan="1" rowspan="1" valign="top">32</td>
<td align="center" colspan="1" rowspan="1" valign="top">205</td>
<td align="center" colspan="1" rowspan="1" valign="top">92</td>
<td align="center" colspan="1" rowspan="1" valign="top">253</td>
<td align="center" colspan="1" rowspan="1" valign="top">108</td>
<td align="center" colspan="1" rowspan="1" valign="top">105</td>
<td align="center" colspan="1" rowspan="1" valign="top">44</td>
<td align="center" colspan="1" rowspan="1" valign="top">160</td>
<td align="center" colspan="1" rowspan="1" valign="top">57</td>
<td align="center" colspan="1" rowspan="1" valign="top">152</td>
<td align="center" colspan="1" rowspan="1" valign="top">41</td>
<td align="center" colspan="1" rowspan="1" valign="top">326</td>
<td align="center" colspan="1" rowspan="1" valign="top">174</td>
</tr>
<tr>
<td align="left" colspan="15" rowspan="1" style="background-color:#bcbdc0" valign="top">
<bold>CODING SILENT</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"> Synonymous</td>
<td align="center" colspan="1" rowspan="1" valign="top">24</td>
<td align="center" colspan="1" rowspan="1" valign="top">5</td>
<td align="center" colspan="1" rowspan="1" valign="top">25</td>
<td align="center" colspan="1" rowspan="1" valign="top">3</td>
<td align="center" colspan="1" rowspan="1" valign="top">24</td>
<td align="center" colspan="1" rowspan="1" valign="top">6</td>
<td align="center" colspan="1" rowspan="1" valign="top">18</td>
<td align="center" colspan="1" rowspan="1" valign="top">1</td>
<td align="center" colspan="1" rowspan="1" valign="top">24</td>
<td align="center" colspan="1" rowspan="1" valign="top">5</td>
<td align="center" colspan="1" rowspan="1" valign="top">23</td>
<td align="center" colspan="1" rowspan="1" valign="top">5</td>
<td align="center" colspan="1" rowspan="1" valign="top">39</td>
<td align="center" colspan="1" rowspan="1" valign="top">7</td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td align="left" colspan="1" rowspan="1" valign="top"> Intronic mutation</td>
<td align="center" colspan="1" rowspan="1" valign="top">4</td>
<td align="center" colspan="1" rowspan="1" valign="top">1</td>
<td align="center" colspan="1" rowspan="1" valign="top">7</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="center" colspan="1" rowspan="1" valign="top">3</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="center" colspan="1" rowspan="1" valign="top">4</td>
<td align="center" colspan="1" rowspan="1" valign="top">2</td>
<td align="center" colspan="1" rowspan="1" valign="top">3</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="center" colspan="1" rowspan="1" valign="top">11</td>
<td align="center" colspan="1" rowspan="1" valign="top">2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">  Total</td>
<td align="center" colspan="1" rowspan="1" valign="top">139</td>
<td align="center" colspan="1" rowspan="1" valign="top">38</td>
<td align="center" colspan="1" rowspan="1" valign="top">237</td>
<td align="center" colspan="1" rowspan="1" valign="top">95</td>
<td align="center" colspan="1" rowspan="1" valign="top">280</td>
<td align="center" colspan="1" rowspan="1" valign="top">114</td>
<td align="center" colspan="1" rowspan="1" valign="top">123</td>
<td align="center" colspan="1" rowspan="1" valign="top">45</td>
<td align="center" colspan="1" rowspan="1" valign="top">188</td>
<td align="center" colspan="1" rowspan="1" valign="top">64</td>
<td align="center" colspan="1" rowspan="1" valign="top">178</td>
<td align="center" colspan="1" rowspan="1" valign="top">46</td>
<td align="center" colspan="1" rowspan="1" valign="top">376</td>
<td align="center" colspan="1" rowspan="1" valign="top">183</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>Overview of recurrent mutations of the <italic>TRAF</italic> family in human cancers. Recurrent mutations of the <italic>TRAF</italic> family that are identified in at least 2 cancer patients are summarized in this figure. The composition of recurrent mutation types are shown in a pie graph for each <italic>TRAF</italic> gene. The total count of recurrent mutations and the actual count of each category of recurrent mutation for each <italic>TRAF</italic> gene are indicated in each pie graph.</p>
</caption>
<graphic xlink:href="fimmu-09-02111-g0002"></graphic>
</fig>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<p>Map of recurrent <italic>TRAF</italic> mutations of human cancers on the TRAF proteins. The distribution of recurrent mutations on the domain structure of each TRAF protein is depicted in this figure. The domain structures of TRAF proteins shown include the zinc RING (Zn RING), zinc fingers (Zn Fingers), coiled-coil (TRAF-N) domain, TRAF-C domain, nuclear localization signals, and WD40 repeats. For each recurrent mutation, the nature of the mutation is indicated by a mutation symbol code and the patient count is indicated by a color code as shown at the bottom legend of the figure. The actual amino acid changes are also given for each recurrent mutation: letter change, missense mutation; *, Nonsense mutation (truncation); fs*, frameshift insertion or deletion; del, in frame deletion.</p>
</caption>
<graphic xlink:href="fimmu-09-02111-g0003"></graphic>
</fig>
</sec>
<sec>
<title>Fusion</title>
<p>There is only one fusion of the <italic>TRAF1</italic> gene detected in human cancers, the TRAF1-ALK fusion that has been detected in five patients with anaplastic large cell lymphoma (ALCL) (<xref ref-type="bibr" rid="B16">16</xref>–<xref ref-type="bibr" rid="B19">19</xref>). All five cases contain the identical in frame fusion of <italic>TRAF1</italic> and <italic>ALK</italic> that generates a chimeric protein linking the N-terminal 1–294 aa of <italic>TRAF1</italic> to the entire intracellular domain of <italic>ALK</italic> (1,058–1,620 aa), including its kinase domain (<xref ref-type="bibr" rid="B16">16</xref>–<xref ref-type="bibr" rid="B19">19</xref>). Interestingly, expression of the TRAF1-ALK fusion protein leads to constitutive activation of the <italic>ALK</italic> and NF-κB pathways as demonstrated by the elevated levels of phosphorylated <italic>ALK</italic> (pALK) and STAT3 (pSTAT3) as well as nuclear p50 NF-κB1 and p52 NF-κB2 in ALCL cells (<xref ref-type="bibr" rid="B18">18</xref>). Similar to wild type (WT) TRAF1, the TRAF1-ALK fusion protein also binds to TRAF2 in co-immunoprecipitation experiments (<xref ref-type="bibr" rid="B18">18</xref>), suggesting the involvement of <italic>TRAF2</italic> in the activation of NF-κB pathways. Furthermore, treatment of patient ALCL cells expressing the TRAF1-ALK fusion protein with proteasome inhibitors that decrease NF-κB1/2 or a selective <italic>ALK</italic> inhibitor (CEP28122) results in significant inhibition on lymphoma growth but could not eradicate lymphoma cells (<xref ref-type="bibr" rid="B18">18</xref>). Thus, constitutive activation of NF-κB1/2 pathways contributes to the neoplastic phenotype of TRAF1-ALK-expressing ALCL.</p>
</sec>
<sec>
<title><italic>In vivo</italic> causal oncogenic roles</title>
<p>Gene amplification is the most common <italic>TRAF1</italic> genetic alteration in human cancers. <italic>TRAF1</italic> expression is ubiquitously elevated in skin squamous cell carcinoma (SSCC), non-small cell lung cancer (NSCLC), Hodgkin lymphomas (HLs) and non-Hodgkin lymphomas (NHLs) (<xref ref-type="bibr" rid="B20">20</xref>–<xref ref-type="bibr" rid="B25">25</xref>). Notably, <italic>TRAF1</italic> protein is consistently elevated in B cell leukemias and lymphomas without evidence of gene amplification (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B23">23</xref>). In this case, <italic>TRAF1</italic> upregulation might be the result of epigenetic alterations and/or aberrant activation of NF-κB1/2, as <italic>TRAF1</italic> is a direct target gene of NF-κB (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>). Interestingly, <italic>TRAF1</italic> expression levels are increased in chronic lymphocytic leukemia (CLL) cells from patients with refractory disease, suggesting a role for <italic>TRAF1</italic> in the progression of this disease and in the development of chemoresistance (<xref ref-type="bibr" rid="B23">23</xref>). Furthermore, genetic association studies identify <italic>TRAF1</italic> as a susceptibility gene for risk of CLL (<xref ref-type="bibr" rid="B28">28</xref>). Thus, human evidence implicates <italic>TRAF1</italic> as a candidate oncogene. Indeed, <italic>in vivo</italic> evidence obtained from mouse models demonstrates the causal oncogenic roles of <italic>TRAF1</italic> in the skin, lung, T cells, and B cells (Table <xref ref-type="table" rid="T2">2</xref>). TRAF1<sup>−/−</sup> mice exhibit increased skin sensitivity to TNFα-induced necrosis and reduced skin tumor formation induced by DMBA/chronic solar UV radiation (UVR) (<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B29">29</xref>). Mechanistically, TRAF1 enhances the ubiquitination of ERK5 and is required for UVR-induced ERK5 phosphorylation and the expression of AP-1 family members (c-Fos/c-Jun) in keratinocytes and epithelial cells (<xref ref-type="bibr" rid="B20">20</xref>). TRAF1<sup>−/−</sup> mice also show reduced lung tumorigenesis induced by i.p. administration of urethane (<xref ref-type="bibr" rid="B30">30</xref>). In this lung cancer model, TRAF1 affects TRAF2-mediated K48-linked ubiquitination and degradation of BRAF, and thereby promotes the survival and proliferation of lung cancer cells (<xref ref-type="bibr" rid="B30">30</xref>). Consistent with studies of the TRAF1-ALK fusion protein in ALCL, transgenic mice overexpressing <italic>TRAF1</italic> in T cells exhibit decreased antigen-induced apoptosis of CD8 T cells (<xref ref-type="bibr" rid="B35">35</xref>), while TRAF1<sup>−/−</sup> mice display impaired survival and altered proliferation of T cells in response to the 4-1BB-NF-κB2 and T cell receptor (TCR)-NF-κB1 signaling pathways, respectively (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B31">31</xref>–<xref ref-type="bibr" rid="B34">34</xref>). In line with the evidence of <italic>TRAF1</italic> overexpression in HLs and NHLs, <italic>TRAF1</italic> deficiency inhibits the spontaneous development of small B cell lymphoma in a transgenic mouse model that expresses the human lymphoma-associated NF-κB2 mutant p80HT specifically in lymphocytes (p80HT tg mice) (Table <xref ref-type="table" rid="T2">2</xref>) (<xref ref-type="bibr" rid="B27">27</xref>). Taken together, these findings identify <italic>TRAF1</italic> as a therapeutic target in skin cancer, lung cancer, and T cell and B cell lymphomas.</p>
<table-wrap id="T2" position="float">
<label>Table 2</label>
<caption>
<p><italic>In vivo</italic> evidence of the causal roles of genetic alterations of the TRAF family in cancer pathogenesis.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Mouse models</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Cancer-related phenotype</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>References</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="3" rowspan="1" style="background-color:#bcbdc0" valign="top">
<bold>TRAF1</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"> TRAF1<sup>−/−</sup></td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased skin sensitivity to TNFα-induced necrosis</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B29">29</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" style="color:#769ddd" valign="top">Reduced skin tumors induced by DMBA/solar UVR due to defective UVR-induced</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B20">20</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" style="color:#769ddd" valign="top">ERK5 phosphorylation<break></break> Reduced lung tumors induced by urethane i.p. administration due to increased</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B30">30</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" style="color:#769ddd" valign="top">TRAF2-mediated ubiquitination and degradation of BRAF</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Enhanced T cell proliferation in response to TCR-NF-κB1 signaling</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B31">31</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Impaired CD8 and memory T cell survival in response to 4-1BB-NF-κB2 signaling</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B31">31</xref>–<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B34">34</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"> TRAF1-tg</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased antigen-induced apoptosis of CD8 T lymphocytes</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B35">35</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"> p80HT tg/TRAF1<sup>−/−</sup></td>
<td align="left" colspan="1" rowspan="1" style="color:#769ddd" valign="top">Reduced development of small lymphocytic lymphoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B27">27</xref>)</td>
</tr>
<tr>
<td align="left" colspan="3" rowspan="1" style="background-color:#bcbdc0" valign="top">
<bold>TRAF2</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"> TRAF2<sup>−/−</sup></td>
<td align="left" colspan="1" rowspan="1" valign="top">Early lethality, reduced TNFα-mediated JNK activation</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B36">36</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Spontaneous severe colitis and TNFα-dependent apoptosis of colonic epithelial cells</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B37">37</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased viability of skeletal muscle tissue due to impaired TNFα-induced NF-κB activation in myotubes</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B38">38</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"> B cell KO: TRAF3flox/flox, CD19-Cre</td>
<td align="left" colspan="1" rowspan="1" valign="top">Prolonged B cell survival, splenomegaly and lymphadenopathy due to constitutive NF-κB2 activation, but defective CD40-induced NF-κB1 activation and proliferation</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B39">39</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"> B cell tg: Igh-TRAF2DN (ΔN240aa) tg</td>
<td align="left" colspan="1" rowspan="1" valign="top">Lymphadenopathy and splenomegaly due to increased number of B cells</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B40">40</xref>, <xref ref-type="bibr" rid="B41">41</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">  Igh-TRAF2DN (ΔN240aa)/Bcl-2 tg</td>
<td align="left" colspan="1" rowspan="1" style="color:#769ddd" valign="top">Spontaneously development of small lymphocytic lymphoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B42">42</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"> Liver parenchymal cell KO: TRAF2flox/flox, Ripk1flox/flox, Alfp-Cre</td>
<td align="left" colspan="1" rowspan="1" style="color:#769ddd" valign="top">Spontaneous development of hepatocellular carcinoma due to extensive hepatocyte apoptosis, caspase 8 hyperactivation and impaired TNFα-induced NF-κB activation</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B43">43</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"> Induced KO: TRAF2flox/flox, Rosa-creERT2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Rapid lethality that is dependent on Ripk3, TNFR1, DR5 and Fas signaling and increased hepatic necroptosome assembly and necroptosis</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B44">44</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"> Keratinocyte KO: TRAF2flox/flox, K14-Cre</td>
<td align="left" colspan="1" rowspan="1" valign="top">Psoriatic skin inflammation and epidermal hyperplasia that is partially dependent on TNFα, constitutive NF-κB2 activation and inflammatory cytokine expression</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B45">45</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"> Myeloid cell KO: TRAF2flox/flox, LysM-Cre</td>
<td align="left" colspan="1" rowspan="1" valign="top">Exacerbated DSS-induced colitis due to increased TLR-induced inflammatory cytokine production caused by elevated c-Rel and IRF5 protein levels in macrophages</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B46">46</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"> T cell KO: TRAF2flox/flox, Lck-Cre</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased NKT cells and CD8 naïve and memory T cells due to impaired IL-15 signaling in NKT cells and defective IL-15-induced proliferation of CD8 T cells</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B47">47</xref>)</td>
</tr>
<tr>
<td align="left" colspan="3" rowspan="1" style="background-color:#bcbdc0" valign="top">
<bold>TRAF3</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"> TRAF3<sup>−/−</sup></td>
<td align="left" colspan="1" rowspan="1" valign="top">Early lethality, which could be resued by compound loss of p100 NF-κB2 or NIK</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B48">48</xref>–<xref ref-type="bibr" rid="B50">50</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Defective antigen-induced T cell proliferation</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B49">49</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"> B cell KO: TRAF3flox/flox, CD19-Cre</td>
<td align="left" colspan="1" rowspan="1" valign="top">Expanded B cell compartment, splenomegaly and lymphadenopathy due to prolonged B cell survival caused by constitutive NF-κB2 activation</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B39">539</xref>, <xref ref-type="bibr" rid="B51">51</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" style="color:#769ddd" valign="top">Spontaneous development of splenic marginal zone lymphoma and B1 lymphoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B52">52</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Enhanced signaling by TLR3, TLR4, TLR7, and TLR9 in B cells</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B53">53</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Accelerated CD40-induced phosphorylation of JNK, p38, and ERK</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B54">54</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"> B cell Tg: Igh-TRAF3 Tg</td>
<td align="left" colspan="1" rowspan="1" style="color:#769ddd" valign="top">Spontaneous plasmacytosis, autoimmunity, inflammation and cancer, particularly squamous cell carcinomas of the tongue and salivary gland tumors</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B55">55</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"> Myeloid cell KO: TRAF3flox/flox, LysM-Cre</td>
<td align="left" colspan="1" rowspan="1" style="color:#769ddd" valign="top">Spontaneous development of histiocytic sarcoma, B lymphoma, liver cancer, or chronic inflammation that often affect multiple organs in aging mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B56">56</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Exacerbated DSS-induced colitis due to increased TLR-induced inflammatory cytokine production caused by elevated c-Rel and IRF5 protein levels in macrophages</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B46">46</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"> T cell KO: TRAF3flox/flox, CD4-Cre</td>
<td align="left" colspan="1" rowspan="1" valign="top">Impaired T cell proliferation in response to co-engagement of TCR and CD28</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B57">57</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased number of Treg cells due to enhanced IL-2 signaling</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B57">57</xref>, <xref ref-type="bibr" rid="B58">58</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Impaired IL-15-induced iNKT cell proliferation and survival</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B59">59</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced number of CD8 central memory T cells due to impaired IL-15 signaling</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B60">60</xref>)</td>
</tr>
<tr>
<td align="left" colspan="3" rowspan="1" style="background-color:#bcbdc0" valign="top">
<bold>TRAF4</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"> TRAF4<sup>−/−</sup></td>
<td align="left" colspan="1" rowspan="1" valign="top">Defects in embryonic development and neurulation</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B61">61</xref>–<xref ref-type="bibr" rid="B63">63</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced migration of DCs</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B64">64</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" style="color:#769ddd" valign="top">Reduced skin tumors induced by DMBA/TPA due to diminished IL-17A–induced ERK5 activation and epidermal hyperplasia</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B65">65</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Blunted airway inflammation and Th2 cytokine production in response to IL-25 administration due to defective IL-25R-Act1 signaling</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B66">66</xref>)</td>
</tr>
<tr>
<td align="left" colspan="3" rowspan="1" style="background-color:#bcbdc0" valign="top">
<bold>TRAF5</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"> TRAF5<sup>−/−</sup></td>
<td align="left" colspan="1" rowspan="1" valign="top">Defective CD40-induced proliferation and surface molecule upregulation in B cells</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B67">67</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased CD40 plus IL-4-induced Ig production in B cells</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B67">67</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Impaired CD27-induced survival and proliferation in CD4 and CD8 T cells</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B67">67</xref>, <xref ref-type="bibr" rid="B68">68</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Defective GITR-induced proliferation, IL-2 production and NF-κB/p38/ERK1/2 activation in CD4 T cells</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B69">69</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Enhanced OX40-induced Th2 differentiation of CD4 T cells and exacerbated Th2-driven lung inflammation</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B70">70</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Enhanced IL-6-induced CD4 Th17 differentiation due to increased IL-6-gp130-STAT3 signaling and exaggerated Th17-driven experimental autoimmune encephalomyelitis</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B71">71</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Exacerbated DSS-induced colitis and increased NF-κB activation in the colon</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B72">72</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"> CD40LMP1-tg/TRAF5<sup>−/−</sup></td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced spleen and LN size compared to CD40LMP1-tg mice, decreased serum IL-6 and autoantibodies, and decreased LMP1-mediated JNK activation in B cells.</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B73">73</xref>)</td>
</tr>
<tr>
<td align="left" colspan="3" rowspan="1" style="background-color:#bcbdc0" valign="top">
<bold>TRAF6</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"> TRAF6<sup>−/−</sup></td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced number of immature B cells in the bone marrow</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B74">74</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Defective differentiation of osteoclasts, DCs, and Treg cells</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B74">74</xref>–<xref ref-type="bibr" rid="B77">77</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Defective IL-1, CD40, LPS and RANK signaling</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B74">74</xref>, <xref ref-type="bibr" rid="B75">75</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Loss of NF-κB activity in the epithelia and vasculature during development</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B78">78</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Impaired NGF-p75NTR-induced NF-κB activation and survival in Schwann cells</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B79">79</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Defective BDNF-p75NTR-induced JNK activation and apoptosis in neurons</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B79">79</xref>, <xref ref-type="bibr" rid="B80">80</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"> Hematopoietic KO:TRAF6flox/flox, Vav-Cre</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased basal IKKβ-NF-κB activation, impaired hematopoietic stem cell self-renewal and loss of hematopoietic stem/progenitor cells (HSPCs)</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B81">81</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"> B cell KO: TRAF6flox/flox, CD19-Cre</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced number of mature B cells in the bone marrow and spleen, defective development of B1 B cells, and defective CD40 and TLR signaling in B cells</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B82">82</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"> T cell KO: TRAF6flox/flox, CD4-Cre</td>
<td align="left" colspan="1" rowspan="1" valign="top">Multiorgan inflammation and hyperactivation of TCR-PI3K-Akt signaling in CD4 T cells</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B83">83</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Defects in generating CD8 memory T cells due to impaired AMPK-activation and mitochondrial fatty acid oxidation in response to growth factor withdrawal</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B84">84</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased Th17 differentiation due to increased sensitivity of CD4 T cells to TGFβ-induced Smad2/3 activation and proliferation arrest</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B85">85</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Impaired OX40-induced Th9 differentiation due to defective OX40-NIK-NF-κB2 signaling</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B86">86</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"> Intestinal epithelial cell KO: TRAF6flox/flox, Villin-Cre</td>
<td align="left" colspan="1" rowspan="1" valign="top">Exacerbated DSS-induced colitis due to altered gut microbiota, which is independent of TLR signaling in intestinal epithelial cells</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B87">87</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"> Skeletal muscle KO:TRAF6flox/flox, MCK-Cre</td>
<td align="left" colspan="1" rowspan="1" valign="top">Minimal muscle loss in response to transplanted tumor growth due to defective activation of NF-κB, ubiquitin-proteasome and autophagy-lysosomal systems</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B88">88</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Improved regeneration of myofibers upon injury due to upregulated Notch signaling but downregulated NF-κB activation and inflammatory cytokine production</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B89">89</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced starvation-induced skeletal muscle atrophy due to increased phosphorylation of Akt and FoxO3a and decreased AMPK activation</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B90">90</xref>)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>Direct evidence in tumorigenesis is highlighted in blue font</italic>.</p>
</table-wrap-foot>
</table-wrap>
</sec>
<sec>
<title>Key oncogenic pathways</title>
<p>In addition to the above <italic>TRAF1</italic>-dependent oncogenic pathways (ERK5-AP1, BRAF-ERK, NF-κB1, and NF-κB2) that have been verified in both human cancers and <italic>in vivo</italic> mouse models, several oncogenic pathways involving TRAF1 have been suggested by studies using patient samples, cultured human cancer cells or xenograft models. These include: (1) CD30-TRAF1 in HL and ALCL tumors (<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B91">91</xref>); (2) TNF-R1/2-TRAF1/TRAF2-JNK/NF-κB in cervical and colon cancer cells (<xref ref-type="bibr" rid="B92">92</xref>); (3) Wnt/β-catenin-NF-κB-TRAF1/iNOS in colon, breast and liver cancer cells (<xref ref-type="bibr" rid="B93">93</xref>, <xref ref-type="bibr" rid="B94">94</xref>); and (4) TWEAK-Fn14-TRAF1 in solid tumors (<xref ref-type="bibr" rid="B95">95</xref>–<xref ref-type="bibr" rid="B97">97</xref>). Further investigation of these signaling pathways using TRAF1<sup>−/−</sup> or <italic>TRAF1</italic>-transgenic animal models would provide new insights on the roles and mechanisms of <italic>TRAF1</italic> in cancer pathogenesis.</p>
</sec>
</sec>
<sec id="s3">
<title>TRAF2</title>
<sec>
<title>Landscape of genetic alterations</title>
<p>The frequency of genetic alterations of <italic>TRAF2</italic> is generally &lt;6% in human cancers (Figure <xref ref-type="fig" rid="F1">1A</xref>) based on the TCGA and COSMIC datasets of sample size n &gt; 180. The eight human cancers with relatively higher genetic alterations of <italic>TRAF2</italic> are prostate cancer (5.5%) (<xref ref-type="bibr" rid="B98">98</xref>), ovarian cancer (5.1%) (TCGA, Provisional), uterine cancer (4.4%) (TCGA, PanCancer Atlas), esophageal cancer (3.9%) (TCGA, PanCancer Atlas), skin cutaneous melanoma (3.4%) (TCGA, PanCancer Atlas), head and neck squamous cell carcinoma (HNSCC, 3.2%) (TCGA, Provisional), bladder cancer (3.2%) (TCGA, PanCancer Atlas), and stomach cancer (3.1%) (<xref ref-type="bibr" rid="B8">8</xref>). Notably, although not cataloged in TCGA, mutations of <italic>TRAF2</italic> are recognized as one of the most frequent somatic mutations in mantle cell lymphoma (MCL, 6.1%, 10/165) (<xref ref-type="bibr" rid="B99">99</xref>, <xref ref-type="bibr" rid="B100">100</xref>, <xref ref-type="bibr" rid="B101">101</xref>) and diffuse large B-cell lymphoma (DLBCL, 6%, 6/101) (Figure <xref ref-type="fig" rid="F1">1B</xref>) (<xref ref-type="bibr" rid="B102">102</xref>). In addition, <italic>TRAF2</italic> has been identified as an oncogene that is recurrently amplified and rearranged in 15% of human epithelial cancers (Figure <xref ref-type="fig" rid="F1">1B</xref>) (<xref ref-type="bibr" rid="B103">103</xref>). Thus, the most common genetic alterations of <italic>TRAF2</italic> are deep deletion, gene amplification and mutation (Figure <xref ref-type="fig" rid="F1">1</xref>). Truncation and fusion of <italic>TRAF2</italic> are relatively rare but also detected in human cancers (Figure <xref ref-type="fig" rid="F1">1</xref>).</p>
</sec>
<sec>
<title>Overview and map of recurrent mutations</title>
<p>There are 237 different mutations of <italic>TRAF2</italic> detected in human cancers, comprising 86% (205/237) mutations that change the protein sequence of <italic>TRAF2</italic> and 14% (32/237) coding silent mutations (Table <xref ref-type="table" rid="T1">1</xref>). Notably, 45% (92/205) of the coding-altering mutations of <italic>TRAF2</italic> are recurrently detected in at least two cancer patients. Recurrent mutations of <italic>TRAF2</italic> are more complex than those of <italic>TRAF1</italic>, including not only missense mutations (82%, 75/92), but also frameshifts (11%, 10/92), truncations (4%, 4/92), in frame deletions (2%, 2/92) and fusion (1%, 1/92) (Table <xref ref-type="table" rid="T1">1</xref> and Figure <xref ref-type="fig" rid="F2">2</xref>). <italic>TRAF2</italic> recurrent mutations are identified at 52 different amino acids that are almost evenly distributed in all the structural motifs and domains of the TRAF2 protein (Figure <xref ref-type="fig" rid="F3">3</xref>). Interestingly, four mutation hotspots of <italic>TRAF2</italic> are detected in more than 5 cancer patients, specifically P9, G10, R372, and Q457 (Figure <xref ref-type="fig" rid="F3">3</xref>). In particular, the frameshift deletion occurred at P9 (P9fs<sup>*</sup>77) is found in 16 patients with colon cancer, colorectal cancer (CRC), uterine cancer, stomach cancer, and sarcoma, and an additional missense mutation at P9 (P9S) is also detected in a CRC patient (TCGA) (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B104">104</xref>–<xref ref-type="bibr" rid="B108">108</xref>). The amino acid right next to P9, G10, also exhibits similar frameshift deletion (G10fs<sup>*</sup>76) or insertion (G10fs<sup>*</sup>70) or missense mutation (G10D) in five patients with colon cancer, CRC, gallbladder cancer, and glioblastoma (TCGA) (<xref ref-type="bibr" rid="B105">105</xref>, <xref ref-type="bibr" rid="B106">106</xref>, <xref ref-type="bibr" rid="B109">109</xref>). Missense mutations at R372 (R372C, H or S) of the TRAF-C domain of <italic>TRAF2</italic> are detected in eight patients with HNSCC, melanoma, and prostate, uterine, cervical, stomach, and liver cancers (TCGA; COSMIC) (<xref ref-type="bibr" rid="B110">110</xref>–<xref ref-type="bibr" rid="B113">113</xref>). Another amino acid of the TRAF-C domain, Q457, shows complex mutations, including a truncation (Q457<sup>*</sup>), a frameshift insertion (Q457fs<sup>*</sup>277), and missense mutations (Q457K or L) in six patients of HNSCC, oral squamous cell carcinoma (OSCC), stomach cancer, melanoma, and breast cancer (TCGA; COSMIC) (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B114">114</xref>). Frameshift mutations occurring at P9 and G10 are functionally equivalent to deletion of <italic>TRAF2</italic>. Missense mutations at R372 and the complex mutations at Q457 of the TRAF-C domain of <italic>TRAF2</italic> are predicted to result in inactivation of the TRAF2 protein (<xref ref-type="bibr" rid="B99">99</xref>–<xref ref-type="bibr" rid="B102">102</xref>).</p>
</sec>
<sec>
<title>Fusion</title>
<p>There are five different fusions of the <italic>TRAF2</italic> gene detected in human cancers, including <italic>TRAF2-CCDC183</italic> in breast and bladder cancers, <italic>TRAF2-CACNA1B</italic> in bladder cancer, <italic>TMEM141-TRAF2</italic> in breast cancer (TCGA), <italic>TRAF2-NOTCH1</italic> in ovarian cancer (<xref ref-type="bibr" rid="B106">106</xref>) and <italic>NTRK2-TRAF2</italic> in melanoma (<xref ref-type="bibr" rid="B115">115</xref>). Among these, only the <italic>TRAF2-CCDC183</italic> fusion is recurrently detected in two patients with breast cancer and bladder cancer (TCGA). Functional contribution of these <italic>TRAF2</italic> fusions to cancer pathogenesis is currently unclear.</p>
</sec>
<sec>
<title><italic>In vivo</italic> tumor suppressive roles</title>
<p>Inactivating mutations of <italic>TRAF2</italic> are frequently detected in human MCL and DLBCL, resulting in elevated activation of NF-κB1 and NF-κB2 in malignant B cells (<xref ref-type="bibr" rid="B99">99</xref>–<xref ref-type="bibr" rid="B102">102</xref>). <italic>TRAF2</italic> is also involved in human MALT lymphomagenesis induced by the oncogenic cIAP2-MALT1 fusion protein through the interaction between TRAF2 and the BIR1 domain of cIAP2 portion of the fusion protein, leading to activation of the TRAF2-RIP1-NF-κB pathway (<xref ref-type="bibr" rid="B116">116</xref>). Consistent with the human evidence, B cell-specific TRAF2<sup>−/−</sup> (B-TRAF2<sup>−/−</sup>) mice exhibit expanded B cell compartment in lymphoid organs due to constitutive NF-κB2 activation and survival advantage independent of the B cell survival factor BAFF (Table <xref ref-type="table" rid="T2">2</xref>) (<xref ref-type="bibr" rid="B117">117</xref>). Similarly in TRAF2DN-tg mice that express a dominant negative form of <italic>TRAF2</italic> specifically in lymphocytes (Igh-TRAF2DN), inhibition of TRAF2 also leads to splenomegaly and lymphadenopathy due to constitutive NF-κB2 activation and increased numbers of B cells (<xref ref-type="bibr" rid="B40">40</xref>, <xref ref-type="bibr" rid="B42">42</xref>). Remarkably, TRAF2DN/Bcl-2 double-transgenic mice spontaneously develop small B cell lymphoma progressing to leukemia with many similarities to human CLL (Table <xref ref-type="table" rid="T2">2</xref>) (<xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B42">42</xref>). Thus, TRAF2 acts as a tumor suppressor in B lymphocytes primarily by inhibiting the NF-κB2 pathway through the well-established cIAP1/2-TRAF2-TRAF3-NIK axis (<xref ref-type="bibr" rid="B48">48</xref>, <xref ref-type="bibr" rid="B54">54</xref>, <xref ref-type="bibr" rid="B118">118</xref>).</p>
<p>Genetic alterations of <italic>TRAF2</italic> are detected in 1–2% of human liver cancers, including deletion, mutation and amplification (TCGA, PanCancer Atlas) (<xref ref-type="bibr" rid="B119">119</xref>). In human hepatocellular carcinoma (HCC), low expression of <italic>TRAF2</italic> and its interacting partner RIP1 is associated with an unfavorable prognosis (<xref ref-type="bibr" rid="B43">43</xref>). In line with human evidence, deletion of both <italic>TRAF2</italic> and RIP1 in liver parenchymal cells (LPC) leads to spontaneous development of hepatocellular carcinoma, which results from extensive hepatocyte apoptosis due to hyperactivation of caspase-8 but impaired NF-κB activation induced by TNFα (Table <xref ref-type="table" rid="T2">2</xref>) (<xref ref-type="bibr" rid="B43">43</xref>). Interestingly, TRAF2 also suppresses TNFα-induced necroptosis in hepatocytes by constitutively interacting with MLKL, thereby disrupting the TNFα-induced RIPK3-MLKL association and necroptosome formation. Induced <italic>TRAF2</italic> deletion in adult mice results in rapid lethality, in conjunction with increased hepatic necroptosome assembly (Table <xref ref-type="table" rid="T2">2</xref>) (<xref ref-type="bibr" rid="B44">44</xref>). Therefore, TRAF2 protects hepatocytes from death and tumorigenesis by inhibiting both the TNFα-TNFR1-TRADD-FADD-caspase 8 apoptosis and TNFα-TNFR1-RIPK1-RIPK3-MLKL necroptosis pathways.</p>
<p>Genetic alterations of <italic>TRAF2</italic> are detected in 3–4% of human HNSCC and melanoma (Figure <xref ref-type="fig" rid="F1">1A</xref>). In cultured HNSCC cell lines, TRAF2 is required for cellular proliferation by acting in the TNFα-TNFR1-TRADD-TRAF2-RIPK1-TAK1-IKK-NF-κB pathway (<xref ref-type="bibr" rid="B120">120</xref>). In primary human keratinocytes, exposure to UV light triggers association of TRAF2 with TNF-R1 to induce NF-κB activation and inflammation (<xref ref-type="bibr" rid="B121">121</xref>). Keratinocyte-specific TRAF2<sup>−/−</sup> mice exhibit psoriatic skin inflammation associated with apoptotic death and epidermal hyperplasia, which is dependent on TNFα, constitutive NF-κB2 activation and inflammatory cytokine production (<xref ref-type="bibr" rid="B45">45</xref>). Further in support of a role for TRAF2 in skin tumorigenesis, mutations of the TRAF2-deubiquitinating enzyme CYLD are identified in patients with familial cylindromatosis, a condition that results in benign tumors of skin appendages, and CYLD<sup>−/−</sup> mice are highly susceptible to chemically induced skin tumors (<xref ref-type="bibr" rid="B122">122</xref>). Similarly, genetic alterations of <italic>TRAF2</italic> are also identified in 2.7% (12/439) of human colon cancers (TCGA, PanCancer Atlas). In cultured primary human colon cancer cells, TRAF2 mediates the apoptosis by acting in the AMPK-ASK1-TRAF2-JNK-p53 axis in response to chemotherapies (<xref ref-type="bibr" rid="B123">123</xref>). Consistent with a potential role of TRAF2 in colon tumorigenesis, germline TRAF2<sup>−/−</sup> mice spontaneously develop severe colitis, which results from TNFα-TNFR1-mediated apoptosis of TRAF2<sup>−/−</sup> colonic epithelial cells and altered colonic microbiota (<xref ref-type="bibr" rid="B37">37</xref>). Interestingly, myeloid cell-specific ablation of <italic>TRAF2</italic> markedly exacerbates DSS-induced colitis in mice due to enhanced TLR-induced proinflammatory cytokine expression in macrophages (<xref ref-type="bibr" rid="B46">46</xref>). This is caused by constitutively elevated levels of the transcription factors c-Rel and IRF5 that are targeted for proteasome-dependent degradation by the cIAP1/2-TRAF2-TRAF3 E3 ubiquitin ligase complex (<xref ref-type="bibr" rid="B46">46</xref>). Together, the above evidence consistently supports a suppressive role for TRAF2 in skin and colon tumorigenesis.</p>
<p>It is also noteworthy that genetic alterations of <italic>TRAF2</italic> are detected in 2.6% (7/265) of human sarcomas (TCGA) and TRAF2<sup>−/−</sup> mice display decreased viability of skeletal muscle tissue because of defective TNFα-induced NF-κB activation in myotubes (Table <xref ref-type="table" rid="T2">2</xref>) (<xref ref-type="bibr" rid="B38">38</xref>). Additionally, specific deletion of <italic>TRAF2</italic> in T cells results in decreased numbers of CD8 naïve and memory T cells as well as NKT cells, due to impaired IL-15-induced signaling in these cells (Table <xref ref-type="table" rid="T2">2</xref>). However, evidence of <italic>TRAF2</italic> genetic alteration in T cell neoplasms is still lacking. Potential causal roles of <italic>TRAF2</italic> dysregulation in muscle or T cell tumorigenesis remain to be elucidated.</p>
</sec>
<sec>
<title>Key signaling pathways in cancer pathogenesis</title>
<p>In addition to the above TRAF2-dependent tumor suppressive pathways verified in both human cancers and <italic>in vivo</italic> mouse models, several important tumor suppressive pathways involving TRAF2 have been suggested by evidence obtained from cultured human cancer cells or xenograft models. These are: (1) IRE1α-TRAF2-ASK1-JNK in the apoptosis of melanoma, lung cancer and OSCC cells induced by chemotherapies or ER stress (<xref ref-type="bibr" rid="B124">124</xref>–<xref ref-type="bibr" rid="B126">126</xref>); (2) the TRAF2-caspase-2 complex in mediating DNA damage- or chemotherapy-induced apoptosis of breast, cervical and lung cancer cells, in which TRAF2-mediated ubiquitination of caspase-2 stabilizes the caspase-2 dimer complex and enhances its activity to fully commit the cell to apoptosis (<xref ref-type="bibr" rid="B127">127</xref>, <xref ref-type="bibr" rid="B128">128</xref>); (3) TRAF2-mediated inhibition of constitutive NF-κB2 activation, cell proliferation, and anchorage-independent growth in pancreatic cancer, and a similar TRAF2-mediatied inhibition of the Eva1-induced NF-κB2-Sox2/CD15/CD49f pathway in the stemness of glioblastoma (<xref ref-type="bibr" rid="B129">129</xref>, <xref ref-type="bibr" rid="B130">130</xref>); and (4) TRAF2-mediated K63-linked ubiquitination of MLST8 that disrupts the MLST8-SIN1-mTORC2-Akt pathway in the Kras-driven lung tumorigenesis (<xref ref-type="bibr" rid="B131">131</xref>). Together, these data suggest that <italic>TRAF2</italic> is a tumor suppressor in many human cancers.</p>
<p>Interestingly however, increasing evidence indicates that TRAF2 also plays oncogenic roles in epithelial cancers and some other neoplasms. Consistent with the frequent amplification of <italic>TRAF2</italic> detected in human epithelial cancers (Figure <xref ref-type="fig" rid="F1">1B</xref>) (<xref ref-type="bibr" rid="B103">103</xref>), <italic>TRAF2</italic> expression is higher in prostate cancer (<xref ref-type="bibr" rid="B133">133</xref>), pancreatic cancer (<xref ref-type="bibr" rid="B132">132</xref>), lung cancer (<xref ref-type="bibr" rid="B134">134</xref>), stomach cancer (<xref ref-type="bibr" rid="B135">135</xref>), colon cancer (<xref ref-type="bibr" rid="B136">136</xref>), glioblastoma (<xref ref-type="bibr" rid="B137">137</xref>) than in normal tissues. Increased <italic>TRAF2</italic> expression is recognized as a prognostic factor in pancreatic cancer (<xref ref-type="bibr" rid="B132">132</xref>), stomach cancer (<xref ref-type="bibr" rid="B135">135</xref>), and glioblastoma (<xref ref-type="bibr" rid="B137">137</xref>). Importantly, suppression of <italic>TRAF2</italic> in cancer cells harboring a <italic>TRAF2</italic> copy number gain inhibits proliferation, NF-κB activation, anchorage-independent growth, and tumorigenesis (<xref ref-type="bibr" rid="B103">103</xref>). Knockdown of <italic>TRAF2</italic> also enhances TRAIL-induced apoptosis in prostate cancer (<xref ref-type="bibr" rid="B133">133</xref>) and inhibits the growth but induces radiosensitization of lung cancer and glioblastoma cells (<xref ref-type="bibr" rid="B134">134</xref>). Thus, TRAF2 is required for the maintenance of the malignant state in certain cancer cells containing <italic>TRAF2</italic> amplification or overexpression, and TRAF2 protein levels also regulate the sensitivity of cancer cells to chemotherapy and radiotherapy.</p>
<p>A variety of TRAF2-dependent oncogenic pathways have been reported based on studies of patient samples, cultured human cancer cells or xenograft models. Examples include: (1) TRAF2-NEMO-p65-NF-κB1-Bcl2/XIAP/Survivin/TNFα/IL-1/IL-8/HIF-1α in the migration, invasion, metastasis, or drug resistance of breast, stomach and pancreatic cancer cells as well as DLBCL (<xref ref-type="bibr" rid="B135">135</xref>, <xref ref-type="bibr" rid="B138">138</xref>–<xref ref-type="bibr" rid="B140">140</xref>); (2) EGF-EGFR-TRAF2-RSK2-AP1 in the growth of colon cancer cells (<xref ref-type="bibr" rid="B136">136</xref>) and EGFR-TRAF2-RIP1-IKK-NF-κB1 in the resistance to chemotherapy (EGFR inhibitors) in lung cancer cells (<xref ref-type="bibr" rid="B141">141</xref>); (3) cIAP1-cIAP2-TRAF2-IKKε-TBK1-IRF3/7/NF-κB1/STAT3 in the tumorigenesis of breast cancer, in which IKKε is amplified in 30% of patients (<xref ref-type="bibr" rid="B142">142</xref>, <xref ref-type="bibr" rid="B143">143</xref>); (4) Although TRAF2 is generally considered as a K63-specific E3 ubiquitin ligase (<xref ref-type="bibr" rid="B144">144</xref>), a few studies reported TRAF2-mediated K48-linked ubiquitination and degradation of Caspase 8 in the switch of the DR5-Caspase 8 apoptotic pathway to the DR5-Cbl-TRAF2-JNK-AP1-MMP1 invasion/metastasis pathway or the cytoprotective TRAF2-RIPK1-JNK autophagic survival pathway following TRAIL treatment in HNSCC, prostate, lung, stomach, colorectal, and bladder cancer cells (<xref ref-type="bibr" rid="B145">145</xref>–<xref ref-type="bibr" rid="B148">148</xref>); (5) S100A9-CD147-TRAF2-cdc42 in the metastasis of melanoma (<xref ref-type="bibr" rid="B149">149</xref>); (6) TNFα-TRAF2-NF-κB1/AP1-COX2/IL-6/IL-8-PGE2-NOS2 and NOS2-NO-IRE1α-TRAF2-NF-κB1/AP1-COX2/IL-6/IL-8-PGE2 in the growth of breast cancer (<xref ref-type="bibr" rid="B150">150</xref>); (7) CD95-TRAF2-NF-κB1/AP1-IL-8/uPA in the invasion of pancreatic cancer (<xref ref-type="bibr" rid="B132">132</xref>); and (8) TWEAK-Fn14-TRAF2-SGEF-RhoG-Rac1 in the migration and invasion of glioma (<xref ref-type="bibr" rid="B151">151</xref>). Taken together, it is perplexing that both tumor suppressive and oncogenic roles of TRAF2 have been reported in the same type of human cancers. The exact roles of TRAF2 may be dependent on the genetic alteration context and malignant stage of the cancer cells as well as the nature of the environmental cue and treatment regimen.</p>
</sec>
</sec>
<sec id="s4">
<title>TRAF3</title>
<sec>
<title>Landscape of genetic alterations</title>
<p>The frequency of genetic alterations of <italic>TRAF3</italic> is generally &lt;6% in human cancers (Figure <xref ref-type="fig" rid="F1">1A</xref>) according to the TCGA and COSMIC datasets of sample size n &gt; 250. The eight human cancers with relatively higher genetic alterations of <italic>TRAF3</italic> are HNSCC (5.4%) (<xref ref-type="bibr" rid="B113">113</xref>), lung cancer (5.3%) (TCGA, PanCancer Atlas), cervical cancer (4.7%) (TCGA, PanCancer Atlas), uterine cancer (4.5%) (TCGA, PanCancer Atlas), stomach cancer (4.1%) (TCGA, PanCancer Atlas), bladder cancer (3.6%) (<xref ref-type="bibr" rid="B152">152</xref>), ovarian cancer (3.4%) (TCGA, PanCancer Atlas), and skin cutaneous melanoma (3.4%) (TCGA, PanCancer Atlas). Interestingly however, a subgroup among the 279 cases of HNSCC cataloged in TCGA, the human papilloma virus-positive (HPV+) HNSCC tumors, has much higher frequency (22%, 8/36) of deep deletions and truncations of <italic>TRAF3</italic> than the HPV- HNSCC tumors (Figure <xref ref-type="fig" rid="F1">1B</xref>) (<xref ref-type="bibr" rid="B113">113</xref>). Notably, although not cataloged in TCGA, deletions and mutations of <italic>TRAF3</italic> are recognized as one of the most frequent genetic alterations in a variety of B cell malignancies (<xref ref-type="bibr" rid="B153">153</xref>), including gastric marginal zone lymphoma (MZL, 21%) (<xref ref-type="bibr" rid="B154">154</xref>), multiple myeloma (MM, 17%) (<xref ref-type="bibr" rid="B155">155</xref>, <xref ref-type="bibr" rid="B156">156</xref>), HL (15%) (<xref ref-type="bibr" rid="B157">157</xref>), DLBCL (14.3%) (<xref ref-type="bibr" rid="B158">158</xref>), splenic MZL (10%) (<xref ref-type="bibr" rid="B159">159</xref>), and Waldenstrom's macroglobulinemia (WM, 5.3%) (<xref ref-type="bibr" rid="B160">160</xref>) (Figure <xref ref-type="fig" rid="F1">1B</xref>). Furthermore, somatic mutations of <italic>TRAF3</italic> are also frequently detected in human nasopharyngeal cancer (NPC, 8.6%) (<xref ref-type="bibr" rid="B161">161</xref>) (Figure <xref ref-type="fig" rid="F1">1B</xref>). Together, the most common genetic alteration of <italic>TRAF3</italic> is deep deletion, followed by mutation and then amplification. Truncation and fusion of <italic>TRAF3</italic> are less common but also detected in several different types of human cancers (Figure <xref ref-type="fig" rid="F1">1</xref>).</p>
</sec>
<sec>
<title>Overview and map of recurrent mutations</title>
<p>There are 280 different mutations of <italic>TRAF3</italic> detected in human cancers, comprising 90% (253/280) mutations that change the protein sequence of TRAF3 and 10% (27/280) coding silent mutations (Table <xref ref-type="table" rid="T1">1</xref>). Approximately 43% (108/253) of the coding-altering mutations of <italic>TRAF3</italic> are recurrently detected in at least two cancer patients. Among all the <italic>TRAF</italic> genes, <italic>TRAF3</italic> recurrent mutations exhibit the most complex pattern and include the highest frequencies of frameshift mutations (19%, 21/108) and truncations (8%, 9/108). <italic>TRAF3</italic> recurrent mutations also include 69% (75/108) missense mutations, 1% (1/108) in frame deletion, 1% splice mutation, and 1% fusion (Table <xref ref-type="table" rid="T1">1</xref> and Figure <xref ref-type="fig" rid="F2">2</xref>). These recurrent mutations occurred at 67 amino acid positions that are distributed in almost the entire length of the TRAF3 protein (Figure <xref ref-type="fig" rid="F3">3</xref>).</p>
<p>Five mutation hotspots of <italic>TRAF3</italic> are identified in more than 5 cancer patients, specifically N16, N285, K286, R310, and R376 (Figure <xref ref-type="fig" rid="F3">3</xref>). <italic>TRAF3</italic> mutations at N16 have the highest patient count, including the missense mutation (N16T) identified in 10 patients with HNSCC (COSMIC) and the frameshift deletion (N16fs<sup>*</sup>3) detected in a patient with splenic MZL (<xref ref-type="bibr" rid="B162">162</xref>, <xref ref-type="bibr" rid="B163">163</xref>). Mutations at the two consecutive amino acids N285 and K286 of the coiled-coil domain of TRAF3 exhibit the most complex pattern. N285 contains frameshift deletion (N285fs<sup>*</sup>38), frameshift insertion (N285fs<sup>*</sup>13) and missense mutation (N285S) identified in 8 patients with HNSCC, MZL, NPC, CRC, stomach cancer and uterine cancer (TCGA; COSMIC) (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B107">107</xref>, <xref ref-type="bibr" rid="B161">161</xref>, <xref ref-type="bibr" rid="B164">164</xref>, <xref ref-type="bibr" rid="B165">165</xref>). Similarly, K286 exhibits frameshift deletion (K286fs<sup>*</sup>7 or fs<sup>*</sup>11) and truncation (K286<sup>*</sup>) detected in six patients with B cell malignancies, including MM, CLL and WM (<xref ref-type="bibr" rid="B155">155</xref>, <xref ref-type="bibr" rid="B160">160</xref>, <xref ref-type="bibr" rid="B166">166</xref>, <xref ref-type="bibr" rid="B167">167</xref>). A third amino acid of the coiled-coil domain, R310, is consistently targeted by truncation (R310<sup>*</sup>) as detected in 8 patients with DLBCL, MM, HNSCC, cervical cancer and uterine cancer (TCGA) (<xref ref-type="bibr" rid="B113">113</xref>, <xref ref-type="bibr" rid="B155">155</xref>, <xref ref-type="bibr" rid="B158">158</xref>, <xref ref-type="bibr" rid="B166">166</xref>, <xref ref-type="bibr" rid="B168">168</xref>). Missense mutations at R376 (R376W or Q) located in the linker between the coiled-coil and TRAF-C domains of TRAF3 are detected in six patients with lung cancer, CRC, SSCC, and melanoma (TCGA; COSMIC) (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B108">108</xref>, <xref ref-type="bibr" rid="B169">169</xref>). Many of these truncations, frameshifts and missense mutations have been shown to result in inactivation of TRAF3 by disrupting its interaction with NIK, thereby inducing constitutive NF-κB2 activation (<xref ref-type="bibr" rid="B155">155</xref>, <xref ref-type="bibr" rid="B156">156</xref>, <xref ref-type="bibr" rid="B158">158</xref>, <xref ref-type="bibr" rid="B159">159</xref>, <xref ref-type="bibr" rid="B170">170</xref>). Thus, most of the recurrent genetic alterations of <italic>TRAF3</italic> identified in human cancers cause complete loss or inactivation of the TRAF3 protein.</p>
</sec>
<sec>
<title>Fusion</title>
<p>There are 14 different fusions of <italic>TRAF3</italic> detected in human cancers, including <italic>TRAF3-WDR20</italic> in stomach and uterine cancers, four fusions of <italic>TRAF3-MYO16, TRAF3-RCOR1, TRAF3-KLC1</italic>, and <italic>EVL-TRAF3</italic> in breast cancer, <italic>TRAF3-SFXN1</italic> in cervical cancer, <italic>UBR5-TRAF3</italic> in HNSCC, two fusions of <italic>TRAF3-ZNF839</italic> and <italic>TRAF3-MARK3</italic> in kidney cancer, two fusions of TRAF3-BMP3 and <italic>SLC22A23-TRAF3</italic> in lung cancer, <italic>TRAF3-IFNL1</italic> in ovarian cancer, <italic>TRAF3-ITPK1</italic> in pheochromocytoma and <italic>TRAF3-SIVA1</italic> in stomach cancer (TCGA). Among the 14 fusions, only the <italic>TRAF3-WDR20</italic> fusion is recurrently detected in two patients with stomach cancer and uterine cancer (TCGA, PanCancer Atlas). However, the functional significance of these TRAF3 fusions is currently unknown.</p>
</sec>
<sec>
<title><italic>In vivo</italic> causal roles in cancer pathogenesis</title>
<p>Similar to <italic>TRAF2</italic> and also consistent with the frequent deletions and inactivating mutations of TRAF3 identified in human B cell malignancies (Figure <xref ref-type="fig" rid="F1">1B</xref>), a tumor suppressive role for TRAF3 in B lymphocytes has been demonstrated by <italic>in vivo</italic> evidence obtained from mouse models. As shown for B-TRAF2<sup>−/−</sup> mice, B cell-specific TRAF3<sup>−/−</sup> (B-TRAF3<sup>−/−</sup>) mice also exhibit severe peripheral B cell hyperplasia due to prolonged survival of mature B cells independent of BAFF, which results from constitutive NF-κB2 activation (<xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B51">51</xref>). These B-TRAF3<sup>−/−</sup> mice spontaneously develop splenic MZL or B1 lymphoma at high incidence (<xref ref-type="bibr" rid="B52">52</xref>). Interestingly, B-TRAF3<sup>−/−</sup> mice also have doubled number of plasma cells due to enhanced responsiveness to IL-6 (<xref ref-type="bibr" rid="B171">171</xref>). Mechanistically, TRAF3 inhibits the IL-6-IL-6R-JAK1-STAT3 survival and differentiation pathway in plasma cells by facilitating the association of PTPN22 with JAK1 (<xref ref-type="bibr" rid="B171">171</xref>). Furthermore, the EBV-encoded oncoprotein LMP1 sequesters TRAF3 to produce functional TRAF3 deficiency in human and mouse B lymphoma cells (<xref ref-type="bibr" rid="B172">172</xref>, <xref ref-type="bibr" rid="B173">173</xref>). Intriguingly, lymphocyte-specific TRAF3 transgenic mice also develop plasmacytosis, autoimmunity, inflammation, and cancers, which are likely caused by hyper-responsiveness of B cells to antigens and TLR agonists (<xref ref-type="bibr" rid="B55">55</xref>). Thus, TRAF3 acts as a tumor suppressor in naïve B cells, but an appropriate and balanced level, neither too high nor too low, of TRAF3 is required to maintain the homeostasis of plasma cells and protect them from tumorigenesis.</p>
<p>Interestingly, specific deletion of TRAF3 from myeloid cells (granulocytes, monocytes, and macrophages) leads to spontaneous development of histiocytic sarcomas derived from TRAF3<sup>−/−</sup> tissue-resident macrophages in aging mice (<xref ref-type="bibr" rid="B56">56</xref>, <xref ref-type="bibr" rid="B174">174</xref>). The pathogenic mechanisms are likely related to the enhanced TLR-induced inflammatory responses observed in TRAF3<sup>−/−</sup> macrophages through constitutive activation of NF-κB2, c-Rel, and IRF5, as described for TRAF2<sup>−/−</sup> macrophages (<xref ref-type="bibr" rid="B56">56</xref>, <xref ref-type="bibr" rid="B174">174</xref>). Two other mouse models with functional relevance to TRAF3, Dok1<sup>−/−</sup>Dok2<sup>−/−</sup>Dok3<sup>−/−</sup> mice and humanized TLR7/TLR8 transgenic mice, also spontaneously develop histiocytic sarcomas (<xref ref-type="bibr" rid="B175">175</xref>, <xref ref-type="bibr" rid="B176">176</xref>). DOK3, a negative regulator of protein tyrosine kinase (PTK)-mediated signaling, has recently been identified as a TRAF3-interacting protein (<xref ref-type="bibr" rid="B177">177</xref>). Similar to TRAF3<sup>−/−</sup> macrophages, DOK3<sup>−/−</sup> macrophages are defective in the TLR3-IRF3-IFNβ antiviral pathway (<xref ref-type="bibr" rid="B177">177</xref>). TRAF3 is also a transducer of TLR7 and TLR8 signaling through direct interaction with MyD88 (<xref ref-type="bibr" rid="B1">1</xref>). Transgenic expression of human TLR7/TLR8 in mice deficient for endogenous TLR7/TLR8 drives inflammation and proliferative histiocytosis, which can be reversed by compound deletion of MyD88 (<xref ref-type="bibr" rid="B176">176</xref>). Collectively, the above <italic>in vivo</italic> evidence indicates that TRAF3 is a tumor suppressor in macrophages and that dysregulation of the TLR-MyD88-TRAF3-Dok3 axis in macrophages plays causal roles in the pathogenesis of histiocytic sarcoma. However, because histiocytic sarcoma in humans is a rare malignancy with sparse pathologic and cytogenetic data (<xref ref-type="bibr" rid="B178">178</xref>, <xref ref-type="bibr" rid="B179">179</xref>), potential TRAF3 genetic alterations in human histiocytic sarcomas require future investigation.</p>
<p>In addition to the phenotype of histiocytic sarcoma, aging myeloid cell-specific TRAF3<sup>−/−</sup> (M-TRAF3<sup>−/−</sup>) mice spontaneously develop chronic inflammation and other cancers that often affect multiple organs including the gastrointestinal tract (<xref ref-type="bibr" rid="B56">56</xref>). Similar to M-TRAF2<sup>−/−</sup> mice, young adult M-TRAF3<sup>−/−</sup> mice exhibit exacerbated DSS-induced colitis with increased levels of inflammatory cytokines produced by TRAF3<sup>−/−</sup> macrophages in response to TLR signaling (<xref ref-type="bibr" rid="B46">46</xref>). Notably, another mouse model with functional relevance to TRAF3, NLRP12<sup>−/−</sup> mice, is highly susceptible to colitis and colitis-associated colon cancer (<xref ref-type="bibr" rid="B180">180</xref>). NLRP12 interacts with both TRAF3 and NIK, and NLRP12<sup>−/−</sup> cells have constitutively activated NF-κB2 associated with a decreased protein level of TRAF3 (<xref ref-type="bibr" rid="B180">180</xref>). Interestingly, both NLRP12<sup>−/−</sup> hematopoietic and non-hematopoietic cells contribute to inflammation, but the latter dominantly contributes to colon tumorigenesis (<xref ref-type="bibr" rid="B180">180</xref>). In line with the <italic>in vivo</italic> data, mutations and deletions of TRAF3 are detected in 2.3% (10/439) of human colon cancers (TCGA, PanCancer Atlas). Furthermore, miR-32-TRAF3-mediated inhibition of the NIK-NF-κB2 pathway protects human colorectal epithelium against colorectal cancer in response to a diet of non-digestible carbohydrates (<xref ref-type="bibr" rid="B181">181</xref>). Thus, TRAF3 appears to act in both epithelial cells and myeloid cells to suppress colon tumorigenesis by inhibiting the NF-κB2 and TLR-induced inflammatory pathways.</p>
<p>Although most evidence identifies TRAF3 as a tumor suppressor, studies of the T cell-specific TRAF3<sup>−/−</sup> (T-TRAF3<sup>−/−</sup>) mouse model suggest an oncogenic role for TRAF3 in T cells. Despite their constitutive NF-κB2 activation, TRAF3<sup>−/−</sup> T cells exhibit impaired proliferation and activation in response to TCR and CD28 co-stimulation (<xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B57">57</xref>). T-TRAF3<sup>−/−</sup> mice show defects in T cell-mediated immunity and IL-15-induced proliferation and survival of iNKT cells, and also have reduced number of CD8 central memory T cells (Table <xref ref-type="table" rid="T2">2</xref>) (<xref ref-type="bibr" rid="B57">57</xref>, <xref ref-type="bibr" rid="B59">59</xref>, <xref ref-type="bibr" rid="B60">60</xref>). Consistent with these <italic>in vivo</italic> data, TRAF3 is required for the proliferation of human neoplastic ALCL cells in culture (<xref ref-type="bibr" rid="B182">182</xref>). Silencing of TRAF3 in ALCL cells not only results in aberrant activation of the NIK-NF-κB2 pathway, but also affects the continued PI3K-AKT and JAK-STAT signaling (<xref ref-type="bibr" rid="B182">182</xref>). Therefore, distinct tumor suppressive and oncogenic roles of TRAF3 in different cellular contexts have been revealed from studies of both human and mouse models.</p>
</sec>
<sec>
<title>Key tumor suppressive pathways</title>
<p>In addition to the above TRAF3-dependent tumor suppressive pathways verified in both human cancers and <italic>in vivo</italic> mouse models, several additional tumor suppressive pathways involving TRAF3 have been suggested by studies of cultured human cancer cells or xenograft models. These include: (1) TRAF3-mediated inhibition of the oncogenic RelB-SMAD4 association that represses TGFβ-SMAD target gene expression to promote the tumorigenesis of lung cancer, in which TRAF3 is targeted by RAS-NDP52-mediated autophagic degradation via the NDP52-TRAF3 interaction (<xref ref-type="bibr" rid="B183">183</xref>); (2) LIGHT-LTβR-TRAF3/TRAF5-ROS-ASK1-Caspase3 in the apoptosis of human colon cancer and hepatoma cells (<xref ref-type="bibr" rid="B184">184</xref>); (3) membrane-bound CD40L-CD40-TRAF3-p40phox-ROS-ASK1-MKK4-JNK-AP1-caspase 9/3/Bax/Bak in the apoptosis of human bladder and CRC cells but not normal epithelial cells (<xref ref-type="bibr" rid="B185">185</xref>–<xref ref-type="bibr" rid="B187">187</xref>); and (4) TRAF3-mediated inhibition of the oncogenic RIP2-NF-κB1/NF-κB2/p38-Bcl-xL pathway in the survival and proliferation of glioblastoma cells (<xref ref-type="bibr" rid="B188">188</xref>). Taken together, available evidence supports that TRAF3 acts as a tumor suppressor in a variety of cell types, but we cannot rule out that TRAF3 upregulation might also alter normal cell homeostasis in the same or other cell types and therefore contribute to transformation, as it has been observed in B cells and T cells.</p>
</sec>
</sec>
<sec id="s5">
<title>TRAF4</title>
<sec>
<title>Landscape of genetic alterations</title>
<p>The frequency of genetic alterations of <italic>TRAF4</italic> is generally &lt;11% in human cancers (Figure <xref ref-type="fig" rid="F1">1A</xref>) based on the TCGA and COSMIC datasets of sample size n &gt; 100. The eight human cancers with relatively higher genetic alterations of <italic>TRAF4</italic> are pancreatic cancer (10.1%) (<xref ref-type="bibr" rid="B7">7</xref>), bladder cancer (7.3%) (<xref ref-type="bibr" rid="B152">152</xref>), breast cancer (5.5%) (<xref ref-type="bibr" rid="B189">189</xref>), uterine cancer (5.1%) (TCGA, PanCancer Atlas), esophageal cancer (3.2%) (TCGA, Provisional), lung cancer (2.6%) (<xref ref-type="bibr" rid="B190">190</xref>), melanoma (2.5%) (<xref ref-type="bibr" rid="B191">191</xref>), and ovarian cancer (2.4%) (TCGA, PanCancer Atlas). The most common genetic alteration of <italic>TRAF4</italic> is amplification, followed by mutation (Figure <xref ref-type="fig" rid="F1">1</xref>). Deep deletion, truncation and fusion of <italic>TRAF4</italic> are relatively rare in human cancers.</p>
</sec>
<sec>
<title>Overview and map of recurrent mutations</title>
<p>There are 123 different mutations of <italic>TRAF4</italic> detected in human cancers, comprising 85% (105/123) mutations that cause changes in the amino acid sequence of <italic>TRAF4</italic> and 15% (18/123) coding silent mutations (Table <xref ref-type="table" rid="T1">1</xref>). About 42% (44/105) of the coding-altering mutations of the <italic>TRAF4</italic> gene are recurrent and detected in at least two cancer patients, including mostly missense mutations (89%, 39/44), 3 truncations, 1 frameshift deletion, and 1 in frame deletion (Table <xref ref-type="table" rid="T1">1</xref> and Figure <xref ref-type="fig" rid="F2">2</xref>). <italic>TRAF4</italic> recurrent mutations occurred at 32 different amino acids that are distributed in the entire length of the <italic>TRAF4</italic> protein but are relatively enriched in the TRAF-C domain (Figure <xref ref-type="fig" rid="F3">3</xref>). Only two specific amino acids, R448 and R452 located at the C-terminal TRAF-C domain, are mutated in more than 3 patients (Figure <xref ref-type="fig" rid="F3">3</xref>). For R448, mixed missense mutations (R448Q or L) and a truncation (R448<sup>*</sup>) are identified in 4 patients with prostate cancer, uterine cancer, HNSCC, and OSCC (<xref ref-type="bibr" rid="B192">192</xref>–<xref ref-type="bibr" rid="B195">195</xref>). For R452, missense mutations (R452W or Q or L) are detected in four patients with uterine, colorectal and lung cancers (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B108">108</xref>, <xref ref-type="bibr" rid="B193">193</xref>). Further studies are needed to determine whether such missense mutations in the TRAF-C domain result in loss- or gain-of-function of TRAF4.</p>
</sec>
<sec>
<title>Fusion</title>
<p>There is only one fusion of <italic>TRAF4</italic> detected in human cancers, the <italic>TRAF4-FASN</italic> fusion identified in a glioma patient (TCGA), with currently unknown functional significance.</p>
</sec>
<sec>
<title><italic>In vivo</italic> causal oncogenic roles</title>
<p>Available human evidence indicates that gene amplification is the most common <italic>TRAF4</italic> genetic alteration in cancers and that <italic>TRAF4</italic> expression is ubiquitously elevated in many human cancers (<xref ref-type="bibr" rid="B196">196</xref>–<xref ref-type="bibr" rid="B204">204</xref>). This suggests that <italic>TRAF4</italic> overexpression may play causal roles in cancer initiation, progression and metastasis. Similar to classical oncogenes (such as c-Myc and K-ras), <italic>TRAF4</italic> is also required for ontogenic processes and TRAF4<sup>−/−</sup> mice show defects in embryonic development and neurulation (<xref ref-type="bibr" rid="B61">61</xref>, <xref ref-type="bibr" rid="B62">62</xref>, <xref ref-type="bibr" rid="B205">205</xref>). Interestingly, TRAF4<sup>−/−</sup> dendritic cells (DCs) derived from the null mice exhibit reduced <italic>in vivo</italic> and <italic>in vitro</italic> migration (<xref ref-type="bibr" rid="B64">64</xref>). Furthermore, recent <italic>in vivo</italic> evidence obtained from mouse models demonstrates the causal oncogenic roles of <italic>TRAF4</italic> in skin tumorigenesis (Table <xref ref-type="table" rid="T2">2</xref>) (<xref ref-type="bibr" rid="B65">65</xref>). <italic>TRAF4</italic> deficiency substantially diminishes IL-17A-induced ERK5 activation and epidermal hyperplasia in mice. In the DMBA/TPA-induced skin cancer model, TRAF4<sup>−/−</sup> mice exhibit remarkably reduced tumor incidence and tumor numbers. Mechanistically, <italic>TRAF4</italic> bridges the interaction between Act1 and MEKK3 in response to IL-17A signaling, and therefore is required for the activation of the downstream MEK5-ERK5-Steap4/p63 pathway. The transcription factor p63 directly induces <italic>TRAF4</italic> expression in keratinocytes, promoting positive feedback on TRAF4 in the epidermis and thus sustaining the activation of the TRAF4-ERK5 axis to induce keratinocyte proliferation and skin tumorigenesis (<xref ref-type="bibr" rid="B65">65</xref>). These <italic>in vivo</italic> findings are reinforced by the examination of human SSCC samples, which also demonstrates the presence of the IL-17A-Act1-TRAF4-MEKK3-MEK5-ERK5-Steap4/p63 pathway (<xref ref-type="bibr" rid="B65">65</xref>). Together, both human and <italic>in vivo</italic> mouse evidence supports an oncogenic role for TRAF4.</p>
</sec>
<sec>
<title>Key oncogenic pathways</title>
<p>In addition to the established IL-17A-TRAF4-ERK5 axis, a variety of potential <italic>TRAF4</italic>-dependent oncogenic pathways have been suggested by studies of patient samples, cultured human cancer cells or their xenografts in immunodeficient mice. These include: (1) TRAF4-Akt/NF-κB-Glut1/HK2/RSK4/Slug in the proliferation and metastasis of lung and breast cancer cells as well as the migration and epithelial-mesenchymal transition (EMT) of hepatocellular carcinoma cells (HCC) (<xref ref-type="bibr" rid="B199">199</xref>, <xref ref-type="bibr" rid="B203">203</xref>, <xref ref-type="bibr" rid="B206">206</xref>); (2) TGFβ-TβRI-TRAF4-Smurf1/Smurf2/USP15-SMAD2/TAK1-N-cadherin/Fibronectin/Vimentin/SMA in the migration, EMT, and metastasis of breast cancer cells (<xref ref-type="bibr" rid="B200">200</xref>, <xref ref-type="bibr" rid="B207">207</xref>); (3) SRC3-TRAF4-mediated inhibition of the USP7-p53 interaction, leading to the loss of p53 deubiquitination/stabilization and thus the resistance to cytotoxic drugs and stress in breast cancer (<xref ref-type="bibr" rid="B208">208</xref>); (4) NGF-TrkA-TRAF4-Akt/p38-IL-6/Integrins/COX2 in the metastasis of prostate cancer cells (<xref ref-type="bibr" rid="B204">204</xref>); (5) TNFα-TRAF4/TRAF2-NF-κB1 in the survival and proliferation of breast cancer cells (<xref ref-type="bibr" rid="B209">209</xref>); (6) TRAF4-mediated up-regulation and nuclear translocation of β-catenin in the Wnt/β-catenin-cyclin D1/c-myc/Bcl-2/MMPs pathway that promote the growth and migration of OSCC and breast cancer cells (<xref ref-type="bibr" rid="B210">210</xref>, <xref ref-type="bibr" rid="B211">211</xref>); (7) TRAF4-mTOR-p70S6K-S6 in the proliferation of breast cancer cells (<xref ref-type="bibr" rid="B212">212</xref>); and (8) the TRAF4-phosphoinositide (PIP) interaction at tight junctions that favors breast cancer cell migration (<xref ref-type="bibr" rid="B213">213</xref>). It would be interesting to verify these TRAF4-dependent oncogenic pathways using <italic>in vivo</italic> models.</p>
</sec>
</sec>
<sec id="s6">
<title>TRAF5</title>
<sec>
<title>Landscape of genetic alterations</title>
<p>The landscape of <italic>TRAF5</italic> genetic alterations is similar to that of <italic>TRAF4</italic>. The frequency of genetic alterations of <italic>TRAF5</italic> is generally &lt;13% in human cancers (Figure <xref ref-type="fig" rid="F1">1A</xref>) according to the TCGA and COSMIC datasets of sample size n &gt; 140. The eight human cancers with relatively higher genetic alterations of <italic>TRAF5</italic> are breast cancer (12.2%) (<xref ref-type="bibr" rid="B189">189</xref>), liver cancer (8.4%) (TCGA, Provisional), uterine cancer (6.4%) (TCGA, PanCancer Atlas), lung cancer (5.3%) (TCGA, Provisional), ovarian cancer (5.1%) (TCGA, Provisional), melanoma (4.0%) (TCGA, Provisional), esophageal cancer (3.8%) (TCGA, Provisional), and prostate cancer (3.3%) (<xref ref-type="bibr" rid="B214">214</xref>). As described for <italic>TRAF4</italic>, the most common genetic alteration of <italic>TRAF5</italic> is also amplification, followed by mutation (Figure <xref ref-type="fig" rid="F1">1A</xref>). Deep deletion, truncation and fusion of <italic>TRAF5</italic> are rare events in human cancers.</p>
</sec>
<sec>
<title>Overview and map of recurrent mutations</title>
<p>There are 188 different mutations of <italic>TRAF5</italic> detected in human cancers, comprising 85% (160/188) mutations that alter the amino acid sequence of <italic>TRAF5</italic> and 15% (28/188) coding silent mutations (Table <xref ref-type="table" rid="T1">1</xref>). Approximately 36% (57/160) of the coding-altering mutations of <italic>TRAF5</italic> are recurrent in human cancers. Similar to <italic>TRAF4, TRAF5</italic> recurrent mutations also include mostly missense mutations (85%, 49/57), but also some truncations (9%, 5/57), frameshift deletions (4%, 2/57), and an in frame deletion (2%, 1/57) (Table <xref ref-type="table" rid="T1">1</xref> and Figure <xref ref-type="fig" rid="F2">2</xref>). These recurrent mutations occurred at 36 different amino acids that are mainly enriched in the TRAF-C domain but also scattered in other regions of the TRAF5 protein (Figure <xref ref-type="fig" rid="F3">3</xref>). Mutations of three specific amino acids, R164, T232, and A548, are detected in more than three patients (Figure <xref ref-type="fig" rid="F3">3</xref>). Complex alterations of R164 of the zinc finger motif, including truncation (R164<sup>*</sup>) and missense mutations (R164Q or L), are detected in six patients with uterine, colon and bile duct cancers and DLBCL (TCGA) (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B193">193</xref>, <xref ref-type="bibr" rid="B215">215</xref>). Another missense mutation of the zinc finger motif, T232M, is detected in four patients with colon, breast, and prostate cancers (TCGA; COSMIC) (<xref ref-type="bibr" rid="B98">98</xref>). Missense mutation A548V of the TRAF-C domain is identified in four patients with uterine, cervical, stomach, and breast cancers (TCGA) (<xref ref-type="bibr" rid="B107">107</xref>). The functional consequences of these recurrent <italic>TRAF5</italic> mutations await further investigation.</p>
</sec>
<sec>
<title><italic>In vivo</italic> causal oncogenic roles</title>
<p>Although not cataloged in TCGA, <italic>TRAF5</italic> mutations are detected in 5% (5/101) of human DLBCL (<xref ref-type="bibr" rid="B102">102</xref>). <italic>TRAF5</italic> expression is upregulated in human splenic MZL (<xref ref-type="bibr" rid="B216">216</xref>). In addition, apoptosis-resistant B cell-acute lymphoblastic leukemia (B-ALL) cells have aberrantly higher protein level of TRAF5 and TRAF6 in response to irradiation than apoptosis-proficient B-ALL cells (<xref ref-type="bibr" rid="B217">217</xref>). The above evidence suggests that TRAF5 may be oncogenic in B cells. Consistent with human evidence, B cells of TRAF5<sup>−/−</sup> mice show defects in CD40-induced proliferation and up-regulation of surface molecules and activation markers as well as CD40 plus IL-4-induced Ig production (Table <xref ref-type="table" rid="T2">2</xref>) (<xref ref-type="bibr" rid="B67">67</xref>). Using a chimeric CD40-LMP1 transgenic (CD40LMP1-tg) mouse model that mimics the B cell hyperactivation induced by the EBV-encoded oncoprotein LMP1 (<xref ref-type="bibr" rid="B218">218</xref>), Kraus et al. demonstrated that TRAF5 is a critical mediator of the <italic>in vivo</italic> functions of LMP1 (<xref ref-type="bibr" rid="B73">73</xref>). <italic>TRAF5</italic> deficiency reverses the CD40-LMP1-induced enlargement of the spleen and lymph nodes, decreases the serum levels of IL-6 and autoantibodies that are elevated by CD40-LMP1-tg expression, and also inhibits LMP1-mediated JNK activation in B lymphocytes (Table <xref ref-type="table" rid="T2">2</xref>) (<xref ref-type="bibr" rid="B73">73</xref>). Together, both human and mouse evidence supports an oncogenic role for TRAF5 in B cells that appears to be required for LMP1-mediated B lymphomagenesis and is likely also involved in spontaneous B lymphomagenesis initiated by genetic alterations.</p>
<p>Additionally, available <italic>in vivo</italic> evidence indicates the importance of TRAF5 in the survival, proliferation and differentiation of different T cell subsets as detailed in Table <xref ref-type="table" rid="T2">2</xref>, suggesting that TRAF5 malfunction may contribute to T cell malignancies. However, the evidence of <italic>TRAF5</italic> alterations in human T cell lymphomas/leukemias is still lacking.</p>
</sec>
<sec>
<title>TRAF5-dependent signaling pathways in human cancer cells</title>
<p>In addition to the signaling pathways of B cells and T cells revealed by the <italic>in vivo</italic> studies of TRAF5<sup>−/−</sup> mice, a number of TRAF5-dependent signaling pathways have been proposed based on the studies of patient samples, cultured human cancer cells or their xenografts in immunodeficient mice. These include: (1) CD30-TRAF2/TRAF5-NIK-IKKα-NF-κB-IL-13 in the survival of Hodgkin-Reed-Sternberg (H-RS) cells of HL (<xref ref-type="bibr" rid="B219">219</xref>, <xref ref-type="bibr" rid="B220">220</xref>) and a similar CD30v-TRAF2/TRAF5-NIK-NF-κB pathway in acute myeloid leukemia (AML) and ALL (<xref ref-type="bibr" rid="B221">221</xref>); (2) LIGHT-LTβR-TRAF3/TRAF5-ROS-ASK1-Caspase 3 in the apoptosis of human colon cancer and hepatoma cells (<xref ref-type="bibr" rid="B184">184</xref>); (3) upregulated TRAF5-NF-κB in the migration and invasion of glioma cells, in which TRAF5 is directly targeted for degradation by the tumor suppressor Numbl (<xref ref-type="bibr" rid="B222">222</xref>); (4) TRAF5/TRAF6-NF-κB-Vimentin/TWIST1/SNAIL2/MMP13/IL-11 in the EMT and metastasis of prostate cancer cells, in which TRAF5 is directly targeted for downregulation by the tumor suppressive miR-141-3p (<xref ref-type="bibr" rid="B223">223</xref>); and (5) TRAF5-MEK1/2-ERK1/2-Bcl2 in the survival and proliferation of melanoma cells, in which TRAF5 is directly targeted for downregulation by tumor suppressive MiR-26b (<xref ref-type="bibr" rid="B224">224</xref>). The above evidence supports the hypothesis that TRAF5 plays oncogenic roles in various human cancer cells primarily by inducing NF-κB activation but also by activating the ERK1/2 pathway.</p>
</sec>
</sec>
<sec id="s7">
<title>TRAF6</title>
<sec>
<title>Landscape of genetic alterations</title>
<p>The frequency of genetic alterations of <italic>TRAF6</italic> is generally &lt;7% in human cancers (Figure <xref ref-type="fig" rid="F1">1A</xref>) based on the TCGA and COSMIC datasets of sample size n &gt; 120. The eight human cancers with relatively higher genetic alterations of <italic>TRAF6</italic> are breast cancer (6.9%) (<xref ref-type="bibr" rid="B225">225</xref>), uterine cancer (4.5%) (TCGA, PanCancer Atlas), stomach cancer (4.1%) (<xref ref-type="bibr" rid="B8">8</xref>), HNSCC (3.6%) (<xref ref-type="bibr" rid="B113">113</xref>), lung cancer (3.4%) (<xref ref-type="bibr" rid="B10">10</xref>), bladder cancer (3.1%) (<xref ref-type="bibr" rid="B226">226</xref>), sarcoma (3%) (TCGA, Provisional), and ovarian cancer (2.8%) (TCGA, Provisional). Although not listed in TCGA, <italic>TRAF6</italic> amplification is recognized as one of the most frequent genomic alterations in human lung cancer (9.2%, 24/261) (<xref ref-type="bibr" rid="B227">227</xref>) and OSCC (10%, 2/20) (<xref ref-type="bibr" rid="B228">228</xref>). Consistent with the frequent amplification of <italic>TRAF6</italic> in human cancers, <italic>TRAF6</italic> is overexpressed in many human cancers such as breast cancer, HCC, colon cancer, esophageal cancer, and melanoma (<xref ref-type="bibr" rid="B229">229</xref>–<xref ref-type="bibr" rid="B233">233</xref>). <italic>TRAF6</italic> overexpression is also identified as a prognostic factor for breast and esophageal cancers (<xref ref-type="bibr" rid="B229">229</xref>, <xref ref-type="bibr" rid="B232">232</xref>). Together, the most common genetic alterations of <italic>TRAF6</italic> are mutation and amplification (Figure <xref ref-type="fig" rid="F1">1A</xref>). Deep deletion of <italic>TRAF6</italic> is less common but also detected in several different types of human cancers. Truncation and fusion of <italic>TRAF6</italic> are rare in human cancers.</p>
</sec>
<sec>
<title>Overview and map of recurrent mutations</title>
<p>There are 178 different mutations of <italic>TRAF6</italic> detected in human cancers, comprising 85% (152/178) mutations that alter the protein sequence of <italic>TRAF6</italic> and 15% (26/178) coding silent mutations (Table <xref ref-type="table" rid="T1">1</xref>). Only 27% (41/152) of the coding-altering mutations of <italic>TRAF6</italic> are recurrently detected in at least two cancer patients. Similar to <italic>TRAF1, TRAF6</italic> recurrent mutations also have the simplest composition and are almost exclusively missense mutations (93%, 38/41) except 2 truncations and 1 frameshift insertion (Table <xref ref-type="table" rid="T1">1</xref> and Figure <xref ref-type="fig" rid="F2">2</xref>). These recurrent mutations occurred at 30 different amino acids that are distributed in all the major domains but are enriched in the coiled-coil and TRAF-C domains of the TRAF6 protein (Figure <xref ref-type="fig" rid="F3">3</xref>). Mutations of only two specific amino acids, R335 and P398, are detected in more than three patients (Figure <xref ref-type="fig" rid="F3">3</xref>). A truncation (R335<sup>*</sup>) and missense mutation (R335Q) at R335 within the coiled-coil domain of TRAF6 are detected in five patients with colon and uterine cancers (TCGA) (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B234">234</xref>). Missense mutations at P398 (P398L or S) of the TRAF-C domain are identified in 4 patients with uterine, lung, and stomach cancers (TCGA) (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B193">193</xref>, <xref ref-type="bibr" rid="B235">235</xref>). Functional significance of these <italic>TRAF6</italic> recurrent mutations in cancer pathogenesis remains to be elucidated.</p>
</sec>
<sec>
<title><italic>In vivo</italic> evidence of potential roles for TRAF6 in tumorigenesis</title>
<p>Causal roles of TRAF6 in tumorigenesis have not been directly demonstrated with <italic>TRAF6</italic> knockout or transgenic mice yet. However, available <italic>in vivo</italic> evidence supports potential contributions of TRAF6 dysregulation in tumorigenesis. Consistent with the genetic alterations (mainly amplification and mutation) and frequent overexpression of TRAF6 detected in human epithelial cancers such as breast cancer and uterine cancer (Figure <xref ref-type="fig" rid="F1">1A</xref>) (<xref ref-type="bibr" rid="B229">229</xref>–<xref ref-type="bibr" rid="B233">233</xref>), deletion of <italic>TRAF6</italic> in mice results in loss of NF-κB activity in epithelia and vasculature during mouse development (Table <xref ref-type="table" rid="T2">2</xref>) (<xref ref-type="bibr" rid="B78">78</xref>). Corroborating initial evidence, intestinal epithelial cell-specific TRAF6<sup>−/−</sup> mice exhibit exacerbated DSS-induced colitis (<xref ref-type="bibr" rid="B87">87</xref>). In line with the <italic>in vivo</italic> data, knockdown of TRAF6 or inhibition of TRAF6 E3 ligase activity suppresses the survival, proliferation, migration, and metastasis of many human epithelial cancers, including breast, lung, liver, and colon cancers as well as HNSCC (<xref ref-type="bibr" rid="B230">230</xref>–<xref ref-type="bibr" rid="B232">232</xref>, <xref ref-type="bibr" rid="B236">236</xref>–<xref ref-type="bibr" rid="B240">240</xref>). In the majority of these cases, the TRAF6-NF-κB axis is identified as the main oncogenic pathway, which is constitutively activated by TRAF6 overexpression or hyperactivated by upstream receptors such as TNFα, RANK, and TLR4/3 (<xref ref-type="bibr" rid="B236">236</xref>–<xref ref-type="bibr" rid="B240">240</xref>).</p>
<p>Similar findings have been obtained in the hematopoietic/lymphoid system. Hematopoietic-specific deletion of <italic>TRAF6</italic> in mice leads to decreased tonic IKKβ-NF-κB activation, impaired hematopoietic stem cell (HSC) self-renewal and loss of hematopoietic stem/progenitor cells (HSPCs) in the bone marrow (BM) (Table <xref ref-type="table" rid="T2">2</xref>) (<xref ref-type="bibr" rid="B81">81</xref>). Knockdown of TRAF6 in human AML cell lines or patient samples results in rapid apoptosis and impaired malignant HSPC function as well as increased sensitivity to bortezomib (<xref ref-type="bibr" rid="B241">241</xref>). In the lymphoid lineage, <italic>TRAF6</italic> mutations have been detected in 2.1% human DLBCL (TCGA) and 2.4% human cutaneous T cell lymphoma (CTCL) (<xref ref-type="bibr" rid="B242">242</xref>). TRAF6<sup>−/−</sup> mice have reduced numbers of immature B cells in the BM and B cells from the null mice show defects in CD40 and LPS-induced proliferation and NF-κB activation (Table <xref ref-type="table" rid="T2">2</xref>) (<xref ref-type="bibr" rid="B74">74</xref>, <xref ref-type="bibr" rid="B75">75</xref>). B cell-specific TRAF6<sup>−/−</sup> mice (B-TRAF6<sup>−/−</sup>) mice also exhibit reduced numbers of mature B cells in the BM and spleen as well as defective B1 B cell development (Table <xref ref-type="table" rid="T2">2</xref>) (<xref ref-type="bibr" rid="B82">82</xref>). Knockdown of TRAF6 or inhibition of the TRAF6-NF-κB axis induces apoptosis and cell cycle arrest in DLBCL, and also inhibits the proliferation and bone resorption of MM (<xref ref-type="bibr" rid="B243">243</xref>, <xref ref-type="bibr" rid="B244">244</xref>). Interestingly, T cell-specific TRAF6<sup>−/−</sup> mice (T-TRAF6<sup>−/−</sup>) mice show multiorgan inflammation due to hyperactivation of the PI3K-Akt pathway in T cells (Table <xref ref-type="table" rid="T2">2</xref>) (<xref ref-type="bibr" rid="B83">83</xref>). T-TRAF6<sup>−/−</sup> mice also exhibit increased Th17 differentiation due to enhanced sensitivity of CD4 T cells to TGFβ signaling (<xref ref-type="bibr" rid="B85">85</xref>), but have defects in generating CD8 memory T cells caused by defective AMPK activation in activated CD8 T cells (<xref ref-type="bibr" rid="B84">84</xref>). In addition, T-TRAF6<sup>−/−</sup> mice exhibit impaired OX40-induced CD4 Th9 differentiation, which requires TRAF6-mediated activation of the NIK-NF-κB2 pathway in CD4 T cells (Table <xref ref-type="table" rid="T2">2</xref>) (<xref ref-type="bibr" rid="B86">86</xref>). In support of a role for TRAF6 in T cell tumorigenesis, inhibition of the TRAF6-NF-κB-c-Myc axis through miR-146a/b-mediated downregulation of TRAF6 delays PTEN<sup>−/−</sup> T cell lymphomagenesis in mice (<xref ref-type="bibr" rid="B245">245</xref>). Furthermore, inhibition of the IRAK1/4-TRAF6 axis sensitizes human T cell ALL (T-ALL) to chemotherapies (<xref ref-type="bibr" rid="B246">246</xref>). Collectively, the above evidence is consistent with the hypothesis that TRAF6 may serve as an oncoprotein in epithelial cancers and hematopoietic/lymphoid neoplasms mainly through inducing aberrant NF-κB activation.</p>
<p>Interestingly, <italic>in vivo</italic> evidence also indicates the functional importance of TRAF6 in the brain and muscle (Table <xref ref-type="table" rid="T2">2</xref>). TRAF6<sup>−/−</sup> mice show defective neural tube closure and exencephaly (<xref ref-type="bibr" rid="B80">80</xref>). Mechanistically, TRAF6 interacts with the p75 neurotrophin receptor (p75NTR), and thus is required for NGF-induced NF-κB activation and survival in Schwann cells as well as BDNF-induced JNK activation and apoptosis in superior cervical ganglia neurons (<xref ref-type="bibr" rid="B79">79</xref>). In skeletal muscle, TRAF6 deficiency prevents muscle loss and cancer cachexia in response to transplanted tumor growth, improves regeneration of myofibers upon injury and reduces skeletal muscle atrophy upon starvation through regulating NF-κB activation/ubiquitin-proteasome/autophagy-lysosomal systems, Akt/FoxO3a/AMPK activation and Notch signaling, respectively (<xref ref-type="bibr" rid="B88">88</xref>–<xref ref-type="bibr" rid="B90">90</xref>). In line with the mouse data, genetic alterations of <italic>TRAF6</italic>, including amplification, mutation and deletion, are detected in 1% of human glioblastoma (<xref ref-type="bibr" rid="B247">247</xref>, <xref ref-type="bibr" rid="B248">248</xref>) and 3% of human sarcoma (TCGA) (<xref ref-type="bibr" rid="B9">9</xref>). It would be interesting to test potential causal roles of TRAF6 in brain and muscle tumorigenesis in future studies.</p>
</sec>
<sec>
<title>Key signaling pathways in human cancers</title>
<p>In addition to the TRAF6-NF-κB axis that has been verified in both human cancers and <italic>in vivo</italic> mouse models, numerous TRAF6-dependent oncogenic pathways have been reported with studies of patient samples, cultured human cancer cells or their xenografts in mice. Examples are: (1) the TRAF6-p53 crosstalk, in which TRAF6 promotes K63-linked ubiquitination of p53 and limits the tumor suppressive function of p53 in cancer development and resistance to chemotherapy and radiotherapy (<xref ref-type="bibr" rid="B249">249</xref>); (2) the Ras-TRAF6-NF-κB axis in the tumorigenesis of lung and pancreatic cancers (<xref ref-type="bibr" rid="B227">227</xref>, <xref ref-type="bibr" rid="B250">250</xref>, <xref ref-type="bibr" rid="B251">251</xref>); (3) the TRAF6-Akt axis in the tumorigenesis of glioblastoma, HNSCC, prostate cancer, oral cancer, and CRC (<xref ref-type="bibr" rid="B252">252</xref>–<xref ref-type="bibr" rid="B255">255</xref>); (4) the EGFR-TRAF6 axis in the growth, migration and metastasis of lung cancer and cutaneous SCC (<xref ref-type="bibr" rid="B256">256</xref>, <xref ref-type="bibr" rid="B257">257</xref>); (5) the TRAF6-HIF1α axis in the tumorigenesis, angiogenesis, and metastasis of breast and colon cancers (<xref ref-type="bibr" rid="B258">258</xref>, <xref ref-type="bibr" rid="B259">259</xref>); (6) the TGFβ-TβRI/II-TRAF6 axis in the proliferation, migration, and invasion of prostate cancer (<xref ref-type="bibr" rid="B260">260</xref>–<xref ref-type="bibr" rid="B263">263</xref>); (7) TRAF6-AEP-HSP90α in the invasion and metastasis of breast cancer (<xref ref-type="bibr" rid="B229">229</xref>); (8) nutrients-MEKK3-MEK3/6-p38δ-p62-TRAF6-mTORC1 in the growth of prostate cancer (<xref ref-type="bibr" rid="B264">264</xref>); (9) pVHL inactivation-CARD9-BCL10-TRAF6-TAK1-MKK4-JNK-AP1-Twist in the EMT of renal cell carcinoma (<xref ref-type="bibr" rid="B265">265</xref>); (10) ADAM10-p75NTR ICD-TRAF6 in the metastasis and chemoresistance of HNSCC and breast cancer (<xref ref-type="bibr" rid="B266">266</xref>); (11) TRAF6-DNMT1-DNA methylation in chemoresistance of breast cancer (<xref ref-type="bibr" rid="B267">267</xref>); and (12) IL-1β-TRAF6-TNFα and TRAF6-Cdc42-F-actin in the invasion of SCC (<xref ref-type="bibr" rid="B268">268</xref>). Interestingly, the importance of TRAF6-dependent oncogenic pathways in human cancers is also underscored by the findings that <italic>TRAF6</italic> mRNA is the direct target of tumor suppressive mi-RNAs, including miR-146a (<xref ref-type="bibr" rid="B269">269</xref>–<xref ref-type="bibr" rid="B274">274</xref>), and miR-141-3p (<xref ref-type="bibr" rid="B223">223</xref>). Thus, most evidence indicates that <italic>TRAF6</italic> is an oncogene in human cancers.</p>
<p>Intriguingly, several TRAF6-dependent tumor suppressive pathways have also been described for human cancers in the literature. Examples are: (1) TRAF6-p62-mediated inhibition of the HK2 glycolytic activity and the growth of liver cancer, in which TRAF6 catalyzes the K63-linked ubiquitination of HK2 and targets HK2 for p62-mediated autophagic degradation (<xref ref-type="bibr" rid="B275">275</xref>); (2) TRAF6-mediated suppression of the EZH2-H3K27me3 pathway and the progression of prostate cancer, in which TRAF6 mediates K63-linked ubiquitination and degradation of EZH2 (<xref ref-type="bibr" rid="B276">276</xref>); and (3) TRAF6-mediated decrease of the H3K4me3 level and thus the tumorigenesis of prostate cancer, in which TRAF6 mediates K63-linked ubiquitination of JARID1B to increase the demethylase activity of JARID1B on H3K4me3 (<xref ref-type="bibr" rid="B277">277</xref>). Taken together, both tumor suppressive and oncogenic roles of TRAF6 have been reported in human liver cancer and prostate cancer. As discussed for TRAF2, this phenomenon may be related to the mutational profile and malignant stage of the cancer cells as well as the nature of the environmental cue or treatment regimen.</p>
</sec>
</sec>
<sec id="s8">
<title>TRAF7</title>
<sec>
<title>Landscape of genetic alterations</title>
<p>TRAF7 lacks the TRAF homology domain and does not directly interact with any member of the TNFR superfamily, two defining features of the TRAF family (<xref ref-type="bibr" rid="B278">278</xref>, <xref ref-type="bibr" rid="B279">279</xref>), and is therefore still controversial to be considered as a genuine member of the TRAF family. The frequency of genetic alterations of TRAF7 is generally &lt;7% in human cancers (Figure <xref ref-type="fig" rid="F1">1A</xref>) according to the TCGA and COSMIC datasets of sample size n &gt; 150. The eight human cancers with relatively higher genetic alterations of <italic>TRAF7</italic> are breast cancer (6%) (<xref ref-type="bibr" rid="B189">189</xref>), prostate cancer (5.1%) (<xref ref-type="bibr" rid="B280">280</xref>), stomach cancer (4.8%) (8), sarcoma (3.8%) (TCGA, Provisional), esophageal cancer (3.3%) (TCGA, PanCancer Atlas), uterine cancer (3.2%) (TCGA, PanCancer Atlas), melanoma (3.1%) (TCGA, PanCancer Atlas), and liver cancer (2.4%) (TCGA, PanCancer Atlas). However, it should be noted that although not yet cataloged in TCGA, the rate of <italic>TRAF7</italic> mutation is overwhelmingly high in patients with adenomatoid tumors of the male and female genital tracts (100%, 31/31) (<xref ref-type="bibr" rid="B281">281</xref>), secretory meningiomas (97%, 29/30) (<xref ref-type="bibr" rid="B282">282</xref>), intraneural perineuriomas (62.5%, 10/16) (<xref ref-type="bibr" rid="B283">283</xref>), and meningiomas 23% (182/775) (<xref ref-type="bibr" rid="B284">284</xref>) (Figure <xref ref-type="fig" rid="F1">1B</xref>). In particular, high frequencies (15–26%) of <italic>TRAF7</italic> mutations has been reproducibly detected in multiple studies (<xref ref-type="bibr" rid="B284">284</xref>–<xref ref-type="bibr" rid="B288">288</xref>), and knowledge of <italic>TRAF7</italic> mutations has contributed significantly to improving the diagnosis, classification, prognosis, and treatment of patients with meningiomas (<xref ref-type="bibr" rid="B282">282</xref>, <xref ref-type="bibr" rid="B286">286</xref>, <xref ref-type="bibr" rid="B289">289</xref>–<xref ref-type="bibr" rid="B291">291</xref>). Additionally, deletion of <italic>TRAF7</italic> is detected in 67% (18/27) of malignant mesothelioma patients' malignant cells in pleural fluids (<xref ref-type="bibr" rid="B292">292</xref>). The most common genetic alteration of <italic>TRAF7</italic> is mutation, followed by amplification and then deep deletion (Figure <xref ref-type="fig" rid="F1">1</xref>). Truncation and fusion of <italic>TRAF7</italic> are rarely detected in human cancers.</p>
</sec>
<sec>
<title>Overview and map of recurrent mutations</title>
<p>In the <italic>TRAF</italic> family, <italic>TRAF7</italic> has the highest counts of total and recurrent mutations. There are 376 different mutations of <italic>TRAF7</italic> detected in human cancers, including 87% (326/376) coding-altering mutations and 13% (50/376) coding silent mutations (Table <xref ref-type="table" rid="T1">1</xref>). Over half (53%, 174/326) of the <italic>TRAF7</italic> coding-altering mutations are recurrently detected in at least two cancer patients. <italic>TRAF7</italic> recurrent mutations are mostly missense mutations (92%, 161/174). Small percentages of other recurrent mutations include 5 frameshifts, 3 truncations, 2 in frame deletions, 2 splice mutations, and 1 fusion (Table <xref ref-type="table" rid="T1">1</xref> and Figure <xref ref-type="fig" rid="F2">2</xref>). These recurrent mutations occurred at 89 different amino acids covering different regions of the entire length but highly enriched in the last 4 WD40 repeats of the TRAF7 protein (Figure <xref ref-type="fig" rid="F3">3</xref>). Of particular interest, missense mutations of six specific amino acids located within the C-terminal WD40 repeats, N520, H521, G536, S561, K615, and R641, are identified as mutation hotspots of <italic>TRAF7</italic> detected in more than 15 cancer patients (Figure <xref ref-type="fig" rid="F3">3</xref>). N520 mutations (N520S, H, Y, or T) are found in 31 patients with meningioma, mesothelioma, sarcoma and colon cancer (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B106">106</xref>, <xref ref-type="bibr" rid="B282">282</xref>, <xref ref-type="bibr" rid="B284">284</xref>, <xref ref-type="bibr" rid="B285">285</xref>, <xref ref-type="bibr" rid="B293">293</xref>, <xref ref-type="bibr" rid="B294">294</xref>). Mutations of the next amino acid H521 (H521R or N) are identified in 15 patients with adenomatoid tumor, perineurioma, and meningioma (<xref ref-type="bibr" rid="B281">281</xref>, <xref ref-type="bibr" rid="B283">283</xref>, <xref ref-type="bibr" rid="B284">284</xref>). G536 mutations (G536S or V) are detected in 16 patients with meningioma, pancreatic cancer, mesothelioma and stomach cancer (<xref ref-type="bibr" rid="B106">106</xref>, <xref ref-type="bibr" rid="B282">282</xref>, <xref ref-type="bibr" rid="B284">284</xref>, <xref ref-type="bibr" rid="B285">285</xref>, <xref ref-type="bibr" rid="B293">293</xref>–<xref ref-type="bibr" rid="B295">295</xref>). S561 mutations (S561R, N or T) are identified in 19 patients with adenomatoid tumor, perineurioma and meningioma (<xref ref-type="bibr" rid="B281">281</xref>, <xref ref-type="bibr" rid="B283">283</xref>, <xref ref-type="bibr" rid="B284">284</xref>). K615E mutations are detected in 15 patients with meningioma and OSCC (<xref ref-type="bibr" rid="B284">284</xref>, <xref ref-type="bibr" rid="B296">296</xref>). R641 mutations (R641H, C, P, or L) are detected in 24 patients with uterine, bile duct, colon, stomach and lung cancers and meningioma (TCGA, PanCancer Atlas) (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B106">106</xref>, <xref ref-type="bibr" rid="B282">282</xref>, <xref ref-type="bibr" rid="B284">284</xref>, <xref ref-type="bibr" rid="B285">285</xref>, <xref ref-type="bibr" rid="B294">294</xref>, <xref ref-type="bibr" rid="B297">297</xref>–<xref ref-type="bibr" rid="B299">299</xref>). Although the functional significance of most <italic>TRAF7</italic> mutations is currently unclear, the exceptionally high recurrence and clustering of missense mutations implicate TRAF7 malfunction as a critical pathogenic event in relevant human cancers.</p>
</sec>
<sec>
<title>Fusion</title>
<p>There are six different fusions of <italic>TRAF7</italic> and other genes detected in human cancers, including <italic>TRAF7-LRRC1</italic> in lung cancer, <italic>GFER-TRAF7</italic> in mesothelioma, <italic>CORO7-TRAF7</italic> in glioma, <italic>TRAF7-MAPK8IP3</italic> in bladder cancer, and <italic>TRAF7-RAB26</italic> and <italic>E4F1-TRAF7</italic> in ovarian cancer (TCGA) (<xref ref-type="bibr" rid="B106">106</xref>). Among these, only the <italic>TRAF7-LRRC1</italic> fusion is recurrently detected in two patients with lung cancer (TCGA). However, all the <italic>TRAF7</italic> gene fusions have not been verified at the protein level and their functional consequence is unknown.</p>
</sec>
<sec>
<title><italic>In vivo</italic> evidence of potential roles in cancer pathogenesis</title>
<p>No TRAF7<sup>−/−</sup> or TRAF7-tg mouse model has been published yet. Importantly however, Tokita et al. recently reported that <italic>de novo</italic> missense mutations in <italic>TRAF7</italic> cause developmental abnormalities and other clinical symptoms in seven unrelated patients, including developmental delay (5/5), congenital heart defects (6/7), limb and digital anomalies (7/7), and dysmorphic facial features (7/7) (<xref ref-type="bibr" rid="B300">300</xref>). <italic>TRAF7</italic> mutations identified in this study include a recurrent R655Q mutation found in four patients, and another 3 single mutations each identified in one patient, including K346E, R371G, and T601A (<xref ref-type="bibr" rid="B300">300</xref>). Interestingly, R371 recurrent mutations are also detected in human cancers (Figure <xref ref-type="fig" rid="F3">3</xref>). K346 is a ubiquitination site of TRAF7 (<xref ref-type="bibr" rid="B301">301</xref>). Both K346 and R371 are located in the coiled-coil domain of TRAF7 that is important for TRAF7 homodimerization (<xref ref-type="bibr" rid="B302">302</xref>, <xref ref-type="bibr" rid="B303">303</xref>). The recurrent R655Q mutation has also been previously identified as a <italic>de novo</italic> event in an autism patient (<xref ref-type="bibr" rid="B304">304</xref>). Both T601 and R665 are located in the C-terminal WD40 repeats of TRAF7, which contain most mutation hotspots of <italic>TRAF7</italic> detected in human cancers (Figure <xref ref-type="fig" rid="F3">3</xref>) and are known to mediate the interaction of TRAF7 with MEKK3 or c-Myb (<xref ref-type="bibr" rid="B302">302</xref>, <xref ref-type="bibr" rid="B305">305</xref>). Tokita et al. further revealed that transfection of the R665Q, T601A, or R371G mutants of <italic>TRAF7</italic> into HEK293T cells results in significantly reduced levels of ERK1/2 phosphorylation, both basal and in response to TNFα signaling (<xref ref-type="bibr" rid="B300">300</xref>). Consistent with this biochemical evidence, conditional ERK2<sup>−/−</sup> mice show a phenotype mirroring that observed in the seven patients with <italic>TRAF7</italic> mutations, including craniofacial abnormalities, cardiovascular malformations and limb defects (<xref ref-type="bibr" rid="B306">306</xref>). These highly interesting findings warrant further investigation of the <italic>in vivo</italic> functions of <italic>TRAF7</italic> mutations in cancer pathogenesis using animal models.</p>
</sec>
<sec>
<title>TRAF7-mediated signaling pathways</title>
<p>Compared to other TRAF proteins, the signaling mechanisms of TRAF7 are understudied and remain poorly defined (<xref ref-type="bibr" rid="B289">289</xref>, <xref ref-type="bibr" rid="B307">307</xref>). In addition to the above TRAF7-ERK1/2 pathway revealed by studying <italic>TRAF7</italic> mutants of patients with developmental defects, the following TRAF7 signaling pathways have been proposed based on <italic>in vitro</italic> studies. (1) Transfection of tumor-derived <italic>TRAF7</italic> mutants (H521R, Y538S, or S561R) but not WT <italic>TRAF7</italic> in 293T cells causes increased phosphorylation of RelA and expression of the NF-κB target gene L1CAM, which is also elevated in adenomatoid tumors (<xref ref-type="bibr" rid="B281">281</xref>). (2) Overexpression of <italic>TRAF7</italic> or TNFα induces caspase-dependent apoptosis in HEK293 and HeLa cells via the TRAF7-MEKK3-NF-κB/p38/JNK-AP1/CHOP pathway, in which TRAF7 interacts with MEKK3 and potentiates the kinase activity of MEKK3 (<xref ref-type="bibr" rid="B302">302</xref>, <xref ref-type="bibr" rid="B303">303</xref>). (3) TRAF7 mediates TNFα-induced apoptosis in Jurkat and HeLa cells via promoting the K29-, K33-, and K63-linked ubiquitination and lysosomal degradation of c-FLIP, an inhibitor of caspase activation (<xref ref-type="bibr" rid="B308">308</xref>). (4) TRAF7 represses TNFα-induced NF-κB activation to enhance apoptosis in HEK293 cells by promoting K29-linked ubiquitination and lysosomal degradation of NEMO and RelA (<xref ref-type="bibr" rid="B309">309</xref>). Paradoxically, TRAF7 is identified as an activator of the NEMO-RelA-NF-κB-cyclin D1 pathway in mouse myoblasts and thus a suppressor of myoblast differentiation (<xref ref-type="bibr" rid="B310">310</xref>). (5) TRAF7 participates in TLR2-induced production of inflammatory cytokines (TNFα, IL-1β, and IL-8) in A549 and HeLa cells by acting in the TLR2-TRAF6/TRAF7-IKK1/2/NEMO-NF-κB and TLR2-TRAF6/TRAF7-MKK3/6-p38 pathways (<xref ref-type="bibr" rid="B311">311</xref>). (6) TRAF7 inhibits the transcriptional activity of the oncoprotein c-Myb in M1 mouse leukemia cells and DND39 human Burkitt's B lymphoma cells by directly interacting with c-Myb and stimulating the sumoylation of c-Myb to sequester c-Myb in the cytoplasm (<xref ref-type="bibr" rid="B305">305</xref>). (7) TRAF7 mediates K48-linked ubiquitination of p53 as demonstrated by an <italic>in vitro</italic> ubiquitination assay, which likely induces p53 degradation. Correspondingly, TRAF7 protein is downregulated and p53 protein is upregulated in a panel of breast cancer specimens, and TRAF7 downregulation correlates with poor prognosis in breast cancer (<xref ref-type="bibr" rid="B312">312</xref>). In summary, WT TRAF7 appears to be a tumor suppressor that promotes cell apoptosis. <italic>TRAF7</italic> mutations or downregulated protein levels may lead to aberrant NF-κB activation or altered signaling of ERK1/2, p38, JNK, c-FLIP, c-Myb, or p53 to drive tumorigenesis. Further studies are required to clarify the roles and mechanisms of <italic>TRAF7</italic> alterations in cancer pathogenesis.</p>
</sec>
</sec>
<sec id="s9">
<title>Combined genetic alterations of all <italic>TRAFs</italic> in the same human cancer</title>
<p>After analyzing the genetic alterations of each <italic>TRAF</italic> gene in human cancers individually, we next examined the combined genetic alterations of all <italic>TRAFs</italic> in the same type of human cancer using the TCGA tool. Although the frequency of the genetic alterations of each <italic>TRAF</italic> is generally low (usually &lt;5%), their combined rate is substantially increased to 10–35% in many types of human cancers (Figure <xref ref-type="fig" rid="F4">4</xref>) (TCGA). For example, the combined frequency of gene amplification of all seven TRAFs is 35% (709/2015) in breast cancer (<xref ref-type="bibr" rid="B313">313</xref>, <xref ref-type="bibr" rid="B314">314</xref>). The combined frequency of genetic alterations of all seven TRAFs is 23% (71/311) in ovarian cancer (TCGA, Provisional), 19% (77/408) in bladder cancer (<xref ref-type="bibr" rid="B152">152</xref>), 19% (45/240) in uterine cancer (<xref ref-type="bibr" rid="B193">193</xref>), 17% (81/469) in lung cancer (TCGA, PanCancer Atlas), 15% (41/265) in oesophageal cancer (<xref ref-type="bibr" rid="B315">315</xref>), 14% (48/353) in liver cancer (TCGA, PanCancer Atlas), 13% (35/279) in HNSCC (<xref ref-type="bibr" rid="B113">113</xref>), 13% (36/278) in cervical cancer (TCGA, PanCancer Atlas), 13% (58/438) in melanoma (TCGA, PanCancer Atlas), 12% (46/389) in colon cancer (TCGA, PanCancer Atlas), and 10% (106/1013) in prostate cancer (<xref ref-type="bibr" rid="B98">98</xref>). It is interesting that genetic alterations of different <italic>TRAFs</italic> are often mutually exclusive in the same cancer patient and simultaneous genetic alterations of two or three different <italic>TRAFs</italic> in the same cancer patient are generally rare events (Figure <xref ref-type="fig" rid="F4">4</xref>) except for ovarian cancer (TCGA, Provisional), uterine cancer and melanoma (TCGA, PanCancer Atlas).</p>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<p>Combined genetic alterations of the <italic>TRAF</italic> family in human cancers. Representative results of the combined genetic alterations of the <italic>TRAF</italic> family in individual human cancers are retrieved from TCGA, specifically bladder cancer, lung cancer, melanoma, cervical cancer, HNSCC, and colon cancer. The sample size and the number of patients containing genetic alterations of <italic>TRAFs</italic> as well as the frequency of each <italic>TRAF</italic> alteration are indicated for each type of cancer in the figure. The nature of <italic>TRAF</italic> genetic alteration identified in each patient is indicated by a mutation symbol as shown at the bottom legend of the figure.</p>
</caption>
<graphic xlink:href="fimmu-09-02111-g0004"></graphic>
</fig>
<p>We summarize key oncogenic pathways that involve multiple TRAF proteins in skin carcinogenesis as depicted in Figure <xref ref-type="fig" rid="F5">5</xref> as well as in B cell malignancies as depicted in Figure <xref ref-type="fig" rid="F6">6</xref>, both of which have been verified by studies of human cancers and <italic>in vivo</italic> mouse models. However, we believe current understanding only represents “the tip of the iceberg” of oncogenic mechanisms involving TRAF proteins. Given the often mutually exclusive genetic alterations of different TRAFs in the same cancer, it is very likely that all seven TRAFs may have non-overlapping and distinct contributions to different aspects or at different stages of the initiation, progression and metastasis of the same cancer. These unanswered questions represent fascinating areas for future exploration.</p>
<fig id="F5" position="float">
<label>Figure 5</label>
<caption>
<p>Causal roles and signaling mechanisms of TRAF proteins in skin carcinogenesis. Evidence of both genetic alterations of <italic>TRAFs</italic> in human patients as well as <italic>in vivo</italic> TRAF<sup>−/−</sup> mouse models indicates that alterations of multiple TRAF proteins, specifically TRAF1, TRAF2, and TRAF4, play causal roles in skin carcinogenesis. Oncogenic TRAF proteins (TRAF1 and TRAF4) are depicted in red, while tumor suppressive TRAF2 proteins are depicted in blue. This figure depicts a simplified model of keratinocyte-intrinsic, TRAF-dependent signaling mechanisms in skin carcinogenesis. Only key TRAF-dependent receptors, TRAF-interacting proteins and downstream kinases and transcription factors that have been verified in both human cancers and <italic>in vivo</italic> mouse models are shown. Keratinocyte-extrinsic, indirect mechanisms of TRAF proteins in skin carcinogenesis are not depicted in the figure, including the known roles of TRAFs in tumor immunity, inflammation and bone resorption and thus their indirect contributions in tumorigenesis and metastasis.</p>
</caption>
<graphic xlink:href="fimmu-09-02111-g0005"></graphic>
</fig>
<fig id="F6" position="float">
<label>Figure 6</label>
<caption>
<p>Complex protective and pathogenic roles as well as signaling mechanisms of TRAF proteins in B cell malignancies. Evidence of both genetic alterations of <italic>TRAFs</italic> in human patients as well as <italic>in vivo</italic> TRAF knockout and transgenic mouse models indicates that alterations of multiple TRAF proteins, specifically TRAF1, TRAF2, TRAF3, TRAF5, and TRAF6, play causal roles in the pathogenesis of B cell malignancies, such as B lymphomas and multiple myeloma. Tumor suppressive TRAF proteins (TRAF2 and TRAF3) are depicted in blue, while oncogenic TRAF proteins (TRAF1, TRAF5, and TRAF6) are depicted in red. This figure depicts a simplified model of B cell-intrinsic, TRAF-dependent signaling mechanisms in B cell malignancies. Only key TRAF-dependent receptors, TRAF-interacting proteins and downstream kinases and transcription factors that have been verified in both human cancers and <italic>in vivo</italic> mouse models are shown. Potential contribution of TRAF1, TRAF2, and TRAF6 in LMP1 signaling, TRAF6 in B cell receptor (BCR) signaling and TRAFs in CD40- and LMP1-induced activation of PI-3K-Akt to B cell tumorigenesis are not included in the figure.</p>
</caption>
<graphic xlink:href="fimmu-09-02111-g0006"></graphic>
</fig>
</sec>
<sec id="s10">
<title>TRAF proteins in pathogen-induced carcinogenesis</title>
<p>The importance of TRAF proteins in cancer pathogenesis is strengthened by mounting evidence that demonstrates their involvement in pathogen-mediated carcinogenesis in certain human cancers. For example, chronic infection with the bacteria <italic>Helicobacter pylori (H. pylori)</italic> is a major cause of gastric cancer. <italic>H. pylori</italic> infection induces TRAF1 overexpression and the expression of the transcription factor Cdx2 in both human gastric epithelial cells and mice, which are mainly driven by NF-κB activation. TRAF1 overexpression plays an antiapoptotic role in <italic>H. pylori</italic>-infected gastric cells (<xref ref-type="bibr" rid="B316">316</xref>). Induction of Cdx2 contributes to intestinal metaplasia, a precursor event to gastric cancer. Interestingly, TRAF3 inhibits <italic>H. pylori</italic> infection-induced NF-κB activation and Cdx2 expression, and is required to resist the infection by acting in the NOD1-RIP2-TRAF3 pathway in gastric epithelial cells (<xref ref-type="bibr" rid="B317">317</xref>, <xref ref-type="bibr" rid="B318">318</xref>). Furthermore, the oncoprotein <italic>cag</italic> PAI of <italic>H. pylori</italic> activates NF-κB and induces IL-8 secretion through the TRAF2/TRAF6-NIK-IKK pathway in gastric cancer cells (<xref ref-type="bibr" rid="B319">319</xref>). Another carcinogenic factor, Tip-α, of <italic>H. pylori</italic> activates NF-κB by inhibiting the expression of miR-3178, which directly targets TRAF3 mRNA for downregulation, in gastric epithelial cells (<xref ref-type="bibr" rid="B320">320</xref>). Therefore, <italic>H. pylori</italic> chronic infection-induced gastric tumorigenesis involves activation of TRAF1, TRAF2, and <italic>TRAF6</italic> as well as inhibition of TRAF3 (Table <xref ref-type="table" rid="T3">3</xref>).</p>
<table-wrap id="T3" position="float">
<label>Table 3</label>
<caption>
<p>Pathogen-encoded proteins that exploit or target TRAFs to induce carcinogenesis in humans.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Pathogen proteins</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>TRAFs</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Mechanisms</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Cancer type</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>References</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="5" rowspan="1" style="background-color:#bcbdc0" valign="top">
<bold>BACTERIAL ONCOPROTEINS</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cag PAI of <italic>H. pylori</italic></td>
<td align="left" colspan="1" rowspan="1" valign="top">TRAF1, 2, 6</td>
<td align="left" colspan="1" rowspan="1" valign="top">Utilizes TRAF1, 2, and 6 to induce NF-κB activation and IL-8 secretion</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gastric cancer</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B316">316</xref>, <xref ref-type="bibr" rid="B319">319</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Tip-α of <italic>H. pylori</italic></td>
<td align="left" colspan="1" rowspan="1" valign="top">TRAF3</td>
<td align="left" colspan="1" rowspan="1" valign="top">Induces TRAF3 protein and NF-κB activation by inhibiting miR-3178 expression, which targets TRAF3</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gastric cancer</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B320">320</xref>)</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" style="background-color:#bcbdc0" valign="top">
<bold>VIRAL ONCOPROTEINS</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">LMP1 of EBV</td>
<td align="left" colspan="1" rowspan="1" valign="top">TRAF1, 2, 3, 5, 6</td>
<td align="left" colspan="1" rowspan="1" valign="top">Sequesters cellular TRAF3, and usurps TRAF1, 2, 3, 5, and 6 to mimic constitutively activated CD40 signaling, induces NF-κB1 and NF-κB2 activation, and induces</td>
<td align="left" colspan="1" rowspan="1" valign="top">B lymphomas</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B172">172</xref>, <xref ref-type="bibr" rid="B173">173</xref>, <xref ref-type="bibr" rid="B321">321</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">EGFR expression</td>
<td align="left" colspan="1" rowspan="1" valign="top">Nasopharyngeal carcinoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B322">322</xref>–<xref ref-type="bibr" rid="B324">324</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">TRAF5, 6</td>
<td align="left" colspan="1" rowspan="1" valign="top">Recruits TRAF5 and 6 to activate p38 and suppress the replication of EBV, maintaining the lalent state of EBV</td>
<td align="left" colspan="1" rowspan="1" valign="top">Burkitt's lymphoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B325">325</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">v-FLIP of KSHV</td>
<td align="left" colspan="1" rowspan="1" valign="top">TRAF2, 3</td>
<td align="left" colspan="1" rowspan="1" valign="top">Recruits TRAF2 and 3 to activate NF-κB and JNK, and to induce cell survival</td>
<td align="left" colspan="1" rowspan="1" valign="top">Primary effusion lymphoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B326">326</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">pUL48 of HCMV</td>
<td align="left" colspan="1" rowspan="1" valign="top">TRAF3, 6</td>
<td align="left" colspan="1" rowspan="1" valign="top">Deubiquitinates TRAF3 and 6 to inhibit type I IFN production, enhances cellular metabolic activity and upregulates anti-apoptotic proteins</td>
<td align="left" colspan="1" rowspan="1" valign="top">Breast cancer, glioma</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B327">327</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">E6 protein of HPV</td>
<td align="left" colspan="1" rowspan="1" valign="top">TRAF3</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibits p53 and RB expression, but E6 protein levels are inhibited by TRAF3</td>
<td align="left" colspan="1" rowspan="1" valign="top">HNSCC</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B328">328</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Core protein of HCV</td>
<td align="left" colspan="1" rowspan="1" valign="top">TRAF2, 5, 6</td>
<td align="left" colspan="1" rowspan="1" valign="top">Interacts with TRAF2, 5, and 6 to activate NF-κB and induce inflammation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hepatocellular carcinoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B329">329</xref>, <xref ref-type="bibr" rid="B330">330</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Tax of HTLV-1</td>
<td align="left" colspan="1" rowspan="1" valign="top">TRAF3, 6</td>
<td align="left" colspan="1" rowspan="1" valign="top">Interacts with TRAF3 and 6 to induce TBK1-IKKε activation, type I IFN production and Mcl-1 stabilization</td>
<td align="left" colspan="1" rowspan="1" valign="top">T cell leukemia</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B331">331</xref>, <xref ref-type="bibr" rid="B332">332</xref>)</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" style="background-color:#bcbdc0" valign="top">
<bold>VIRAL TUMOR SUPPRESSORS</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">E2 protein of HPV</td>
<td align="left" colspan="1" rowspan="1" valign="top">TRAF5, 6</td>
<td align="left" colspan="1" rowspan="1" valign="top">Interacts with TRAF5 and 6, promotes K63-linked ubiquitination of TRAF5, and potentiates TNFα-induced NF-κB activation by activating TRAF5</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cervical cancer, HNSCC</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B333">333</xref>, <xref ref-type="bibr" rid="B334">334</xref>)</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>A variety of viral infections have also been linked to cancer development. DNA viruses, such as Epstein-Barr virus (EBV), Kaposi's sarcoma-associated herpesvirus (KSHV), human cytomegalovirus (HCMV) and human papilloma virus (HPV), cause NPC, B lymphomas, breast cancer, glioma, cervical cancer, and HNSCC in the host (<xref ref-type="bibr" rid="B335">335</xref>, <xref ref-type="bibr" rid="B336">336</xref>). RNA viruses, such as hepatitis C virus (HCV) and human T-cell leukemia virus type 1 (HTLV-1), may lead to HCC and T cell leukemia, respectively, in an infected individual (<xref ref-type="bibr" rid="B335">335</xref>, <xref ref-type="bibr" rid="B336">336</xref>). Notably, oncogenic proteins of these viruses exploit or target one or multiple TRAF proteins for their signal transduction. These include the EBV-encoded oncoprotein LMP1, v-FLIP of KSHV, pUL48 of HCMV, E2 and E6 of HPV, Core protein of HCV and Tax protein of HTLV-1. In particular, consistent with the high frequency of TRAF3 deletions and mutations in HPV+ HNSCC, overexpression of TRAF3 inhibits the growth, migration and chemoresistance of HPV+ HNSCC by decreasing HPV E6 oncoprotein and increasing p53 and RB tumor suppressors (<xref ref-type="bibr" rid="B328">328</xref>). We briefly summarize the TRAF-dependent signaling mechanisms of pathogen-encoded proteins that contribute to human carcinogenesis as detailed in Table <xref ref-type="table" rid="T3">3</xref>.</p>
</sec>
<sec id="s11">
<title>Indirect mechanisms of TRAFs in human cancers</title>
<p>Although beyond the scope of this review, we would like to point out that as critical regulators of adaptive immunity, innate immunity, and inflammation (<xref ref-type="bibr" rid="B1">1</xref>–<xref ref-type="bibr" rid="B4">4</xref>), TRAF proteins may indirectly contribute to the development, progression, and metastasis of various cancers by affecting tumor surveillance, tumor immunity, chronic inflammation and the tumor microenvironment. For example, disorders of innate antibacterial response are of fundamental importance in the development of gastrointestinal cancers, including pancreatic cancer, and increased expression of TRAF6, TLR4, and NOD1 are detected in peripheral blood leukocytes of pancreatic cancer patients (<xref ref-type="bibr" rid="B337">337</xref>). Specific deletion of TRAF3 from myeloid cells leads to development of B lymphomas and liver cancer in mice (<xref ref-type="bibr" rid="B56">56</xref>, <xref ref-type="bibr" rid="B174">174</xref>). Similarly, lymphocyte-specific TRAF3 transgenic mice develop autoimmunity, inflammation and cancers (such as squamous cell carcinomas of the tongue, salivary gland tumors, and hepatoma) (<xref ref-type="bibr" rid="B55">55</xref>). TRAF2 regulates inflammatory cytokine production in tumor-associated macrophages, which facilitates tumor growth (<xref ref-type="bibr" rid="B46">46</xref>). TRAF4 promotes lung cancer aggressiveness by modulating the tumor microenvironment in normal fibroblasts via the TRAF4-NOX2/NOX4/p47-phox-ROS pathway (<xref ref-type="bibr" rid="B338">338</xref>). Importantly, TRAFs are also recognized as potential targets or modulators of cancer immunotherapy. For example, the immune adjuvants dsRNA such as Sendai Virus, poly-I:C, and rintatolimod all activate the TLR3-TRAF3-IRF3 axis to promote CD8 cytotoxic T lymphocytes chemotaxis to the tumor microenvironment in cancer immunotherapy (<xref ref-type="bibr" rid="B339">339</xref>). Anti-GITR immunotherapy-induced tumor-specific Th9 cells, which are highly effective in eradicating advanced tumors <italic>in vivo</italic>, display a unique hyperproliferative feature driven by the Pu.1-TRAF6-NF-κB axis (<xref ref-type="bibr" rid="B340">340</xref>, <xref ref-type="bibr" rid="B341">341</xref>). Furthermore, TRAF3 and TRAF6 are crucial for osteoclast differentiation, and therefore can regulate bone metastasis of various cancers (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B342">342</xref>). We shall witness rapid advancement in these exciting areas in the coming years.</p>
</sec>
<sec id="s12" sec-type="conclusions">
<title>Conclusions</title>
<p>In this article, we have analyzed the current evidence of genetic alterations of the <italic>TRAF</italic> family in human cancers. The results revealed that genetic alterations of all seven <italic>TRAF</italic> genes are present in various human cancers and that recurrent mutations of each <italic>TRAF</italic> gene have been detected in cancer patients. In particular, loss-of-function genetic alterations of <italic>TRAF2</italic> and <italic>TRAF3</italic> are frequently detected in B cell malignancies, and the rates of missense mutations of <italic>TRAF7</italic> are overwhelmingly high in adenomatoid tumors, secretory meningiomas and perineuriomas. Gain-of-function alterations (gene amplification and overexpression) are common for <italic>TRAF1, TRAF4, TRAF5</italic>, and <italic>TRAF6</italic> in human cancers, and are also identified for <italic>TRAF2</italic> in epithelial cancers. Corroborating human evidence, direct causal roles of <italic>TRAF</italic> genetic alterations (except <italic>TRAF7</italic>) in tumorigenesis have been demonstrated <italic>in vivo</italic> with genetically engineered mouse models that have each <italic>TRAF</italic> gene deleted or overexpressed in specific cell types. Importantly, however, the functional significance of most <italic>TRAF</italic> point mutations identified in human cancers remains to be assessed in future studies. A number of interesting TRAF-dependent oncogenic and tumor suppressive pathways have been elucidated from both <italic>in vivo</italic> and <italic>in vitro</italic> studies, although current understanding is still far from complete and further investigation is required. The significance of TRAFs in cancer pathogenesis is reinforced by the evidence that TRAF proteins also participate in pathogen-induced carcinogenesis, including bacteria and viruses. Furthermore, emerging evidence indicates that TRAF proteins can indirectly contribute to tumorigenesis and metastasis by affecting tumor immunity, chronic inflammation, bone resorption, and the tumor microenvironment. In conclusion, the information presented in this article provides a rationale for the development of novel immunotherapies and other strategies to manipulate TRAF proteins or TRAF-dependent signaling pathways in human cancers by precision medicine, which represents the next primary challenge in the field.</p>
</sec>
<sec id="s13">
<title>Author contributions</title>
<p>PX and SZ have taken the leading roles in designing and writing this manuscript, and all co-authors (JJ, SG, AL, HS, and JF) have also made significant contributions to writing this manuscript.</p>
<sec>
<title>Conflict of interest statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</sec>
</body>
<back>
<ack>
<p>This study was supported by the National Institutes of Health grants R01 CA158402 and R21 AI128264 (PX), the Department of Defense grant W81XWH-13-1-0242 (PX), a Busch Biomedical Grant (PX), and a Pilot Award from the Cancer Institute of New Jersey through Grant Number P30CA072720 from the National Cancer Institute (PX).</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>P</given-names></name></person-group>. <article-title>TRAF molecules in cell signaling and in human diseases</article-title>. <source/>J Mol Signal. (<year>2013</year>) <volume>8</volume>:<fpage>7</fpage>. <pub-id pub-id-type="doi">10.1186/1750-2187-8-7</pub-id><pub-id pub-id-type="pmid">23758787</pub-id></mixed-citation>
</ref>
<ref id="B2">
<label>2.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>So</surname><given-names>T</given-names></name><name><surname>Nagashima</surname><given-names>H</given-names></name><name><surname>Ishii</surname><given-names>N</given-names></name></person-group>. <article-title>TNF Receptor-Associated Factor (TRAF) signaling network in CD4(+) T-lymphocytes</article-title>. <source/>Tohoku J Exp Med. (<year>2015</year>) <volume>236</volume>:<fpage>139</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1620/tjem.236.139</pub-id><pub-id pub-id-type="pmid">26072698</pub-id></mixed-citation>
</ref>
<ref id="B3">
<label>3.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>XD</given-names></name><name><surname>Sun</surname><given-names>SC</given-names></name></person-group>. <article-title>Targeting signaling factors for degradation, an emerging mechanism for TRAF functions</article-title>. <source/>Immunol Rev. (<year>2015</year>) <volume>266</volume>:<fpage>56</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1111/imr.12311</pub-id><pub-id pub-id-type="pmid">26085207</pub-id></mixed-citation>
</ref>
<ref id="B4">
<label>4.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lalani</surname><given-names>AI</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Gokhale</surname><given-names>S</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>P</given-names></name></person-group>. <article-title>TRAF molecules in inflammation and inflammatory diseases</article-title>. <source/>Curr Pharmacol Rep. (<year>2018</year>) <volume>4</volume>:<fpage>64</fpage>–<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1007/s40495-017-0117-y</pub-id><pub-id pub-id-type="pmid">29527458</pub-id></mixed-citation>
</ref>
<ref id="B5">
<label>5.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinstein</surname><given-names>JN</given-names></name><name><surname>Collisson</surname><given-names>EA</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>Shaw</surname><given-names>KR</given-names></name><name><surname>Ozenberger</surname><given-names>BA</given-names></name><name><surname>Ellrott</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>The Cancer Genome Atlas Pan-Cancer analysis project</article-title>. <source/>Nat Genet. (<year>2013</year>) <volume>45</volume>:<fpage>1113</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1038/ng.2764</pub-id><pub-id pub-id-type="pmid">24071849</pub-id></mixed-citation>
</ref>
<ref id="B6">
<label>6.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forbes</surname><given-names>SA</given-names></name><name><surname>Bhamra</surname><given-names>G</given-names></name><name><surname>Bamford</surname><given-names>S</given-names></name><name><surname>Dawson</surname><given-names>E</given-names></name><name><surname>Kok</surname><given-names>C</given-names></name><name><surname>Clements</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>The Catalogue of Somatic Mutations in Cancer (COSMIC)</article-title>. <source/>Curr Protoc Hum Genet. (<year>2008</year>) Chapter 10:Unit 10.11. <pub-id pub-id-type="doi">10.1002/0471142905.hg1011s57</pub-id></mixed-citation>
</ref>
<ref id="B7">
<label>7.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witkiewicz</surname><given-names>AK</given-names></name><name><surname>McMillan</surname><given-names>EA</given-names></name><name><surname>Balaji</surname><given-names>U</given-names></name><name><surname>Baek</surname><given-names>G</given-names></name><name><surname>Lin</surname><given-names>WC</given-names></name><name><surname>Mansour</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets</article-title>. <source/>Nat Commun. (<year>2015</year>) <volume>6</volume>:<fpage>6744</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms7744</pub-id><pub-id pub-id-type="pmid">25855536</pub-id></mixed-citation>
</ref>
<ref id="B8">
<label>8.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Network</surname><given-names>TCGAR</given-names></name></person-group>
<article-title>Comprehensive molecular characterization of gastric adenocarcinoma</article-title>. <source/>Nature (<year>2014</year>) <volume>513</volume>:<fpage>202</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/nature13480</pub-id><pub-id pub-id-type="pmid">25079317</pub-id></mixed-citation>
</ref>
<ref id="B9">
<label>9.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barretina</surname><given-names>J</given-names></name><name><surname>Taylor</surname><given-names>BS</given-names></name><name><surname>Banerji</surname><given-names>S</given-names></name><name><surname>Ramos</surname><given-names>AH</given-names></name><name><surname>Lagos-Quintana</surname><given-names>M</given-names></name><name><surname>Decarolis</surname><given-names>PL</given-names></name><etal></etal></person-group>. <article-title>Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy</article-title>. <source/>Nat Genet. (<year>2010</year>) <volume>42</volume>:<fpage>715</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1038/ng.619</pub-id><pub-id pub-id-type="pmid">20601955</pub-id></mixed-citation>
</ref>
<ref id="B10">
<label>10.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Network</surname><given-names>TCGAR</given-names></name></person-group>
<article-title>Comprehensive genomic characterization of squamous cell lung cancers</article-title>. <source/>Nature (<year>2012</year>) <volume>489</volume>:<fpage>519</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1038/nature11404</pub-id><pub-id pub-id-type="pmid">22960745</pub-id></mixed-citation>
</ref>
<ref id="B11">
<label>11.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>TM</given-names></name><name><surname>Jung</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>MS</given-names></name><name><surname>Baek</surname><given-names>IP</given-names></name><name><surname>Park</surname><given-names>SW</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><etal></etal></person-group>. <article-title>The mutational burdens and evolutionary ages of early gastric cancers are comparable to those of advanced gastric cancers</article-title>. <source/>J Pathol. (<year>2014</year>) <volume>234</volume>:<fpage>365</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1002/path.4401</pub-id><pub-id pub-id-type="pmid">25042771</pub-id></mixed-citation>
</ref>
<ref id="B12">
<label>12.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Network</surname><given-names>TCGA</given-names></name></person-group>
<article-title>Comprehensive molecular characterization of human colon and rectal cancer</article-title>. <source/>Nature (<year>2012</year>) <volume>487</volume>:<fpage>330</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/nature11252</pub-id><pub-id pub-id-type="pmid">22810696</pub-id></mixed-citation>
</ref>
<ref id="B13">
<label>13.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanz-Pamplona</surname><given-names>R</given-names></name><name><surname>Lopez-Doriga</surname><given-names>A</given-names></name><name><surname>Pare-Brunet</surname><given-names>L</given-names></name><name><surname>Lazaro</surname><given-names>K</given-names></name><name><surname>Bellido</surname><given-names>F</given-names></name><name><surname>Alonso</surname><given-names>MH</given-names></name><etal></etal></person-group>. <article-title>Exome sequencing reveals AMER1 as a frequently mutated gene in colorectal cancer</article-title>. <source/>Clin Cancer Res. (<year>2015</year>) <volume>21</volume>:<fpage>4709</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-0159</pub-id><pub-id pub-id-type="pmid">26071483</pub-id></mixed-citation>
</ref>
<ref id="B14">
<label>14.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van</surname><given-names>Allen EM</given-names></name><name><surname>Wagle</surname><given-names>N</given-names></name><name><surname>Sucker</surname><given-names>A</given-names></name><name><surname>Treacy</surname><given-names>DJ</given-names></name><name><surname>Johannessen</surname><given-names>CM</given-names></name><name><surname>Goetz</surname><given-names>EM</given-names></name><etal></etal></person-group>
<article-title>The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma</article-title>. <source/>Cancer Discov. (<year>2014</year>) <volume>4</volume>:<fpage>94</fpage>–<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290.CD-13-0617</pub-id><pub-id pub-id-type="pmid">24265153</pub-id></mixed-citation>
</ref>
<ref id="B15">
<label>15.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ljungstrom</surname><given-names>V</given-names></name><name><surname>Cortese</surname><given-names>D</given-names></name><name><surname>Young</surname><given-names>E</given-names></name><name><surname>Pandzic</surname><given-names>T</given-names></name><name><surname>Mansouri</surname><given-names>L</given-names></name><name><surname>Plevova</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations</article-title>. <source/>Blood (<year>2016</year>) <volume>127</volume>:<fpage>1007</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2015-10-674572</pub-id><pub-id pub-id-type="pmid">26675346</pub-id></mixed-citation>
</ref>
<ref id="B16">
<label>16.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feldman</surname><given-names>AL</given-names></name><name><surname>Vasmatzis</surname><given-names>G</given-names></name><name><surname>Asmann</surname><given-names>YW</given-names></name><name><surname>Davila</surname><given-names>J</given-names></name><name><surname>Middha</surname><given-names>S</given-names></name><name><surname>Eckloff</surname><given-names>BW</given-names></name><etal></etal></person-group>. <article-title>Novel TRAF1-ALK fusion identified by deep RNA sequencing of anaplastic large cell lymphoma</article-title>. <source/>Genes Chromosomes Cancer (<year>2013</year>) <volume>52</volume>:<fpage>1097</fpage>–<lpage>102</lpage>. <pub-id pub-id-type="doi">10.1002/gcc.22104</pub-id><pub-id pub-id-type="pmid">23999969</pub-id></mixed-citation>
</ref>
<ref id="B17">
<label>17.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeoka</surname><given-names>K</given-names></name><name><surname>Okumura</surname><given-names>A</given-names></name><name><surname>Honjo</surname><given-names>G</given-names></name><name><surname>Ohno</surname><given-names>H</given-names></name></person-group>. <article-title>Variant translocation partners of the anaplastic lymphoma kinase (ALK) gene in two cases of anaplastic large cell lymphoma, identified by inverse cDNA polymerase chain reaction</article-title>. <source/>J Clin Exp Hematop. (<year>2014</year>) <volume>54</volume>:<fpage>225</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.3960/jslrt.54.225</pub-id><pub-id pub-id-type="pmid">25501114</pub-id></mixed-citation>
</ref>
<ref id="B18">
<label>18.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abate</surname><given-names>F</given-names></name><name><surname>Todaro</surname><given-names>M</given-names></name><name><surname>van</surname><given-names>der Krogt JA</given-names></name><name><surname>Boi</surname><given-names>M</given-names></name><name><surname>Landra</surname><given-names>I</given-names></name><name><surname>Machiorlatti</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation</article-title>. <source/>Leukemia (<year>2015</year>) <volume>29</volume>:<fpage>1390</fpage>–<lpage>401</lpage>. <pub-id pub-id-type="doi">10.1038/leu.2014.347</pub-id><pub-id pub-id-type="pmid">25533804</pub-id></mixed-citation>
</ref>
<ref id="B19">
<label>19.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>K</given-names></name><name><surname>Berry</surname><given-names>B</given-names></name><name><surname>Handshoe</surname><given-names>J</given-names></name><name><surname>Hout</surname><given-names>D</given-names></name><name><surname>Mazzola</surname><given-names>R</given-names></name><name><surname>Morris</surname><given-names>SW</given-names></name><etal></etal></person-group>. <article-title>Detection of a TRAF1-ALK fusion in an anaplastic large cell lymphoma patient with chemotherapy and ALK inhibitor-resistant disease</article-title>. <source/>BMC Res Notes (<year>2015</year>) <volume>8</volume>:<fpage>308</fpage>. <pub-id pub-id-type="doi">10.1186/s13104-015-1277-7</pub-id><pub-id pub-id-type="pmid">26187744</pub-id></mixed-citation>
</ref>
<ref id="B20">
<label>20.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Ryu</surname><given-names>J</given-names></name><name><surname>Min</surname><given-names>E</given-names></name><name><surname>Oi</surname><given-names>N</given-names></name><name><surname>Bai</surname><given-names>R</given-names></name><name><surname>Zykova</surname><given-names>TA</given-names></name><etal></etal></person-group>. <article-title>TRAF1 is critical for DMBA/Solar UVR-induced skin carcinogenesis</article-title>. <source/>J Invest Dermatol. (<year>2017</year>) <volume>137</volume>:<fpage>1322</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.jid.2016.12.026</pub-id><pub-id pub-id-type="pmid">28131816</pub-id></mixed-citation>
</ref>
<ref id="B21">
<label>21.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>X WB</given-names></name><name><surname>Feng</surname><given-names>T</given-names></name><name><surname>Yuan</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Fang</surname><given-names>T</given-names></name></person-group>. <article-title>TNF receptor-associated factor 1 as a biomarker for assessment of non-small cell lung cancer metastasis and overall survival</article-title>. <source/>Clin Respir J. (<year>2018</year>) <volume>12</volume>:<fpage>2197</fpage>–<lpage>203</lpage>. <pub-id pub-id-type="doi">10.1111/crj.12789</pub-id><pub-id pub-id-type="pmid">29528567</pub-id></mixed-citation>
</ref>
<ref id="B22">
<label>22.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durkop</surname><given-names>H</given-names></name><name><surname>Hirsch</surname><given-names>B</given-names></name><name><surname>Hahn</surname><given-names>C</given-names></name><name><surname>Foss</surname><given-names>HD</given-names></name><name><surname>Stein</surname><given-names>H</given-names></name></person-group>. <article-title>Differential expression and function of A20 and TRAF1 in Hodgkin lymphoma and anaplastic large cell lymphoma and their induction by CD30 stimulation</article-title>. <source/>J Pathol. (<year>2003</year>) <volume>200</volume>:<fpage>229</fpage>–<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1002/path.1351</pub-id><pub-id pub-id-type="pmid">12754742</pub-id></mixed-citation>
</ref>
<ref id="B23">
<label>23.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zapata</surname><given-names>JM</given-names></name><name><surname>Krajewska</surname><given-names>M</given-names></name><name><surname>Krajewski</surname><given-names>S</given-names></name><name><surname>Kitada</surname><given-names>S</given-names></name><name><surname>Welsh</surname><given-names>K</given-names></name><name><surname>Monks</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies</article-title>. <source/>J Immunol. (<year>2000</year>) <volume>165</volume>:<fpage>5084</fpage>-96. <pub-id pub-id-type="doi">10.4049/jimmunol.165.9.5084</pub-id><pub-id pub-id-type="pmid">11046039</pub-id></mixed-citation>
</ref>
<ref id="B24">
<label>24.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munzert</surname><given-names>G</given-names></name><name><surname>Kirchner</surname><given-names>D</given-names></name><name><surname>Stobbe</surname><given-names>H</given-names></name><name><surname>Bergmann</surname><given-names>L</given-names></name><name><surname>Schmid</surname><given-names>RM</given-names></name><name><surname>Dohner</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis</article-title>. <source/>Blood (<year>2002</year>) <volume>100</volume>:<fpage>3749</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1182/blood.V100.10.3749</pub-id><pub-id pub-id-type="pmid">12411322</pub-id></mixed-citation>
</ref>
<ref id="B25">
<label>25.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savage</surname><given-names>KJ</given-names></name><name><surname>Monti</surname><given-names>S</given-names></name><name><surname>Kutok</surname><given-names>JL</given-names></name><name><surname>Cattoretti</surname><given-names>G</given-names></name><name><surname>Neuberg</surname><given-names>D</given-names></name><name><surname>De</surname><given-names>Leval L</given-names></name><etal></etal></person-group>. <article-title>The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma</article-title>. <source/>Blood (<year>2003</year>) <volume>102</volume>:<fpage>3871</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2003-06-1841</pub-id><pub-id pub-id-type="pmid">12933571</pub-id></mixed-citation>
</ref>
<ref id="B26">
<label>26.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zapata</surname><given-names>JM</given-names></name><name><surname>Reed</surname><given-names>JC</given-names></name></person-group>. <article-title>TRAF1: lord without a RING</article-title>. Sci STKE (<year>2002</year>) <volume>2002</volume>:<fpage>pe27</fpage>. <pub-id pub-id-type="doi">10.1126/stke.2002.133.pe27</pub-id><pub-id pub-id-type="pmid">12023442</pub-id></mixed-citation>
</ref>
<ref id="B27">
<label>27.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Tsitsikov</surname><given-names>EN</given-names></name><name><surname>Ding</surname><given-names>HF</given-names></name></person-group>. <article-title>NF-kappaB2 mutation targets TRAF1 to induce lymphomagenesis</article-title>. <source/>Blood (<year>2007</year>) <volume>110</volume>:<fpage>743</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2006-11-058446</pub-id><pub-id pub-id-type="pmid">17405906</pub-id></mixed-citation>
</ref>
<ref id="B28">
<label>28.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slager</surname><given-names>SL</given-names></name><name><surname>Kay</surname><given-names>NE</given-names></name><name><surname>Fredericksen</surname><given-names>ZS</given-names></name><name><surname>Wang</surname><given-names>AH</given-names></name><name><surname>Liebow</surname><given-names>M</given-names></name><name><surname>Cunningham</surname><given-names>JM</given-names></name><etal></etal></person-group>. <article-title>Susceptibility genes and B-chronic lymphocytic leukaemia</article-title>. <source/>Br J Haematol. (<year>2007</year>) <volume>139</volume>:<fpage>762</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2141.2007.06872.x</pub-id><pub-id pub-id-type="pmid">18021089</pub-id></mixed-citation>
</ref>
<ref id="B29">
<label>29.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsitsikov</surname><given-names>EN</given-names></name><name><surname>Laouini</surname><given-names>D</given-names></name><name><surname>Dunn</surname><given-names>IF</given-names></name><name><surname>Sannikova</surname><given-names>TY</given-names></name><name><surname>Davidson</surname><given-names>L</given-names></name><name><surname>Alt</surname><given-names>FW</given-names></name><etal></etal></person-group>. <article-title>TRAF1 is a negative regulator of TNF signaling</article-title>. enhanced TNF signaling in TRAF1-deficient mice. <source/>Immunity (<year>2001</year>) <volume>15</volume>:<fpage>647</fpage>–<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1016/S1074-7613(01)00207-2</pub-id><pub-id pub-id-type="pmid">11672546</pub-id></mixed-citation>
</ref>
<ref id="B30">
<label>30.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Gao</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Yao</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Park</surname><given-names>MH</given-names></name><etal></etal></person-group>. <article-title>TRAF1 is critical for regulating the BRAF/MEK/ERK pathway in non-small cell lung carcinogenesis</article-title>. <source/>Cancer Res. (<year>2018</year>) <volume>78</volume>:<fpage>3982</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-18-0429</pub-id><pub-id pub-id-type="pmid">29748372</pub-id></mixed-citation>
</ref>
<ref id="B31">
<label>31.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McPherson</surname><given-names>AJ</given-names></name><name><surname>Snell</surname><given-names>LM</given-names></name><name><surname>Mak</surname><given-names>TW</given-names></name><name><surname>Watts</surname><given-names>TH</given-names></name></person-group>. <article-title>Opposing roles for TRAF1 in the alternative versus classical NF-κB pathway in T cells</article-title>. <source/>J Biol Chem. (<year>2012</year>) <volume>287</volume>:<fpage>23010</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M112.350538</pub-id><pub-id pub-id-type="pmid">22570473</pub-id></mixed-citation>
</ref>
<ref id="B32">
<label>32.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabbagh</surname><given-names>L</given-names></name><name><surname>Srokowski</surname><given-names>CC</given-names></name><name><surname>Pulle</surname><given-names>G</given-names></name><name><surname>Snell</surname><given-names>LM</given-names></name><name><surname>Sedgmen</surname><given-names>BJ</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>A critical role for TNF receptor-associated factor 1 and Bim down-regulation in CD8 memory T cell survival</article-title>. <source/>Proc Natl Acad Sci USA. (<year>2006</year>) <volume>103</volume>:<fpage>18703</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0602919103</pub-id><pub-id pub-id-type="pmid">17116875</pub-id></mixed-citation>
</ref>
<ref id="B33">
<label>33.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabbagh</surname><given-names>L</given-names></name><name><surname>Pulle</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Tsitsikov</surname><given-names>EN</given-names></name><name><surname>Watts</surname><given-names>TH</given-names></name></person-group>. <article-title>ERK-dependent Bim modulation downstream of the 4-1BB-TRAF1 signaling axis is a critical mediator of CD8 T cell survival <italic>in vivo</italic></article-title>. <source/>J Immunol. (<year>2008</year>) <volume>180</volume>:<fpage>8093</fpage>–<lpage>101</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.180.12.8093</pub-id><pub-id pub-id-type="pmid">18523273</pub-id></mixed-citation>
</ref>
<ref id="B34">
<label>34.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>McPherson</surname><given-names>AJ</given-names></name><name><surname>Jones</surname><given-names>RB</given-names></name><name><surname>Kawamura</surname><given-names>KS</given-names></name><name><surname>Lin</surname><given-names>GH</given-names></name><name><surname>Lang</surname><given-names>PA</given-names></name><etal></etal></person-group>. <article-title>Loss of the signaling adaptor TRAF1 causes CD8+ T cell dysregulation during human and murine chronic infection</article-title>. <source/>J Exp Med. (<year>2012</year>) <volume>209</volume>:<fpage>77</fpage>–<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20110675</pub-id><pub-id pub-id-type="pmid">22184633</pub-id></mixed-citation>
</ref>
<ref id="B35">
<label>35.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Speiser</surname><given-names>DE</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Wong</surname><given-names>B</given-names></name><name><surname>Arron</surname><given-names>J</given-names></name><name><surname>Santana</surname><given-names>A</given-names></name><name><surname>Kong</surname><given-names>YY</given-names></name><etal></etal></person-group>. <article-title>A regulatory role for TRAF1 in antigen-induced apoptosis of T cells</article-title>. <source/>J Exp Med. (<year>1997</year>) <volume>185</volume>:<fpage>1777</fpage>–<lpage>83</lpage>.<pub-id pub-id-type="pmid">9151703</pub-id></mixed-citation>
</ref>
<ref id="B36">
<label>36.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>WC</given-names></name><name><surname>Shahinian</surname><given-names>A</given-names></name><name><surname>Speiser</surname><given-names>D</given-names></name><name><surname>Kraunus</surname><given-names>J</given-names></name><name><surname>Billia</surname><given-names>F</given-names></name><name><surname>Wakeham</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice</article-title>. <source/>Immunity (<year>1997</year>) <volume>7</volume>:<fpage>715</fpage>–<lpage>25</lpage>.<pub-id pub-id-type="pmid">9390694</pub-id></mixed-citation>
</ref>
<ref id="B37">
<label>37.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piao</surname><given-names>JH</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name><name><surname>Heissig</surname><given-names>B</given-names></name><name><surname>Hattori</surname><given-names>K</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Iwakura</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Tumor necrosis factor receptor-associated factor (TRAF) 2 controls homeostasis of the colon to prevent spontaneous development of murine inflammatory bowel disease</article-title>. <source/>J Biol Chem. (<year>2011</year>) <volume>286</volume>:<fpage>17879</fpage>–<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M111.221853</pub-id><pub-id pub-id-type="pmid">21393251</pub-id></mixed-citation>
</ref>
<ref id="B38">
<label>38.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacLachlan</surname><given-names>TK</given-names></name><name><surname>Giordano</surname><given-names>A</given-names></name></person-group>. <article-title>TRAF2 expression in differentiated muscle</article-title>. <source/>J Cell Biochem. (<year>1998</year>) <volume>71</volume>:<fpage>461</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">9827692</pub-id></mixed-citation>
</ref>
<ref id="B39">
<label>39.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gardam</surname><given-names>S</given-names></name><name><surname>Sierro</surname><given-names>F</given-names></name><name><surname>Basten</surname><given-names>A</given-names></name><name><surname>Mackay</surname><given-names>F</given-names></name><name><surname>Brink</surname><given-names>R</given-names></name></person-group>. <article-title>TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor</article-title>. <source/>Immunity (<year>2008</year>) <volume>28</volume>:<fpage>391</fpage>–<lpage>401</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2008.01.009</pub-id><pub-id pub-id-type="pmid">18313334</pub-id></mixed-citation>
</ref>
<ref id="B40">
<label>40.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Reichlin</surname><given-names>A</given-names></name><name><surname>Santana</surname><given-names>A</given-names></name><name><surname>Sokol</surname><given-names>KA</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name><name><surname>Choi</surname><given-names>Y</given-names></name></person-group>
<article-title>TRAF2 is essential for JNK but not NF-kappaB activation and regulates lymphocyte proliferation and survival</article-title>. <source/>Immunity (<year>1997</year>) <volume>7</volume>:<fpage>703</fpage>–<lpage>13</lpage>.<pub-id pub-id-type="pmid">9390693</pub-id></mixed-citation>
</ref>
<ref id="B41">
<label>41.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zapata</surname><given-names>JM</given-names></name><name><surname>Krajewska</surname><given-names>M</given-names></name><name><surname>Morse</surname><given-names>HC III</given-names></name><name><surname>Choi</surname><given-names>Y</given-names></name><name><surname>Reed</surname><given-names>JC</given-names></name></person-group>. <article-title>TNF receptor-associated factor (TRAF) domain and Bcl-2 cooperate to induce small B cell lymphoma/chronic lymphocytic leukemia in transgenic mice</article-title>. <source/>Proc Natl Acad Sci USA. (<year>2004</year>) <volume>101</volume>:<fpage>16600</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0407541101</pub-id><pub-id pub-id-type="pmid">15545599</pub-id></mixed-citation>
</ref>
<ref id="B42">
<label>42.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Chacon</surname><given-names>G</given-names></name><name><surname>Llobet</surname><given-names>D</given-names></name><name><surname>Pardo</surname><given-names>C</given-names></name><name><surname>Pindado</surname><given-names>J</given-names></name><name><surname>Choi</surname><given-names>Y</given-names></name><name><surname>Reed</surname><given-names>JC</given-names></name><etal></etal></person-group>. <article-title>TNFR-associated factor 2 deficiency in B lymphocytes predisposes to chronic lymphocytic leukemia/small lymphocytic lymphoma in mice</article-title>. <source/>J Immunol. (<year>2012</year>) <volume>189</volume>:<fpage>1053</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1200814</pub-id><pub-id pub-id-type="pmid">22711886</pub-id></mixed-citation>
</ref>
<ref id="B43">
<label>43.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>AT</given-names></name><name><surname>Gautheron</surname><given-names>J</given-names></name><name><surname>Feoktistova</surname><given-names>M</given-names></name><name><surname>Roderburg</surname><given-names>C</given-names></name><name><surname>Loosen</surname><given-names>SH</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>RIPK1 suppresses a TRAF2-dependent pathway to liver cancer</article-title>. <source/>Cancer Cell (<year>2017</year>) <volume>31</volume>:<fpage>94</fpage>–<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccell.2016.11.009</pub-id><pub-id pub-id-type="pmid">28017612</pub-id></mixed-citation>
</ref>
<ref id="B44">
<label>44.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petersen</surname><given-names>SL</given-names></name><name><surname>Chen</surname><given-names>TT</given-names></name><name><surname>Lawrence</surname><given-names>DA</given-names></name><name><surname>Marsters</surname><given-names>SA</given-names></name><name><surname>Gonzalvez</surname><given-names>F</given-names></name><name><surname>Ashkenazi</surname><given-names>A</given-names></name></person-group>. <article-title>TRAF2 is a biologically important necroptosis suppressor</article-title>. <source/>Cell Death Differ. (<year>2015</year>) <volume>22</volume>:<fpage>1846</fpage>–<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1038/cdd.2015.35</pub-id><pub-id pub-id-type="pmid">25882049</pub-id></mixed-citation>
</ref>
<ref id="B45">
<label>45.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Etemadi</surname><given-names>N</given-names></name><name><surname>Chopin</surname><given-names>M</given-names></name><name><surname>Anderton</surname><given-names>H</given-names></name><name><surname>Tanzer</surname><given-names>MC</given-names></name><name><surname>Rickard</surname><given-names>JA</given-names></name><name><surname>Abeysekera</surname><given-names>W</given-names></name><etal></etal></person-group>
<article-title>TRAF2 regulates TNF and NF-κB signalling to suppress apoptosis and skin inflammation independently of Sphingosine kinase 1</article-title>. <source/>Elife (<year>2015</year>) <volume>4</volume>:<fpage>e10592</fpage>
<pub-id pub-id-type="doi">10.7554/eLife.10592</pub-id><pub-id pub-id-type="pmid">26701909</pub-id></mixed-citation>
</ref>
<ref id="B46">
<label>46.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Zou</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Proinflammatory TLR signalling is regulated by a TRAF2-dependent proteolysis mechanism in macrophages</article-title>. <source/>Nat Commun. (<year>2015</year>) <volume>6</volume>:<fpage>5930</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms6930</pub-id><pub-id pub-id-type="pmid">25565375</pub-id></mixed-citation>
</ref>
<ref id="B47">
<label>47.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villanueva</surname><given-names>JE</given-names></name><name><surname>Malle</surname><given-names>EK</given-names></name><name><surname>Gardam</surname><given-names>S</given-names></name><name><surname>Silveira</surname><given-names>PA</given-names></name><name><surname>Zammit</surname><given-names>NW</given-names></name><name><surname>Walters</surname><given-names>SN</given-names></name><etal></etal></person-group>. <article-title>TRAF2 regulates peripheral CD8(+) T-cell and NKT-cell homeostasis by modulating sensitivity to IL-15</article-title>. <source/>Eur J Immunol. (<year>2015</year>) <volume>45</volume>:<fpage>1820</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1002/eji.201445416</pub-id><pub-id pub-id-type="pmid">25931426</pub-id></mixed-citation>
</ref>
<ref id="B48">
<label>48.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zarnegar</surname><given-names>BJ</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Mahoney</surname><given-names>DJ</given-names></name><name><surname>Dempsey</surname><given-names>PW</given-names></name><name><surname>Cheung</surname><given-names>HH</given-names></name><name><surname>He</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK</article-title>. <source/>Nat Immunol. (<year>2008</year>) <volume>9</volume>:<fpage>1371</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/ni.1676</pub-id><pub-id pub-id-type="pmid">18997794</pub-id></mixed-citation>
</ref>
<ref id="B49">
<label>49.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>G</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group>. <article-title>Targeted disruption of TRAF3 leads to postnatal lethality and defective T-dependent immune responses</article-title>. <source/>Immunity (<year>1996</year>) <volume>5</volume>:<fpage>407</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="pmid">8934568</pub-id></mixed-citation>
</ref>
<ref id="B50">
<label>50.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>JQ</given-names></name><name><surname>Zarnegar</surname><given-names>B</given-names></name><name><surname>Oganesyan</surname><given-names>G</given-names></name><name><surname>Saha</surname><given-names>SK</given-names></name><name><surname>Yamazaki</surname><given-names>S</given-names></name><name><surname>Doyle</surname><given-names>SE</given-names></name><etal></etal></person-group>. <article-title>Rescue of TRAF3-null mice by p100 NF-kappa B deficiency</article-title>. <source/>J Exp Med. (<year>2006</year>) <volume>203</volume>:<fpage>2413</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20061166</pub-id><pub-id pub-id-type="pmid">17015635</pub-id></mixed-citation>
</ref>
<ref id="B51">
<label>51.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>P</given-names></name><name><surname>Stunz</surname><given-names>LL</given-names></name><name><surname>Larison</surname><given-names>KD</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Bishop</surname><given-names>GA</given-names></name></person-group>. <article-title>Tumor necrosis factor receptor-associated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs</article-title>. <source/>Immunity (<year>2007</year>) <volume>27</volume>:<fpage>253</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2007.07.012</pub-id><pub-id pub-id-type="pmid">17723217</pub-id></mixed-citation>
</ref>
<ref id="B52">
<label>52.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>CR</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Shao</surname><given-names>CS</given-names></name><name><surname>Covey</surname><given-names>LR</given-names></name><name><surname>Morse</surname><given-names>HC</given-names><suffix>3rd</suffix></name><name><surname>Xie</surname><given-names>P</given-names></name></person-group>. <article-title>Specific deletion of TRAF3 in B lymphocytes leads to B lymphoma development in mice</article-title>. <source/>Leukemia (<year>2012</year>) <volume>26</volume>:<fpage>1122</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/leu.2011.309</pub-id><pub-id pub-id-type="pmid">22033491</pub-id></mixed-citation>
</ref>
<ref id="B53">
<label>53.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>P</given-names></name><name><surname>Poovassery</surname><given-names>J</given-names></name><name><surname>Stunz</surname><given-names>LL</given-names></name><name><surname>Smith</surname><given-names>SM</given-names></name><name><surname>Schultz</surname><given-names>ML</given-names></name><name><surname>Carlin</surname><given-names>LE</given-names></name><etal></etal></person-group>. <article-title>Enhanced Toll-like receptor (TLR) responses of TNFR-associated factor 3 (TRAF3)-deficient B lymphocytes</article-title>. <source/>J Leukoc Biol. (<year>2011</year>) <volume>90</volume>:<fpage>1149</fpage>–<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1189/jlb.0111044</pub-id><pub-id pub-id-type="pmid">21971520</pub-id></mixed-citation>
</ref>
<ref id="B54">
<label>54.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gardam</surname><given-names>S</given-names></name><name><surname>Turner</surname><given-names>VM</given-names></name><name><surname>Anderton</surname><given-names>H</given-names></name><name><surname>Limaye</surname><given-names>S</given-names></name><name><surname>Basten</surname><given-names>A</given-names></name><name><surname>Koentgen</surname><given-names>F</given-names></name><etal></etal></person-group>. <article-title>Deletion of cIAP1 and cIAP2 in murine B lymphocytes constitutively activates cell survival pathways and inactivates the germinal center response</article-title>. <source/>Blood (<year>2011</year>) <volume>117</volume>:<fpage>4041</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2010-10-312793</pub-id><pub-id pub-id-type="pmid">21300983</pub-id></mixed-citation>
</ref>
<ref id="B55">
<label>55.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zapata</surname><given-names>JM</given-names></name><name><surname>Llobet</surname><given-names>D</given-names></name><name><surname>Krajewska</surname><given-names>M</given-names></name><name><surname>Lefebvre</surname><given-names>S</given-names></name><name><surname>Kress</surname><given-names>CL</given-names></name><name><surname>Reed</surname><given-names>JC</given-names></name></person-group>. <article-title>Lymphocyte-specific TRAF3-transgenic mice have enhanced humoral responses and develop plasmacytosis, autoimmunity, inflammation, and cancer</article-title>. <source/>Blood (<year>2009</year>) <volume>113</volume>:<fpage>4595</fpage>–<lpage>603</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2008-07-165456</pub-id><pub-id pub-id-type="pmid">19074733</pub-id></mixed-citation>
</ref>
<ref id="B56">
<label>56.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lalani</surname><given-names>AI</given-names></name><name><surname>Moore</surname><given-names>CR</given-names></name><name><surname>Luo</surname><given-names>C</given-names></name><name><surname>Kreider</surname><given-names>BZ</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Morse</surname><given-names>HC</given-names><suffix>3rd</suffix></name><etal></etal></person-group>. <article-title>Myeloid cell TRAF3 regulates immune responses and inhibits inflammation and tumor development in mice</article-title>. <source/>J Immunol. (<year>2015</year>) <volume>194</volume>:<fpage>334</fpage>–<lpage>48</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1401548</pub-id><pub-id pub-id-type="pmid">25422508</pub-id></mixed-citation>
</ref>
<ref id="B57">
<label>57.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>P</given-names></name><name><surname>Kraus</surname><given-names>ZJ</given-names></name><name><surname>Stunz</surname><given-names>LL</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Bishop</surname><given-names>GA</given-names></name></person-group>. <article-title>TNF receptor-associated factor 3 is required for T cell-mediated immunity and TCR/CD28 signaling</article-title>. <source/>J Immunol. (<year>2011</year>) <volume>186</volume>:<fpage>143</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.100029</pub-id><pub-id pub-id-type="pmid">21084666</pub-id></mixed-citation>
</ref>
<ref id="B58">
<label>58.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>Z</given-names></name><name><surname>Lin</surname><given-names>WW</given-names></name><name><surname>Stunz</surname><given-names>LL</given-names></name><name><surname>Bishop</surname><given-names>GA</given-names></name></person-group>. <article-title>The adaptor TRAF3 restrains the lineage determination of thymic regulatory T cells by modulating signaling via the receptor for IL-2</article-title>. <source/>Nat Immunol. (<year>2014</year>) <volume>15</volume>:<fpage>866</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1038/ni.2944</pub-id><pub-id pub-id-type="pmid">25029551</pub-id></mixed-citation>
</ref>
<ref id="B59">
<label>59.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>Z</given-names></name><name><surname>Stunz</surname><given-names>LL</given-names></name><name><surname>Bishop</surname><given-names>GA</given-names></name></person-group>. <article-title>TNF receptor associated factor 3 plays a key role in development and function of invariant natural killer T cells</article-title>. <source/>J Exp Med. (<year>2013</year>) <volume>210</volume>:<fpage>1079</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20122135</pub-id><pub-id pub-id-type="pmid">23650438</pub-id></mixed-citation>
</ref>
<ref id="B60">
<label>60.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>Z</given-names></name><name><surname>Stunz</surname><given-names>LL</given-names></name><name><surname>Lin</surname><given-names>WW</given-names></name><name><surname>Bishop</surname><given-names>GA</given-names></name></person-group>. <article-title>TRAF3 regulates homeostasis of CD8+ central memory T cells</article-title>. <source/>PLoS ONE (<year>2014</year>) <volume>9</volume>:<fpage>e102120</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0102120</pub-id><pub-id pub-id-type="pmid">25010048</pub-id></mixed-citation>
</ref>
<ref id="B61">
<label>61.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiels</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Schumacker</surname><given-names>PT</given-names></name><name><surname>Maltepe</surname><given-names>E</given-names></name><name><surname>Padrid</surname><given-names>PA</given-names></name><name><surname>Sperling</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>TRAF4 deficiency leads to tracheal malformation with resulting alterations in air flow to the lungs</article-title>. <source/>Am J Pathol. (<year>2000</year>) <volume>157</volume>:<fpage>679</fpage>–<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1016/S0002-9440(10)64578-6</pub-id><pub-id pub-id-type="pmid">10934170</pub-id></mixed-citation>
</ref>
<ref id="B62">
<label>62.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Regnier</surname><given-names>CH</given-names></name><name><surname>Masson</surname><given-names>R</given-names></name><name><surname>Kedinger</surname><given-names>V</given-names></name><name><surname>Textoris</surname><given-names>J</given-names></name><name><surname>Stoll</surname><given-names>I</given-names></name><name><surname>Chenard</surname><given-names>MP</given-names></name><etal></etal></person-group>. <article-title>Impaired neural tube closure, axial skeleton malformations, and tracheal ring disruption in TRAF4-deficient mice</article-title>. <source/>Proc Natl Acad Sci USA. (<year>2002</year>) <volume>99</volume>:<fpage>5585</fpage>–<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.052124799</pub-id><pub-id pub-id-type="pmid">11943846</pub-id></mixed-citation>
</ref>
<ref id="B63">
<label>63.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blaise</surname><given-names>S</given-names></name><name><surname>Kneib</surname><given-names>M</given-names></name><name><surname>Rousseau</surname><given-names>A</given-names></name><name><surname>Gambino</surname><given-names>F</given-names></name><name><surname>Chenard</surname><given-names>MP</given-names></name><name><surname>Messadeq</surname><given-names>N</given-names></name><etal></etal></person-group>. <article-title><italic>in vivo</italic> evidence that TRAF4 is required for central nervous system myelin homeostasis</article-title>. <source/>PLoS ONE (<year>2012</year>) <volume>7</volume>:<fpage>e30917</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0030917</pub-id><pub-id pub-id-type="pmid">22363515</pub-id></mixed-citation>
</ref>
<ref id="B64">
<label>64.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherfils-Vicini</surname><given-names>J</given-names></name><name><surname>Vingert</surname><given-names>B</given-names></name><name><surname>Varin</surname><given-names>A</given-names></name><name><surname>Tartour</surname><given-names>E</given-names></name><name><surname>Fridman</surname><given-names>WH</given-names></name><name><surname>Sautes-Fridman</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Characterization of immune functions in TRAF4-deficient mice</article-title>. <source/>Immunology (<year>2008</year>) <volume>124</volume>:<fpage>562</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2567.2008.02810.x</pub-id><pub-id pub-id-type="pmid">18284467</pub-id></mixed-citation>
</ref>
<ref id="B65">
<label>65.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>B</given-names></name><name><surname>Zepp</surname><given-names>JA</given-names></name><name><surname>Ko</surname><given-names>JS</given-names></name><etal></etal></person-group>. <article-title>A novel IL-17 signaling pathway controlling keratinocyte proliferation and tumorigenesis via the TRAF4-ERK5 axis</article-title>. <source/>J Exp Med. (<year>2015</year>) <volume>212</volume>:<fpage>1571</fpage>–<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20150204</pub-id><pub-id pub-id-type="pmid">26347473</pub-id></mixed-citation>
</ref>
<ref id="B66">
<label>66.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zepp</surname><given-names>JA</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Qian</surname><given-names>W</given-names></name><name><surname>Ouyang</surname><given-names>W</given-names></name><name><surname>Aronica</surname><given-names>M</given-names></name><name><surname>Erzurum</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>TRAF4-SMURF2-mediated DAZAP2 degradation is critical for IL-25 signaling and allergic airway inflammation</article-title>. <source/>J Immunol. (<year>2015</year>) <volume>194</volume>:<fpage>2826</fpage>–<lpage>37</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1402647</pub-id><pub-id pub-id-type="pmid">25681341</pub-id></mixed-citation>
</ref>
<ref id="B67">
<label>67.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakano</surname><given-names>H</given-names></name><name><surname>Sakon</surname><given-names>S</given-names></name><name><surname>Koseki</surname><given-names>H</given-names></name><name><surname>Takemori</surname><given-names>T</given-names></name><name><surname>Tada</surname><given-names>K</given-names></name><name><surname>Matsumoto</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Targeted disruption of Traf5 gene causes defects in CD40- and CD27-mediated lymphocyte activation</article-title>. <source/>Proc Natl Acad Sci USA. (<year>1999</year>) <volume>96</volume>:<fpage>9803</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">10449775</pub-id></mixed-citation>
</ref>
<ref id="B68">
<label>68.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraus</surname><given-names>ZJ</given-names></name><name><surname>Haring</surname><given-names>JS</given-names></name><name><surname>Bishop</surname><given-names>GA</given-names></name></person-group>. <article-title>TNF receptor-associated factor 5 is required for optimal T cell expansion and survival in response to infection</article-title>. <source/>J Immunol. (<year>2008</year>) <volume>181</volume>:<fpage>7800</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.181.11.7800</pub-id><pub-id pub-id-type="pmid">19017969</pub-id></mixed-citation>
</ref>
<ref id="B69">
<label>69.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esparza</surname><given-names>EM</given-names></name><name><surname>Lindsten</surname><given-names>T</given-names></name><name><surname>Stockhausen</surname><given-names>JM</given-names></name><name><surname>Arch</surname><given-names>RH</given-names></name></person-group>. <article-title>Tumor necrosis factor receptor (TNFR)-associated factor 5 is a critical intermediate of costimulatory signaling pathways triggered by glucocorticoid-induced TNFR in T cells</article-title>. <source/>J Biol Chem. (<year>2006</year>) <volume>281</volume>:<fpage>8559</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M512915200</pub-id><pub-id pub-id-type="pmid">16452475</pub-id></mixed-citation>
</ref>
<ref id="B70">
<label>70.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>So</surname><given-names>T</given-names></name><name><surname>Salek-Ardakani</surname><given-names>S</given-names></name><name><surname>Nakano</surname><given-names>H</given-names></name><name><surname>Ware</surname><given-names>CF</given-names></name><name><surname>Croft</surname><given-names>M</given-names></name></person-group>. <article-title>TNF receptor-associated factor 5 limits the induction of Th2 immune responses</article-title>. <source/>J Immunol. (<year>2004</year>) <volume>172</volume>:<fpage>4292</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.172.7.4292</pub-id><pub-id pub-id-type="pmid">15034043</pub-id></mixed-citation>
</ref>
<ref id="B71">
<label>71.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagashima</surname><given-names>H</given-names></name><name><surname>Okuyama</surname><given-names>Y</given-names></name><name><surname>Asao</surname><given-names>A</given-names></name><name><surname>Kawabe</surname><given-names>T</given-names></name><name><surname>Yamaki</surname><given-names>S</given-names></name><name><surname>Nakano</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>The adaptor TRAF5 limits the differentiation of inflammatory CD4(+) T cells by antagonizing signaling via the receptor for IL-6</article-title>. <source/>Nat Immunol. (<year>2014</year>) <volume>15</volume>:<fpage>449</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1038/ni.2863</pub-id><pub-id pub-id-type="pmid">24681564</pub-id></mixed-citation>
</ref>
<ref id="B72">
<label>72.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Pan</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>He</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>Disruption of tumor necrosis factor receptor-associated factor 5 exacerbates murine experimental colitis via regulating T helper cell-mediated inflammation</article-title>. <source/>Mediators Inflamm. (<year>2016</year>) <volume>2016</volume>:<fpage>9453745</fpage>. <pub-id pub-id-type="doi">10.1155/2016/9453745</pub-id><pub-id pub-id-type="pmid">27110068</pub-id></mixed-citation>
</ref>
<ref id="B73">
<label>73.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraus</surname><given-names>ZJ</given-names></name><name><surname>Nakano</surname><given-names>H</given-names></name><name><surname>Bishop</surname><given-names>GA</given-names></name></person-group>. <article-title>TRAF5 is a critical mediator of <italic>in vitro</italic> signals and <italic>in vivo</italic> functions of LMP1, the viral oncogenic mimic of CD40</article-title>. <source/>Proc Natl Acad Sci USA. (<year>2009</year>) <volume>106</volume>:<fpage>17140</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0903786106</pub-id><pub-id pub-id-type="pmid">19805155</pub-id></mixed-citation>
</ref>
<ref id="B74">
<label>74.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naito</surname><given-names>A</given-names></name><name><surname>Azuma</surname><given-names>S</given-names></name><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Miyazaki</surname><given-names>T</given-names></name><name><surname>Takaki</surname><given-names>S</given-names></name><name><surname>Takatsu</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice</article-title>. <source/>Genes Cells (<year>1999</year>) <volume>4</volume>:<fpage>353</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="pmid">10421844</pub-id></mixed-citation>
</ref>
<ref id="B75">
<label>75.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lomaga</surname><given-names>MA</given-names></name><name><surname>Yeh</surname><given-names>WC</given-names></name><name><surname>Sarosi</surname><given-names>I</given-names></name><name><surname>Duncan</surname><given-names>GS</given-names></name><name><surname>Furlonger</surname><given-names>C</given-names></name><name><surname>Ho</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling</article-title>. <source/>Genes Dev. (<year>1999</year>) <volume>13</volume>:<fpage>1015</fpage>–<lpage>24</lpage>.<pub-id pub-id-type="pmid">10215628</pub-id></mixed-citation>
</ref>
<ref id="B76">
<label>76.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Walsh</surname><given-names>PT</given-names></name><name><surname>Walsh</surname><given-names>MC</given-names></name><name><surname>Speirs</surname><given-names>KM</given-names></name><name><surname>Chiffoleau</surname><given-names>E</given-names></name><name><surname>King</surname><given-names>CG</given-names></name><etal></etal></person-group>. <article-title>TRAF6 is a critical factor for dendritic cell maturation and development</article-title>. <source/>Immunity (<year>2003</year>) <volume>19</volume>:<fpage>353</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/S1074-7613(03)00230-9</pub-id><pub-id pub-id-type="pmid">14499111</pub-id></mixed-citation>
</ref>
<ref id="B77">
<label>77.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimo</surname><given-names>Y</given-names></name><name><surname>Yanai</surname><given-names>H</given-names></name><name><surname>Ohshima</surname><given-names>D</given-names></name><name><surname>Qin</surname><given-names>J</given-names></name><name><surname>Motegi</surname><given-names>H</given-names></name><name><surname>Maruyama</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>TRAF6 directs commitment to regulatory T cells in thymocytes</article-title>. <source/>Genes Cells (<year>2011</year>) <volume>16</volume>:<fpage>437</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2443.2011.01500.x</pub-id><pub-id pub-id-type="pmid">21401811</pub-id></mixed-citation>
</ref>
<ref id="B78">
<label>78.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickson</surname><given-names>KM</given-names></name><name><surname>Bhakar</surname><given-names>AL</given-names></name><name><surname>Barker</surname><given-names>PA</given-names></name></person-group>. <article-title>TRAF6-dependent NF-kB transcriptional activity during mouse development</article-title>. <source/>Dev Dyn. (<year>2004</year>) <volume>231</volume>:<fpage>122</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1002/dvdy.20110</pub-id><pub-id pub-id-type="pmid">15305292</pub-id></mixed-citation>
</ref>
<ref id="B79">
<label>79.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeiser</surname><given-names>EC</given-names></name><name><surname>Rutkoski</surname><given-names>NJ</given-names></name><name><surname>Naito</surname><given-names>A</given-names></name><name><surname>Inoue</surname><given-names>J</given-names></name><name><surname>Carter</surname><given-names>BD</given-names></name></person-group>. <article-title>Neurotrophin signaling through the p75 receptor is deficient in traf6<sup>−/−</sup> mice</article-title>. <source/>J Neurosci (<year>2004</year>) <volume>24</volume>:<fpage>10521</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1390-04.2004</pub-id><pub-id pub-id-type="pmid">15548667</pub-id></mixed-citation>
</ref>
<ref id="B80">
<label>80.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lomaga</surname><given-names>MA</given-names></name><name><surname>Henderson</surname><given-names>JT</given-names></name><name><surname>Elia</surname><given-names>AJ</given-names></name><name><surname>Robertson</surname><given-names>J</given-names></name><name><surname>Noyce</surname><given-names>RS</given-names></name><name><surname>Yeh</surname><given-names>WC</given-names></name><etal></etal></person-group>. <article-title>Tumor necrosis factor receptor-associated factor 6 (TRAF6) deficiency results in exencephaly and is required for apoptosis within the developing CNS</article-title>. <source/>J Neurosci. (<year>2000</year>) <volume>20</volume>:<fpage>7384</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.20-19-07384.2000</pub-id><pub-id pub-id-type="pmid">11007897</pub-id></mixed-citation>
</ref>
<ref id="B81">
<label>81.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Muto</surname><given-names>T</given-names></name><name><surname>Kleppe</surname><given-names>M</given-names></name><name><surname>Bolanos</surname><given-names>LC</given-names></name><name><surname>Hueneman</surname><given-names>KM</given-names></name><name><surname>Walker</surname><given-names>CS</given-names></name><etal></etal></person-group>. <article-title>TRAF6 mediates basal activation of NF-κB necessary for hematopoietic stem cell homeostasis</article-title>. <source/>Cell Rep. (<year>2018</year>) <volume>22</volume>:<fpage>1250</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2018.01.013</pub-id><pub-id pub-id-type="pmid">29386112</pub-id></mixed-citation>
</ref>
<ref id="B82">
<label>82.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>TS</given-names></name><name><surname>Jacob</surname><given-names>A</given-names></name><name><surname>Walsh</surname><given-names>MC</given-names></name><name><surname>Kadono</surname><given-names>Y</given-names></name><name><surname>Fuentes-Panana</surname><given-names>E</given-names></name><etal></etal></person-group>. <article-title>TRAF6 is required for generation of the B-1a B cell compartment as well as T cell-dependent and -independent humoral immune responses</article-title>. <source/>PLoS ONE (<year>2009</year>) <volume>4</volume>:<fpage>e4736</fpage>.<pub-id pub-id-type="pmid">19270748</pub-id></mixed-citation>
</ref>
<ref id="B83">
<label>83.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>CG</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Cejas</surname><given-names>PJ</given-names></name><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Yoon</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>GK</given-names></name><etal></etal></person-group>. <article-title>TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasis</article-title>. <source/>Nat Med. (<year>2006</year>) <volume>12</volume>:<fpage>1088</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1038/nm1449</pub-id><pub-id pub-id-type="pmid">16921377</pub-id></mixed-citation>
</ref>
<ref id="B84">
<label>84.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearce</surname><given-names>EL</given-names></name><name><surname>Walsh</surname><given-names>MC</given-names></name><name><surname>Cejas</surname><given-names>PJ</given-names></name><name><surname>Harms</surname><given-names>GM</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>LS</given-names></name><etal></etal></person-group>. <article-title>Enhancing CD8 T-cell memory by modulating fatty acid metabolism</article-title>. <source/>Nature (<year>2009</year>) <volume>460</volume>:<fpage>103</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/nature08097</pub-id><pub-id pub-id-type="pmid">19494812</pub-id></mixed-citation>
</ref>
<ref id="B85">
<label>85.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cejas</surname><given-names>PJ</given-names></name><name><surname>Walsh</surname><given-names>MC</given-names></name><name><surname>Pearce</surname><given-names>EL</given-names></name><name><surname>Han</surname><given-names>D</given-names></name><name><surname>Harms</surname><given-names>GM</given-names></name><name><surname>Artis</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>TRAF6 inhibits Th17 differentiation and TGF-beta-mediated suppression of IL-2</article-title>. <source/>Blood (<year>2010</year>) <volume>115</volume>:<fpage>4750</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2009-09-242768</pub-id><pub-id pub-id-type="pmid">20351308</pub-id></mixed-citation>
</ref>
<ref id="B86">
<label>86.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Balasubramanian</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Chu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Taparowsky</surname><given-names>EJ</given-names></name><etal></etal></person-group>. <article-title>OX40 signaling favors the induction of T(H)9 cells and airway inflammation</article-title>. <source/>Nat Immunol. (<year>2012</year>) <volume>13</volume>:<fpage>981</fpage>–<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1038/ni.2390</pub-id><pub-id pub-id-type="pmid">22842344</pub-id></mixed-citation>
</ref>
<ref id="B87">
<label>87.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vlantis</surname><given-names>K</given-names></name><name><surname>Polykratis</surname><given-names>A</given-names></name><name><surname>Welz</surname><given-names>PS</given-names></name><name><surname>van</surname><given-names>Loo G</given-names></name><name><surname>Pasparakis</surname><given-names>M</given-names></name><name><surname>Wullaert</surname><given-names>A</given-names></name></person-group>. <article-title>TLR-independent anti-inflammatory function of intestinal epithelial TRAF6 signalling prevents DSS-induced colitis in mice</article-title>. <source/>Gut (<year>2016</year>) <volume>65</volume>:<fpage>935</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1136/gutjnl-2014-308323</pub-id><pub-id pub-id-type="pmid">25761602</pub-id></mixed-citation>
</ref>
<ref id="B88">
<label>88.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>PK</given-names></name><name><surname>Gupta</surname><given-names>SK</given-names></name><name><surname>Bhatnagar</surname><given-names>S</given-names></name><name><surname>Panguluri</surname><given-names>SK</given-names></name><name><surname>Darnay</surname><given-names>BG</given-names></name><name><surname>Choi</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Targeted ablation of TRAF6 inhibits skeletal muscle wasting in mice</article-title>. <source/>J Cell Biol. (<year>2010</year>) <volume>191</volume>:<fpage>1395</fpage>–<lpage>411</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.201006098</pub-id><pub-id pub-id-type="pmid">21187332</pub-id></mixed-citation>
</ref>
<ref id="B89">
<label>89.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hindi</surname><given-names>SM</given-names></name><name><surname>Paul</surname><given-names>PK</given-names></name><name><surname>Dahiya</surname><given-names>S</given-names></name><name><surname>Mishra</surname><given-names>V</given-names></name><name><surname>Bhatnagar</surname><given-names>S</given-names></name><name><surname>Kuang</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Reciprocal interaction between TRAF6 and notch signaling regulates adult myofiber regeneration upon injury</article-title>. <source/>Mol Cell Biol. (<year>2012</year>) <volume>32</volume>:<fpage>4833</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1128/MCB.00717-12</pub-id><pub-id pub-id-type="pmid">23028045</pub-id></mixed-citation>
</ref>
<ref id="B90">
<label>90.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>PK</given-names></name><name><surname>Bhatnagar</surname><given-names>S</given-names></name><name><surname>Mishra</surname><given-names>V</given-names></name><name><surname>Srivastava</surname><given-names>S</given-names></name><name><surname>Darnay</surname><given-names>BG</given-names></name><name><surname>Choi</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>The E3 ubiquitin ligase TRAF6 intercedes in starvation-induced skeletal muscle atrophy through multiple mechanisms</article-title>. <source/>Mol Cell Biol. (<year>2012</year>) <volume>32</volume>:<fpage>1248</fpage>–<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1128/MCB.06351-11</pub-id><pub-id pub-id-type="pmid">22290431</pub-id></mixed-citation>
</ref>
<ref id="B91">
<label>91.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>F</given-names></name><name><surname>Sun</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>TRAF1 is involved in the classical NF-kappaB activation and CD30-induced alternative activity in Hodgkin's lymphoma cells</article-title>. <source/>Mol Immunol. (<year>2009</year>) <volume>46</volume>:<fpage>2441</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.molimm.2009.05.178</pub-id><pub-id pub-id-type="pmid">19540595</pub-id></mixed-citation>
</ref>
<ref id="B92">
<label>92.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wicovsky</surname><given-names>A</given-names></name><name><surname>Henkler</surname><given-names>F</given-names></name><name><surname>Salzmann</surname><given-names>S</given-names></name><name><surname>Scheurich</surname><given-names>P</given-names></name><name><surname>Kneitz</surname><given-names>C</given-names></name><name><surname>Wajant</surname><given-names>H</given-names></name></person-group>. <article-title>Tumor necrosis factor receptor-associated factor-1 enhances proinflammatory TNF receptor-2 signaling and modifies TNFR1-TNFR2 cooperation</article-title>. <source/>Oncogene (<year>2009</year>) <volume>28</volume>:<fpage>1769</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2009.29</pub-id><pub-id pub-id-type="pmid">19287455</pub-id></mixed-citation>
</ref>
<ref id="B93">
<label>93.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>J</given-names></name><name><surname>Miller</surname><given-names>SA</given-names></name><name><surname>Wang</surname><given-names>HY</given-names></name><name><surname>Xia</surname><given-names>W</given-names></name><name><surname>Wen</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>BP</given-names></name><etal></etal></person-group>. <article-title>β-catenin interacts with and inhibits NF-κ B in human colon and breast cancer</article-title>. <source/>Cancer Cell (<year>2002</year>) <volume>2</volume>:<fpage>323</fpage>-34. <pub-id pub-id-type="doi">10.1016/S1535-6108(02)00154-X</pub-id><pub-id pub-id-type="pmid">12398896</pub-id></mixed-citation>
</ref>
<ref id="B94">
<label>94.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Cardinal</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Shao</surname><given-names>L</given-names></name><etal></etal></person-group>. <article-title>Wnt/beta-catenin signaling regulates cytokine-induced human inducible nitric oxide synthase expression by inhibiting nuclear factor-kappaB activation in cancer cells</article-title>. <source/>Cancer Res. (<year>2009</year>) <volume>69</volume>:<fpage>3764</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-0014</pub-id><pub-id pub-id-type="pmid">19383900</pub-id></mixed-citation>
</ref>
<ref id="B95">
<label>95.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carmona</surname><given-names>Arana JA</given-names></name><name><surname>Seher</surname><given-names>A</given-names></name><name><surname>Neumann</surname><given-names>M</given-names></name><name><surname>Lang</surname><given-names>I</given-names></name><name><surname>Siegmund</surname><given-names>D</given-names></name><name><surname>Wajant</surname><given-names>H</given-names></name></person-group>
<article-title>TNF receptor-associated factor 1 is a major target of soluble TWEAK</article-title>. <source/>Front Immunol. (<year>2014</year>) <volume>5</volume>:<fpage>63</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2014.00063</pub-id><pub-id pub-id-type="pmid">24600451</pub-id></mixed-citation>
</ref>
<ref id="B96">
<label>96.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lassen</surname><given-names>UN</given-names></name><name><surname>Meulendijks</surname><given-names>D</given-names></name><name><surname>Siu</surname><given-names>LL</given-names></name><name><surname>Karanikas</surname><given-names>V</given-names></name><name><surname>Mau-Sorensen</surname><given-names>M</given-names></name><name><surname>Schellens</surname><given-names>JH</given-names></name><etal></etal></person-group>. <article-title>A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers</article-title>. <source/>Clin Cancer Res. (<year>2015</year>) <volume>21</volume>:<fpage>258</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-1334</pub-id><pub-id pub-id-type="pmid">25388164</pub-id></mixed-citation>
</ref>
<ref id="B97">
<label>97.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meulendijks</surname><given-names>D</given-names></name><name><surname>Lassen</surname><given-names>UN</given-names></name><name><surname>Siu</surname><given-names>LL</given-names></name><name><surname>Huitema</surname><given-names>AD</given-names></name><name><surname>Karanikas</surname><given-names>V</given-names></name><name><surname>Mau-Sorensen</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Exposure and tumor Fn14 expression as determinants of pharmacodynamics of the anti-TWEAK monoclonal antibody RG7212 in patients with Fn14-positive solid tumors</article-title>. <source/>Clin Cancer Res. (<year>2016</year>) <volume>22</volume>:<fpage>858</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-1506</pub-id><pub-id pub-id-type="pmid">26446946</pub-id></mixed-citation>
</ref>
<ref id="B98">
<label>98.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armenia</surname><given-names>J</given-names></name><name><surname>Wankowicz</surname><given-names>SAM</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Kundra</surname><given-names>R</given-names></name><name><surname>Reznik</surname><given-names>E</given-names></name><etal></etal></person-group>. <article-title>The long tail of oncogenic drivers in prostate cancer</article-title>. <source/>Nat Genet. (<year>2018</year>) <volume>50</volume>:<fpage>645</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1038/s41588-018-0078-z</pub-id><pub-id pub-id-type="pmid">29610475</pub-id></mixed-citation>
</ref>
<ref id="B99">
<label>99.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahal</surname><given-names>R</given-names></name><name><surname>Frick</surname><given-names>M</given-names></name><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Korn</surname><given-names>JM</given-names></name><name><surname>Kridel</surname><given-names>R</given-names></name><name><surname>Chan</surname><given-names>FC</given-names></name><etal></etal></person-group>. <article-title>Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma</article-title>. <source/>Nat Med. (<year>2014</year>) <volume>20</volume>:<fpage>87</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1038/nm.3435</pub-id><pub-id pub-id-type="pmid">24362935</pub-id></mixed-citation>
</ref>
<ref id="B100">
<label>100.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meissner</surname><given-names>B</given-names></name><name><surname>Kridel</surname><given-names>R</given-names></name><name><surname>Lim</surname><given-names>RS</given-names></name><name><surname>Rogic</surname><given-names>S</given-names></name><name><surname>Tse</surname><given-names>K</given-names></name><name><surname>Scott</surname><given-names>DW</given-names></name><etal></etal></person-group>. <article-title>The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma</article-title>. <source/>Blood (<year>2013</year>) <volume>121</volume>:<fpage>3161</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2013-01-478834</pub-id><pub-id pub-id-type="pmid">23407552</pub-id></mixed-citation>
</ref>
<ref id="B101">
<label>101.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saba</surname><given-names>N</given-names></name><name><surname>Wiestner</surname><given-names>A</given-names></name></person-group>. <article-title>Do mantle cell lymphomas have an 'Achilles heel'?</article-title>
<source/>Curr Opin Hematol. (<year>2014</year>) <volume>21</volume>:<fpage>350</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1097/MOH.0000000000000057</pub-id><pub-id pub-id-type="pmid">24857884</pub-id></mixed-citation>
</ref>
<ref id="B102">
<label>102.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Compagno</surname><given-names>M</given-names></name><name><surname>Lim</surname><given-names>WK</given-names></name><name><surname>Grunn</surname><given-names>A</given-names></name><name><surname>Nandula</surname><given-names>SV</given-names></name><name><surname>Brahmachary</surname><given-names>M</given-names></name><name><surname>Shen</surname><given-names>Q</given-names></name><etal></etal></person-group>. <article-title>Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma</article-title>. <source/>Nature (<year>2009</year>) <volume>459</volume>:<fpage>717</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1038/nature07968</pub-id><pub-id pub-id-type="pmid">19412164</pub-id></mixed-citation>
</ref>
<ref id="B103">
<label>103.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>RR</given-names></name><name><surname>Zhou</surname><given-names>AY</given-names></name><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>O'Connell</surname><given-names>JT</given-names></name><name><surname>Hagerstrand</surname><given-names>D</given-names></name><name><surname>Beroukhim</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>TRAF2 is an NF-κB-activating oncogene in epithelial cancers</article-title>. <source/>Oncogene (<year>2015</year>) <volume>34</volume>:<fpage>209</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2013.543</pub-id><pub-id pub-id-type="pmid">24362534</pub-id></mixed-citation>
</ref>
<ref id="B104">
<label>104.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giannakis</surname><given-names>M</given-names></name><name><surname>Hodis</surname><given-names>E</given-names></name><name><surname>Jasmine</surname><given-names>Mu X</given-names></name><name><surname>Yamauchi</surname><given-names>M</given-names></name><name><surname>Rosenbluh</surname><given-names>J</given-names></name><name><surname>Cibulskis</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>RNF43 is frequently mutated in colorectal and endometrial cancers</article-title>. <source/>Nat Genet. (<year>2014</year>) <volume>46</volume>:<fpage>1264</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1038/ng.3127</pub-id><pub-id pub-id-type="pmid">25344691</pub-id></mixed-citation>
</ref>
<ref id="B105">
<label>105.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yaeger</surname><given-names>R</given-names></name><name><surname>Chatila</surname><given-names>WK</given-names></name><name><surname>Lipsyc</surname><given-names>MD</given-names></name><name><surname>Hechtman</surname><given-names>JF</given-names></name><name><surname>Cercek</surname><given-names>A</given-names></name><name><surname>Sanchez-Vega</surname><given-names>F</given-names></name><etal></etal></person-group>. <article-title>Clinical sequencing defines the genomic landscape of metastatic colorectal cancer</article-title>. <source/>Cancer Cell (<year>2018</year>) <volume>33</volume>:<fpage>125</fpage>–<lpage>36.e3</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccell.2017.12.004</pub-id><pub-id pub-id-type="pmid">29316426</pub-id></mixed-citation>
</ref>
<ref id="B106">
<label>106.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zehir</surname><given-names>A</given-names></name><name><surname>Benayed</surname><given-names>R</given-names></name><name><surname>Shah</surname><given-names>RH</given-names></name><name><surname>Syed</surname><given-names>A</given-names></name><name><surname>Middha</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>HR</given-names></name><etal></etal></person-group>
<article-title>Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients</article-title>. <source/>Nat Med. (<year>2017</year>) <volume>23</volume>:<fpage>703</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4333</pub-id><pub-id pub-id-type="pmid">28481359</pub-id></mixed-citation>
</ref>
<ref id="B107">
<label>107.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Yuen</surname><given-names>ST</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>SP</given-names></name><name><surname>Yan</surname><given-names>HH</given-names></name><name><surname>Shi</surname><given-names>ST</given-names></name><etal></etal></person-group>. <article-title>Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer</article-title>. <source/>Nat Genet. (<year>2014</year>) <volume>46</volume>:<fpage>573</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1038/ng.2983</pub-id><pub-id pub-id-type="pmid">24816253</pub-id></mixed-citation>
</ref>
<ref id="B108">
<label>108.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giannakis</surname><given-names>M</given-names></name><name><surname>Mu</surname><given-names>XJ</given-names></name><name><surname>Shukla</surname><given-names>SA</given-names></name><name><surname>Qian</surname><given-names>ZR</given-names></name><name><surname>Cohen</surname><given-names>O</given-names></name><name><surname>Nishihara</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>Genomic correlates of immune-cell infiltrates in colorectal carcinoma</article-title>. <source/>Cell Rep. (<year>2016</year>) <volume>15</volume>:<fpage>857</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2016.03.075</pub-id><pub-id pub-id-type="pmid">27149842</pub-id></mixed-citation>
</ref>
<ref id="B109">
<label>109.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceccarelli</surname><given-names>M</given-names></name><name><surname>Barthel</surname><given-names>FP</given-names></name><name><surname>Malta</surname><given-names>TM</given-names></name><name><surname>Sabedot</surname><given-names>TS</given-names></name><name><surname>Salama</surname><given-names>SR</given-names></name><name><surname>Murray</surname><given-names>BA</given-names></name><etal></etal></person-group>. <article-title>Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma</article-title>. <source/>Cell (<year>2016</year>) <volume>164</volume>:<fpage>550</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2015.12.028</pub-id><pub-id pub-id-type="pmid">26824661</pub-id></mixed-citation>
</ref>
<ref id="B110">
<label>110.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beltran</surname><given-names>H</given-names></name><name><surname>Prandi</surname><given-names>D</given-names></name><name><surname>Mosquera</surname><given-names>JM</given-names></name><name><surname>Benelli</surname><given-names>M</given-names></name><name><surname>Puca</surname><given-names>L</given-names></name><name><surname>Cyrta</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer</article-title>. <source/>Nat Med. (<year>2016</year>) <volume>22</volume>:<fpage>298</fpage>–<lpage>305</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4045</pub-id><pub-id pub-id-type="pmid">26855148</pub-id></mixed-citation>
</ref>
<ref id="B111">
<label>111.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Stransky</surname><given-names>N</given-names></name><name><surname>McCord</surname><given-names>CL</given-names></name><name><surname>Cerami</surname><given-names>E</given-names></name><name><surname>Lagowski</surname><given-names>J</given-names></name><name><surname>Kelly</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes</article-title>. <source/>Nat Commun. (<year>2014</year>) <volume>5</volume>:<fpage>5006</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms6006</pub-id><pub-id pub-id-type="pmid">25233892</pub-id></mixed-citation>
</ref>
<ref id="B112">
<label>112.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>B</given-names></name><name><surname>Song</surname><given-names>F</given-names></name><name><surname>Cao</surname><given-names>W</given-names></name><etal></etal></person-group>. <article-title>Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy</article-title>. <source/>Proc Natl Acad Sci USA. (<year>2015</year>) <volume>112</volume>:<fpage>1107</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1422640112</pub-id><pub-id pub-id-type="pmid">25583476</pub-id></mixed-citation>
</ref>
<ref id="B113">
<label>113.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Network</surname><given-names>TCGA</given-names></name></person-group>
<article-title>Comprehensive genomic characterization of head and neck squamous cell carcinomas</article-title>. <source/>Nature (<year>2015</year>) <volume>517</volume>:<fpage>576</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1038/nature14129</pub-id><pub-id pub-id-type="pmid">25631445</pub-id></mixed-citation>
</ref>
<ref id="B114">
<label>114.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galante</surname><given-names>PA</given-names></name><name><surname>Parmigiani</surname><given-names>RB</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Caballero</surname><given-names>OL</given-names></name><name><surname>de</surname><given-names>Souza JE</given-names></name><name><surname>Navarro</surname><given-names>FC</given-names></name><etal></etal></person-group>. <article-title>Distinct patterns of somatic alterations in a lymphoblastoid and a tumor genome derived from the same individual</article-title>. <source/>Nucleic Acids Res. (<year>2011</year>) <volume>39</volume>:<fpage>6056</fpage>–<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkr221</pub-id><pub-id pub-id-type="pmid">21493686</pub-id></mixed-citation>
</ref>
<ref id="B115">
<label>115.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lezcano</surname><given-names>C</given-names></name><name><surname>Shoushtari</surname><given-names>AN</given-names></name><name><surname>Ariyan</surname><given-names>C</given-names></name><name><surname>Hollmann</surname><given-names>TJ</given-names></name><name><surname>Busam</surname><given-names>KJ</given-names></name></person-group>. <article-title>Primary and metastatic melanoma with NTRK fusions</article-title>. <source/>Am J Surg Pathol. (<year>2018</year>) <volume>42</volume>:<fpage>1052</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1097/PAS.0000000000001070</pub-id><pub-id pub-id-type="pmid">29683819</pub-id></mixed-citation>
</ref>
<ref id="B116">
<label>116.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garrison</surname><given-names>JB</given-names></name><name><surname>Samuel</surname><given-names>T</given-names></name><name><surname>Reed</surname><given-names>JC</given-names></name></person-group>. <article-title>TRAF2-binding BIR1 domain of c-IAP2/MALT1 fusion protein is essential for activation of NF-kappaB</article-title>. <source/>Oncogene (<year>2009</year>) <volume>28</volume>:<fpage>1584</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2009.17</pub-id><pub-id pub-id-type="pmid">19234489</pub-id></mixed-citation>
</ref>
<ref id="B117">
<label>117.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grech</surname><given-names>AP</given-names></name><name><surname>Amesbury</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>T</given-names></name><name><surname>Gardam</surname><given-names>S</given-names></name><name><surname>Basten</surname><given-names>A</given-names></name><name><surname>Brink</surname><given-names>R</given-names></name></person-group>. <article-title>TRAF2 differentially regulates the canonical and noncanonical pathways of NF-kappaB activation in mature B cells</article-title>. <source/>Immunity (<year>2004</year>) <volume>21</volume>:<fpage>629</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2004.09.011</pub-id><pub-id pub-id-type="pmid">15539150</pub-id></mixed-citation>
</ref>
<ref id="B118">
<label>118.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vallabhapurapu</surname><given-names>S</given-names></name><name><surname>Matsuzawa</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Tseng</surname><given-names>PH</given-names></name><name><surname>Keats</surname><given-names>JJ</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling</article-title>. <source/>Nat Immunol. (<year>2008</year>) <volume>9</volume>:<fpage>1364</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1038/ni.1678</pub-id><pub-id pub-id-type="pmid">18997792</pub-id></mixed-citation>
</ref>
<ref id="B119">
<label>119.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>SM</given-names></name><name><surname>Jang</surname><given-names>SJ</given-names></name><name><surname>Shim</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Hong</surname><given-names>SM</given-names></name><name><surname>Sung</surname><given-names>CO</given-names></name><etal></etal></person-group>. <article-title>Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification</article-title>. <source/>Hepatology (<year>2014</year>) <volume>60</volume>:<fpage>1972</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1002/hep.27198</pub-id><pub-id pub-id-type="pmid">24798001</pub-id></mixed-citation>
</ref>
<ref id="B120">
<label>120.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson-Bernitsas</surname><given-names>DG</given-names></name><name><surname>Ichikawa</surname><given-names>H</given-names></name><name><surname>Takada</surname><given-names>Y</given-names></name><name><surname>Myers</surname><given-names>JN</given-names></name><name><surname>Lin</surname><given-names>XL</given-names></name><name><surname>Darnay</surname><given-names>BG</given-names></name><etal></etal></person-group>. <article-title>Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-kappaB activation and proliferation in human head and neck squamous cell carcinoma</article-title>. <source/>Oncogene (<year>2007</year>) <volume>26</volume>:<fpage>1385</fpage>–<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1209945</pub-id><pub-id pub-id-type="pmid">16953224</pub-id></mixed-citation>
</ref>
<ref id="B121">
<label>121.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobin</surname><given-names>D</given-names></name><name><surname>van</surname><given-names>Hogerlinden M</given-names></name><name><surname>Toftgard</surname><given-names>R</given-names></name></person-group>. <article-title>UVB-induced association of tumor necrosis factor (TNF) receptor 1/TNF receptor-associated factor-2 mediates activation of Rel proteins</article-title>. <source/>Proc Natl Acad Sci USA. (<year>1998</year>) <volume>95</volume>:<fpage>565</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">9435232</pub-id></mixed-citation>
</ref>
<ref id="B122">
<label>122.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massoumi</surname><given-names>R</given-names></name><name><surname>Chmielarska</surname><given-names>K</given-names></name><name><surname>Hennecke</surname><given-names>K</given-names></name><name><surname>Pfeifer</surname><given-names>A</given-names></name><name><surname>Fassler</surname><given-names>R</given-names></name></person-group>. <article-title>Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling</article-title>. <source/>Cell (<year>2006</year>) <volume>125</volume>:<fpage>665</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2006.03.041</pub-id><pub-id pub-id-type="pmid">16713561</pub-id></mixed-citation>
</ref>
<ref id="B123">
<label>123.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>MB</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>MX</given-names></name><name><surname>Shen</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>XY</given-names></name><name><surname>Yao</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Activation of AMP-activated protein kinase (AMPK) mediates plumbagin-induced apoptosis and growth inhibition in cultured human colon cancer cells</article-title>. <source/>Cell Signal. (<year>2013</year>) <volume>25</volume>:<fpage>1993</fpage>–<lpage>2002</lpage>. <pub-id pub-id-type="doi">10.1016/j.cellsig.2013.05.026</pub-id><pub-id pub-id-type="pmid">23712032</pub-id></mixed-citation>
</ref>
<ref id="B124">
<label>124.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mhaidat</surname><given-names>NM</given-names></name><name><surname>Thorne</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>XD</given-names></name><name><surname>Hersey</surname><given-names>P</given-names></name></person-group>. <article-title>Involvement of endoplasmic reticulum stress in Docetaxel-induced JNK-dependent apoptosis of human melanoma</article-title>. <source/>Apoptosis (<year>2008</year>) <volume>13</volume>:<fpage>1505</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1007/s10495-008-0276-8</pub-id><pub-id pub-id-type="pmid">18989785</pub-id></mixed-citation>
</ref>
<ref id="B125">
<label>125.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>YouYou</surname></name><name><surname>Yin</surname><given-names>W</given-names></name></person-group>. <article-title>IRE1α-TRAF2-ASK1 pathway is involved in CSTMP-induced apoptosis and ER stress in human non-small cell lung cancer A549 cells</article-title>. <source/>Biomed Pharmacother. (<year>2016</year>) <volume>82</volume>:<fpage>281</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2016.04.050</pub-id><pub-id pub-id-type="pmid">27470364</pub-id></mixed-citation>
</ref>
<ref id="B126">
<label>126.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Pan</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>X</given-names></name><etal></etal></person-group>. <article-title>The molecular mechanisms of XBP-1 gene silencing on IRE1α-TRAF2-ASK1-JNK pathways in oral squamous cell carcinoma under endoplasmic reticulum stress</article-title>. <source/>Biomed Pharmacother. (<year>2016</year>) <volume>77</volume>:<fpage>108</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2015.12.010</pub-id><pub-id pub-id-type="pmid">26796273</pub-id></mixed-citation>
</ref>
<ref id="B127">
<label>127.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamkanfi</surname><given-names>M</given-names></name><name><surname>D'Hondt</surname><given-names>K</given-names></name><name><surname>Vande</surname><given-names>Walle L</given-names></name><name><surname>van</surname><given-names>Gurp M</given-names></name><name><surname>Denecker</surname><given-names>G</given-names></name><name><surname>Demeulemeester</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>A novel caspase-2 complex containing TRAF2 and RIP1</article-title>. <source/>J Biol Chem. (<year>2005</year>) <volume>280</volume>:<fpage>6923</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M411180200</pub-id><pub-id pub-id-type="pmid">15590671</pub-id></mixed-citation>
</ref>
<ref id="B128">
<label>128.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robeson</surname><given-names>AC</given-names></name><name><surname>Lindblom</surname><given-names>KR</given-names></name><name><surname>Wojton</surname><given-names>J</given-names></name><name><surname>Kornbluth</surname><given-names>S</given-names></name><name><surname>Matsuura</surname><given-names>K</given-names></name></person-group>. <article-title>Dimer-specific immunoprecipitation of active caspase-2 identifies TRAF proteins as novel activators</article-title>. <source/>EMBO J. (<year>2018</year>) <volume>37</volume>:<fpage>e97072</fpage>. <pub-id pub-id-type="doi">10.15252/embj.201797072</pub-id><pub-id pub-id-type="pmid">29875129</pub-id></mixed-citation>
</ref>
<ref id="B129">
<label>129.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doppler</surname><given-names>H</given-names></name><name><surname>Liou</surname><given-names>GY</given-names></name><name><surname>Storz</surname><given-names>P</given-names></name></person-group>. <article-title>Downregulation of TRAF2 mediates NIK-induced pancreatic cancer cell proliferation and tumorigenicity</article-title>. <source/>PLoS ONE (<year>2013</year>) <volume>8</volume>:<fpage>e53676</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0053676</pub-id><pub-id pub-id-type="pmid">23301098</pub-id></mixed-citation>
</ref>
<ref id="B130">
<label>130.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohtsu</surname><given-names>N</given-names></name><name><surname>Nakatani</surname><given-names>Y</given-names></name><name><surname>Yamashita</surname><given-names>D</given-names></name><name><surname>Ohue</surname><given-names>S</given-names></name><name><surname>Ohnishi</surname><given-names>T</given-names></name><name><surname>Kondo</surname><given-names>T</given-names></name></person-group>. <article-title>Eva1 maintains the stem-like character of glioblastoma-initiating cells by activating the noncanonical NF-κB signaling pathway</article-title>. <source/>Cancer Res. (<year>2016</year>) <volume>76</volume>:<fpage>171</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-0884</pub-id><pub-id pub-id-type="pmid">26677976</pub-id></mixed-citation>
</ref>
<ref id="B131">
<label>131.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Jie</surname><given-names>Z</given-names></name><name><surname>Joo</surname><given-names>D</given-names></name><name><surname>Ordureau</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Gan</surname><given-names>W</given-names></name><etal></etal></person-group>. <article-title>TRAF2 and OTUD7B govern a ubiquitin-dependent switch that regulates mTORC2 signalling</article-title>. <source/>Nature (<year>2017</year>) <volume>545</volume>:<fpage>365</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/nature22344</pub-id><pub-id pub-id-type="pmid">28489822</pub-id></mixed-citation>
</ref>
<ref id="B132">
<label>132.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trauzold</surname><given-names>A</given-names></name><name><surname>Roder</surname><given-names>C</given-names></name><name><surname>Sipos</surname><given-names>B</given-names></name><name><surname>Karsten</surname><given-names>K</given-names></name><name><surname>Arlt</surname><given-names>A</given-names></name><name><surname>Jiang</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>CD95 and TRAF2 promote invasiveness of pancreatic cancer cells</article-title>. <source/>FASEB J. (<year>2005</year>) <volume>19</volume>:<fpage>620</fpage>–<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1096/fj.04-2984fje</pub-id><pub-id pub-id-type="pmid">15670977</pub-id></mixed-citation>
</ref>
<ref id="B133">
<label>133.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>B</given-names></name><name><surname>Ruan</surname><given-names>J</given-names></name><name><surname>Mi</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><etal></etal></person-group>. <article-title>Knockdown of TNF receptor-associated factor 2 (TRAF2) modulates <italic>in vitro</italic> growth of TRAIL-treated prostate cancer cells</article-title>. <source/>Biomed Pharmacother. (<year>2017</year>) <volume>93</volume>:<fpage>462</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2017.05.145</pub-id><pub-id pub-id-type="pmid">28667915</pub-id></mixed-citation>
</ref>
<ref id="B134">
<label>134.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Morgan-Lappe</surname><given-names>SE</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Bockbrader</surname><given-names>KM</given-names></name><name><surname>Pamarthy</surname><given-names>D</given-names></name><name><surname>Thomas</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>Growth inhibition and radiosensitization of glioblastoma and lung cancer cells by small interfering RNA silencing of tumor necrosis factor receptor-associated factor 2</article-title>. <source/>Cancer Res. (<year>2008</year>) <volume>68</volume>:<fpage>7570</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-0632</pub-id><pub-id pub-id-type="pmid">18794145</pub-id></mixed-citation>
</ref>
<ref id="B135">
<label>135.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Min</surname><given-names>L</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Shu</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>High expression of tumor necrosis factor receptor-associated factor 2 promotes tumor metastasis and is associated with unfavorable prognosis in gastric cancer</article-title>. <source/>J Gastroenterol Hepatol. (<year>2018</year>) <volume>33</volume>:<fpage>431</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1111/jgh.13818</pub-id><pub-id pub-id-type="pmid">28482378</pub-id></mixed-citation>
</ref>
<ref id="B136">
<label>136.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>F</given-names></name><name><surname>Wen</surname><given-names>W</given-names></name><name><surname>Yao</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Zykova</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>Tumor necrosis factor receptor-associated factor family protein 2 is a key mediator of the epidermal growth factor-induced ribosomal S6 kinase 2/cAMP-responsive element-binding protein/Fos protein signaling pathway</article-title>. <source/>J Biol Chem. (<year>2012</year>) <volume>287</volume>:<fpage>25881</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M112.359521</pub-id><pub-id pub-id-type="pmid">22685297</pub-id></mixed-citation>
</ref>
<ref id="B137">
<label>137.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name></person-group>. <article-title>Prognostic significance of TNFR-associated factor 1 and 2 (TRAF1 and TRAF2) in glioblastoma</article-title>. <source/>Med Sci Monit. (<year>2017</year>) <volume>23</volume>:<fpage>4506</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.12659/MSM.903397</pub-id><pub-id pub-id-type="pmid">28926524</pub-id></mixed-citation>
</ref>
<ref id="B138">
<label>138.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peramuhendige</surname><given-names>P</given-names></name><name><surname>Marino</surname><given-names>S</given-names></name><name><surname>Bishop</surname><given-names>RT</given-names></name><name><surname>de</surname><given-names>Ridder D</given-names></name><name><surname>Khogeer</surname><given-names>A</given-names></name><name><surname>Baldini</surname><given-names>I</given-names></name><etal></etal></person-group>. <article-title>TRAF2 in osteotropic breast cancer cells enhances skeletal tumour growth and promotes osteolysis</article-title>. <source/>Sci Rep. (<year>2018</year>) <volume>8</volume>:<fpage>39</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-18327-5</pub-id><pub-id pub-id-type="pmid">29311633</pub-id></mixed-citation>
</ref>
<ref id="B139">
<label>139.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name></person-group>. <article-title>Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activating the NF-κB signaling pathway</article-title>. <source/>Theranostics (<year>2018</year>) <volume>8</volume>:<fpage>3224</fpage>–<lpage>36</lpage>. <pub-id pub-id-type="doi">10.7150/thno.23259</pub-id><pub-id pub-id-type="pmid">29930725</pub-id></mixed-citation>
</ref>
<ref id="B140">
<label>140.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiche</surname><given-names>J</given-names></name><name><surname>Pommier</surname><given-names>S</given-names></name><name><surname>Beneteau</surname><given-names>M</given-names></name><name><surname>Mondragon</surname><given-names>L</given-names></name><name><surname>Meynet</surname><given-names>O</given-names></name><name><surname>Zunino</surname><given-names>B</given-names></name><etal></etal></person-group>. <article-title>GAPDH enhances the aggressiveness and the vascularization of non-Hodgkin's B lymphomas via NF-κB-dependent induction of HIF-1α</article-title>. <source/>Leukemia (<year>2015</year>) <volume>29</volume>:<fpage>1163</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1038/leu.2014.324</pub-id><pub-id pub-id-type="pmid">25394713</pub-id></mixed-citation>
</ref>
<ref id="B141">
<label>141.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blakely</surname><given-names>CM</given-names></name><name><surname>Pazarentzos</surname><given-names>E</given-names></name><name><surname>Olivas</surname><given-names>V</given-names></name><name><surname>Asthana</surname><given-names>S</given-names></name><name><surname>Yan</surname><given-names>JJ</given-names></name><name><surname>Tan</surname><given-names>I</given-names></name><etal></etal></person-group>. <article-title>NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer</article-title>. <source/>Cell Rep. (<year>2015</year>) <volume>11</volume>:<fpage>98</fpage>–<lpage>110</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2015.03.012</pub-id><pub-id pub-id-type="pmid">25843712</pub-id></mixed-citation>
</ref>
<ref id="B142">
<label>142.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>AY</given-names></name><name><surname>Shen</surname><given-names>RR</given-names></name><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Lock</surname><given-names>YJ</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>ZJ</given-names></name><etal></etal></person-group>. <article-title>IKKε-mediated tumorigenesis requires K63-linked polyubiquitination by a cIAP1/cIAP2/TRAF2 E3 ubiquitin ligase complex</article-title>. <source/>Cell Rep. (<year>2013</year>) <volume>3</volume>:<fpage>724</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2013.01.031</pub-id><pub-id pub-id-type="pmid">23453969</pub-id></mixed-citation>
</ref>
<ref id="B143">
<label>143.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>RR</given-names></name><name><surname>Zhou</surname><given-names>AY</given-names></name><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Lim</surname><given-names>E</given-names></name><name><surname>Habelhah</surname><given-names>H</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name></person-group>. <article-title>IκB kinase ε phosphorylates TRAF2 to promote mammary epithelial cell transformation</article-title>. <source/>Mol Cell Biol. (<year>2012</year>) <volume>32</volume>:<fpage>4756</fpage>–<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1128/MCB.00468-12</pub-id><pub-id pub-id-type="pmid">23007157</pub-id></mixed-citation>
</ref>
<ref id="B144">
<label>144.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Forero</surname><given-names>I</given-names></name><name><surname>Rouzaut</surname><given-names>A</given-names></name><name><surname>Palazon</surname><given-names>A</given-names></name><name><surname>Dubrot</surname><given-names>J</given-names></name><name><surname>Melero</surname><given-names>I</given-names></name></person-group>. <article-title>Lysine 63 polyubiquitination in immunotherapy and in cancer-promoting inflammation</article-title>. <source/>Clin Cancer Res. (<year>2009</year>) <volume>15</volume>:<fpage>6751</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-09-1225</pub-id><pub-id pub-id-type="pmid">19887490</pub-id></mixed-citation>
</ref>
<ref id="B145">
<label>145.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalvez</surname><given-names>F</given-names></name><name><surname>Lawrence</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Yee</surname><given-names>S</given-names></name><name><surname>Pitti</surname><given-names>R</given-names></name><name><surname>Marsters</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>TRAF2 Sets a threshold for extrinsic apoptosis by tagging caspase-8 with a ubiquitin shutoff timer</article-title>. <source/>Mol Cell (<year>2012</year>) <volume>48</volume>:<fpage>888</fpage>–<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2012.09.031</pub-id><pub-id pub-id-type="pmid">23142077</pub-id></mixed-citation>
</ref>
<ref id="B146">
<label>146.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>YT</given-names></name><name><surname>Yue</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Tong</surname><given-names>JS</given-names></name><name><surname>Chen</surname><given-names>ZG</given-names></name><name><surname>Khuri</surname><given-names>FR</given-names></name><etal></etal></person-group>. <article-title>Suppression of death receptor 5 enhances cancer cell invasion and metastasis through activation of caspase-8/TRAF2-mediated signaling</article-title>. <source/>Oncotarget (<year>2015</year>) <volume>6</volume>:<fpage>41324</fpage>–<lpage>38</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.5847</pub-id><pub-id pub-id-type="pmid">26510914</pub-id></mixed-citation>
</ref>
<ref id="B147">
<label>147.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Padilla</surname><given-names>MT</given-names></name><name><surname>Ren</surname><given-names>G</given-names></name><etal></etal></person-group>. <article-title>Attenuation of TNFSF10/TRAIL-induced apoptosis by an autophagic survival pathway involving TRAF2- and RIPK1/RIP1-mediated MAPK8/JNK activation</article-title>. <source/>Autophagy (<year>2012</year>) <volume>8</volume>:<fpage>1811</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.4161/auto.22145</pub-id><pub-id pub-id-type="pmid">23051914</pub-id></mixed-citation>
</ref>
<ref id="B148">
<label>148.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Qu</surname><given-names>X</given-names></name><name><surname>Che</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>DR5-Cbl-b/c-Cbl-TRAF2 complex inhibits TRAIL-induced apoptosis by promoting TRAF2-mediated polyubiquitination of caspase-8 in gastric cancer cells</article-title>. <source/>Mol Oncol. (<year>2017</year>) <volume>11</volume>:<fpage>1733</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1002/1878-0261.12140</pub-id><pub-id pub-id-type="pmid">28972304</pub-id></mixed-citation>
</ref>
<ref id="B149">
<label>149.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hibino</surname><given-names>T</given-names></name><name><surname>Sakaguchi</surname><given-names>M</given-names></name><name><surname>Miyamoto</surname><given-names>S</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Motoyama</surname><given-names>A</given-names></name><name><surname>Hosoi</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>S100A9 is a novel ligand of EMMPRIN that promotes melanoma metastasis</article-title>. <source/>Cancer Res. (<year>2013</year>) <volume>73</volume>:<fpage>172</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-3843</pub-id><pub-id pub-id-type="pmid">23135911</pub-id></mixed-citation>
</ref>
<ref id="B150">
<label>150.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basudhar</surname><given-names>D</given-names></name><name><surname>Glynn</surname><given-names>SA</given-names></name><name><surname>Greer</surname><given-names>M</given-names></name><name><surname>Somasundaram</surname><given-names>V</given-names></name><name><surname>No</surname><given-names>JH</given-names></name><name><surname>Scheiblin</surname><given-names>DA</given-names></name><etal></etal></person-group>. <article-title>Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer</article-title>. <source/>Proc Natl Acad Sci USA. (<year>2017</year>) <volume>114</volume>:<fpage>13030</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1709119114</pub-id><pub-id pub-id-type="pmid">29087320</pub-id></mixed-citation>
</ref>
<ref id="B151">
<label>151.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fortin</surname><given-names>Ensign SP</given-names></name><name><surname>Mathews</surname><given-names>IT</given-names></name><name><surname>Eschbacher</surname><given-names>JM</given-names></name><name><surname>Loftus</surname><given-names>JC</given-names></name><name><surname>Symons</surname><given-names>MH</given-names></name><name><surname>Tran</surname><given-names>NL</given-names></name></person-group>
<article-title>The Src homology 3 domain-containing guanine nucleotide exchange factor is overexpressed in high-grade gliomas and promotes tumor necrosis factor-like weak inducer of apoptosis-fibroblast growth factor-inducible 14-induced cell migration and invasion via tumor necrosis factor receptor-associated factor 2</article-title>. <source/>J Biol Chem. (<year>2013</year>) <volume>288</volume>:<fpage>21887</fpage>–<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M113.468686</pub-id><pub-id pub-id-type="pmid">23775076</pub-id></mixed-citation>
</ref>
<ref id="B152">
<label>152.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>AG</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Al-Ahmadie</surname><given-names>H</given-names></name><name><surname>Bellmunt</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>G</given-names></name><name><surname>Cherniack</surname><given-names>AD</given-names></name><etal></etal></person-group>. <article-title>Comprehensive molecular characterization of muscle-invasive bladder cancer</article-title>. <source/>Cell (<year>2017</year>) <volume>171</volume>:<fpage>540</fpage>–<lpage>56.e25</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2017.09.007</pub-id><pub-id pub-id-type="pmid">28988769</pub-id></mixed-citation>
</ref>
<ref id="B153">
<label>153.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>CR</given-names></name><name><surname>Edwards</surname><given-names>SK</given-names></name><name><surname>Xie</surname><given-names>P</given-names></name></person-group>. <article-title>Targeting TRAF3 downstream signaling pathways in b cell neoplasms</article-title>. <source/>J Cancer Sci Ther. (<year>2015</year>) <volume>7</volume>:<fpage>67</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.4172/1948-5956.1000327</pub-id><pub-id pub-id-type="pmid">25960828</pub-id></mixed-citation>
</ref>
<ref id="B154">
<label>154.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hyeon</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Shin</surname><given-names>SH</given-names></name><name><surname>Yoo</surname><given-names>HY</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>WS</given-names></name><etal></etal></person-group>. <article-title>Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement</article-title>. <source/>Mod Pathol. (<year>2018</year>) <volume>31</volume>:<fpage>1418</fpage>–<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1038/s41379-018-0064-0</pub-id><pub-id pub-id-type="pmid">29765142</pub-id></mixed-citation>
</ref>
<ref id="B155">
<label>155.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keats</surname><given-names>JJ</given-names></name><name><surname>Fonseca</surname><given-names>R</given-names></name><name><surname>Chesi</surname><given-names>M</given-names></name><name><surname>Schop</surname><given-names>R</given-names></name><name><surname>Baker</surname><given-names>A</given-names></name><name><surname>Chng</surname><given-names>WJ</given-names></name><etal></etal></person-group>. <article-title>Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma</article-title>. <source/>Cancer Cell (<year>2007</year>) <volume>12</volume>:<fpage>131</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2007.07.003</pub-id><pub-id pub-id-type="pmid">17692805</pub-id></mixed-citation>
</ref>
<ref id="B156">
<label>156.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>BA</given-names></name><name><surname>Boyle</surname><given-names>EM</given-names></name><name><surname>Wardell</surname><given-names>CP</given-names></name><name><surname>Murison</surname><given-names>A</given-names></name><name><surname>Begum</surname><given-names>DB</given-names></name><name><surname>Dahir</surname><given-names>NM</given-names></name><etal></etal></person-group>. <article-title>Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma</article-title>. <source/>J Clin Oncol. (<year>2015</year>) <volume>33</volume>:<fpage>3911</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2014.59.1503</pub-id><pub-id pub-id-type="pmid">26282654</pub-id></mixed-citation>
</ref>
<ref id="B157">
<label>157.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otto</surname><given-names>C</given-names></name><name><surname>Giefing</surname><given-names>M</given-names></name><name><surname>Massow</surname><given-names>A</given-names></name><name><surname>Vater</surname><given-names>I</given-names></name><name><surname>Gesk</surname><given-names>S</given-names></name><name><surname>Schlesner</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Genetic lesions of the TRAF3 and MAP3K14 genes in classical Hodgkin lymphoma</article-title>. <source/>Br J Haematol. (<year>2012</year>) <volume>157</volume>:<fpage>702</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2141.2012.09113.x</pub-id><pub-id pub-id-type="pmid">22469134</pub-id></mixed-citation>
</ref>
<ref id="B158">
<label>158.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Calado</surname><given-names>DP</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Frohler</surname><given-names>S</given-names></name><name><surname>Kochert</surname><given-names>K</given-names></name><name><surname>Qian</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>An oncogenic role for alternative NF-κB signaling in DLBCL revealed upon deregulated BCL6 expression</article-title>. <source/>Cell Rep. (<year>2015</year>) <volume>11</volume>:<fpage>715</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2015.03.059</pub-id><pub-id pub-id-type="pmid">25921526</pub-id></mixed-citation>
</ref>
<ref id="B159">
<label>159.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>D</given-names></name><name><surname>Deaglio</surname><given-names>S</given-names></name><name><surname>Dominguez-Sola</surname><given-names>D</given-names></name><name><surname>Rasi</surname><given-names>S</given-names></name><name><surname>Vaisitti</surname><given-names>T</given-names></name><name><surname>Agostinelli</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma</article-title>. <source/>Blood (<year>2011</year>) <volume>118</volume>:<fpage>4930</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2011-06-359166</pub-id><pub-id pub-id-type="pmid">21881048</pub-id></mixed-citation>
</ref>
<ref id="B160">
<label>160.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braggio</surname><given-names>E</given-names></name><name><surname>Keats</surname><given-names>JJ</given-names></name><name><surname>Leleu</surname><given-names>X</given-names></name><name><surname>Van</surname><given-names>Wier S</given-names></name><name><surname>Jimenez-Zepeda</surname><given-names>VH</given-names></name><name><surname>Valdez</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia</article-title>. <source/>Cancer Res. (<year>2009</year>) <volume>69</volume>:<fpage>3579</fpage>–<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-3701</pub-id><pub-id pub-id-type="pmid">19351844</pub-id></mixed-citation>
</ref>
<ref id="B161">
<label>161.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>YY</given-names></name><name><surname>Chung</surname><given-names>GT</given-names></name><name><surname>Lui</surname><given-names>VW</given-names></name><name><surname>To</surname><given-names>KF</given-names></name><name><surname>Ma</surname><given-names>BB</given-names></name><name><surname>Chow</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations</article-title>. <source/>Nat Commun. (<year>2017</year>) <volume>8</volume>:<fpage>14121</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms14121</pub-id><pub-id pub-id-type="pmid">28098136</pub-id></mixed-citation>
</ref>
<ref id="B162">
<label>162.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>D</given-names></name><name><surname>Abba</surname><given-names>MC</given-names></name><name><surname>Molinolo</surname><given-names>AA</given-names></name><name><surname>Vitale-Cross</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zaida</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies</article-title>. <source/>Oncotarget (<year>2014</year>) <volume>5</volume>:<fpage>8906</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.2417</pub-id><pub-id pub-id-type="pmid">25275298</pub-id></mixed-citation>
</ref>
<ref id="B163">
<label>163.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>D</given-names></name><name><surname>Trifonov</surname><given-names>V</given-names></name><name><surname>Fangazio</surname><given-names>M</given-names></name><name><surname>Bruscaggin</surname><given-names>A</given-names></name><name><surname>Rasi</surname><given-names>S</given-names></name><name><surname>Spina</surname><given-names>V</given-names></name><etal></etal></person-group>. <article-title>The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development</article-title>. <source/>J Exp Med. (<year>2012</year>) <volume>209</volume>:<fpage>1537</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20120904</pub-id><pub-id pub-id-type="pmid">22891273</pub-id></mixed-citation>
</ref>
<ref id="B164">
<label>164.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seiwert</surname><given-names>TY</given-names></name><name><surname>Zuo</surname><given-names>Z</given-names></name><name><surname>Keck</surname><given-names>MK</given-names></name><name><surname>Khattri</surname><given-names>A</given-names></name><name><surname>Pedamallu</surname><given-names>CS</given-names></name><name><surname>Stricker</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas</article-title>. <source/>Clin Cancer Res. (<year>2015</year>) <volume>21</volume>:<fpage>632</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-3310</pub-id><pub-id pub-id-type="pmid">25056374</pub-id></mixed-citation>
</ref>
<ref id="B165">
<label>165.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clipson</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>de</surname><given-names>Leval L</given-names></name><name><surname>Ashton-Key</surname><given-names>M</given-names></name><name><surname>Wotherspoon</surname><given-names>A</given-names></name><name><surname>Vassiliou</surname><given-names>G</given-names></name><etal></etal></person-group>. <article-title>KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype</article-title>. <source/>Leukemia (<year>2014</year>) <volume>29</volume>:<fpage>1177</fpage>–<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1038/leu.2014.330</pub-id><pub-id pub-id-type="pmid">25428260</pub-id></mixed-citation>
</ref>
<ref id="B166">
<label>166.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Annunziata</surname><given-names>CM</given-names></name><name><surname>Davis</surname><given-names>RE</given-names></name><name><surname>Demchenko</surname><given-names>Y</given-names></name><name><surname>Bellamy</surname><given-names>W</given-names></name><name><surname>Gabrea</surname><given-names>A</given-names></name><name><surname>Zhan</surname><given-names>F</given-names></name><etal></etal></person-group>. <article-title>Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma</article-title>. <source/>Cancer Cell (<year>2007</year>) <volume>12</volume>:<fpage>115</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2007.07.004</pub-id><pub-id pub-id-type="pmid">17692804</pub-id></mixed-citation>
</ref>
<ref id="B167">
<label>167.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puente</surname><given-names>XS</given-names></name><name><surname>Bea</surname><given-names>S</given-names></name><name><surname>Valdes-Mas</surname><given-names>R</given-names></name><name><surname>Villamor</surname><given-names>N</given-names></name><name><surname>Gutierrez-Abril</surname><given-names>J</given-names></name><name><surname>Martin-Subero</surname><given-names>JI</given-names></name><etal></etal></person-group>. <article-title>Non-coding recurrent mutations in chronic lymphocytic leukaemia</article-title>. <source/>Nature (<year>2015</year>) <volume>526</volume>:<fpage>519</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1038/nature14666</pub-id><pub-id pub-id-type="pmid">26200345</pub-id></mixed-citation>
</ref>
<ref id="B168">
<label>168.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasqualucci</surname><given-names>L</given-names></name><name><surname>Trifonov</surname><given-names>V</given-names></name><name><surname>Fabbri</surname><given-names>G</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Rossi</surname><given-names>D</given-names></name><name><surname>Chiarenza</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Analysis of the coding genome of diffuse large B-cell lymphoma</article-title>. <source/>Nat Genet. (<year>2011</year>) <volume>43</volume>:<fpage>830</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/ng.892</pub-id><pub-id pub-id-type="pmid">21804550</pub-id></mixed-citation>
</ref>
<ref id="B169">
<label>169.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>South</surname><given-names>AP</given-names></name><name><surname>Purdie</surname><given-names>KJ</given-names></name><name><surname>Watt</surname><given-names>SA</given-names></name><name><surname>Haldenby</surname><given-names>S</given-names></name><name><surname>den</surname><given-names>Breems N</given-names></name><name><surname>Dimon</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis</article-title>. <source/>J Invest Dermatol. (<year>2014</year>) <volume>134</volume>:<fpage>2630</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/jid.2014.154</pub-id><pub-id pub-id-type="pmid">24662767</pub-id></mixed-citation>
</ref>
<ref id="B170">
<label>170.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demchenko</surname><given-names>YN</given-names></name><name><surname>Glebov</surname><given-names>OK</given-names></name><name><surname>Zingone</surname><given-names>A</given-names></name><name><surname>Keats</surname><given-names>JJ</given-names></name><name><surname>Bergsagel</surname><given-names>PL</given-names></name><name><surname>Kuehl</surname><given-names>WM</given-names></name></person-group>. <article-title>Classical and/or alternative NF-kappaB pathway activation in multiple myeloma</article-title>. <source/>Blood (<year>2010</year>) <volume>115</volume>:<fpage>3541</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2009-09-243535</pub-id><pub-id pub-id-type="pmid">20053756</pub-id></mixed-citation>
</ref>
<ref id="B171">
<label>171.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>WW</given-names></name><name><surname>Yi</surname><given-names>Z</given-names></name><name><surname>Stunz</surname><given-names>LL</given-names></name><name><surname>Maine</surname><given-names>CJ</given-names></name><name><surname>Sherman</surname><given-names>LA</given-names></name><name><surname>Bishop</surname><given-names>GA</given-names></name></person-group>. <article-title>The adaptor protein TRAF3 inhibits interleukin-6 receptor signaling in B cells to limit plasma cell development</article-title>. <source/>Sci Signal. (<year>2015</year>) <volume>8</volume>:<fpage>ra88</fpage>. <pub-id pub-id-type="doi">10.1126/scisignal.aaa5157</pub-id><pub-id pub-id-type="pmid">26329582</pub-id></mixed-citation>
</ref>
<ref id="B172">
<label>172.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>P</given-names></name><name><surname>Hostager</surname><given-names>BS</given-names></name><name><surname>Bishop</surname><given-names>GA</given-names></name></person-group>
<article-title>Requirement for TRAF3 in signaling by LMP1 But not CD40 in B lymphocytes</article-title>. <source/>J Exp Med. (<year>2004</year>) <volume>199</volume>:<fpage>661</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20031255</pub-id><pub-id pub-id-type="pmid">14981114</pub-id></mixed-citation>
</ref>
<ref id="B173">
<label>173.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bangalore-Prakash</surname><given-names>P</given-names></name><name><surname>Stunz</surname><given-names>LL</given-names></name><name><surname>Mambetsariev</surname><given-names>N</given-names></name><name><surname>Whillock</surname><given-names>AL</given-names></name><name><surname>Hostager</surname><given-names>BS</given-names></name><name><surname>Bishop</surname><given-names>GA</given-names></name></person-group>. <article-title>The oncogenic membrane protein LMP1 sequesters TRAF3 in B-cell lymphoma cells to produce functional TRAF3 deficiency</article-title>. <source/>Blood Adv. (<year>2017</year>) <volume>1</volume>:<fpage>2712</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1182/bloodadvances.2017009670</pub-id><pub-id pub-id-type="pmid">29296923</pub-id></mixed-citation>
</ref>
<ref id="B174">
<label>174.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lalani</surname><given-names>AI</given-names></name><name><surname>Luo</surname><given-names>C</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>P</given-names></name></person-group>. <article-title>TRAF3: a novel tumor suppressor gene in macrophages</article-title>. <source/>Macrophage (<year>2015</year>) <volume>2</volume>:<fpage>e1009</fpage>. <pub-id pub-id-type="doi">10.14800/macrophage.1009</pub-id><pub-id pub-id-type="pmid">26661944</pub-id></mixed-citation>
</ref>
<ref id="B175">
<label>175.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mashima</surname><given-names>R</given-names></name><name><surname>Honda</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Morita</surname><given-names>Y</given-names></name><name><surname>Inoue</surname><given-names>A</given-names></name><name><surname>Arimura</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Mice lacking Dok-1, Dok-2, and Dok-3 succumb to aggressive histiocytic sarcoma</article-title>. <source/>Lab Invest. (<year>2010</year>) <volume>90</volume>:<fpage>1357</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1038/labinvest.2010.121</pub-id><pub-id pub-id-type="pmid">20548287</pub-id></mixed-citation>
</ref>
<ref id="B176">
<label>176.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snyder</surname><given-names>JM</given-names></name><name><surname>Treuting</surname><given-names>PM</given-names></name><name><surname>Nagy</surname><given-names>L</given-names></name><name><surname>Yam</surname><given-names>C</given-names></name><name><surname>Yi</surname><given-names>J</given-names></name><name><surname>Brasfield</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Humanized TLR7/8 expression drives proliferative multisystemic histiocytosis in C57BL/6 mice</article-title>. <source/>PLoS ONE (<year>2014</year>) <volume>9</volume>:<fpage>e107257</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0107257</pub-id><pub-id pub-id-type="pmid">25229618</pub-id></mixed-citation>
</ref>
<ref id="B177">
<label>177.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SS</given-names></name><name><surname>Lee</surname><given-names>KG</given-names></name><name><surname>Chin</surname><given-names>CS</given-names></name><name><surname>Ng</surname><given-names>SK</given-names></name><name><surname>Pereira</surname><given-names>NA</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>DOK3 is required for IFN-β production by enabling TRAF3/TBK1 complex formation and IRF3 activation</article-title>. <source/>J Immunol. (<year>2014</year>) <volume>193</volume>:<fpage>840</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1301601</pub-id><pub-id pub-id-type="pmid">24929003</pub-id></mixed-citation>
</ref>
<ref id="B178">
<label>178.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrasco</surname><given-names>DR</given-names></name><name><surname>Fenton</surname><given-names>T</given-names></name><name><surname>Sukhdeo</surname><given-names>K</given-names></name><name><surname>Protopopova</surname><given-names>M</given-names></name><name><surname>Enos</surname><given-names>M</given-names></name><name><surname>You</surname><given-names>MJ</given-names></name><etal></etal></person-group>. <article-title>The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans</article-title>. <source/>Cancer Cell (<year>2006</year>) <volume>9</volume>:<fpage>379</fpage>–<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2006.03.028</pub-id><pub-id pub-id-type="pmid">16697958</pub-id></mixed-citation>
</ref>
<ref id="B179">
<label>179.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durham</surname><given-names>BH</given-names></name><name><surname>Diamond</surname><given-names>EL</given-names></name><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name></person-group>. <article-title>Histiocytic neoplasms in the era of personalized genomic medicine</article-title>. <source/>Curr Opin Hematol. (<year>2016</year>) <volume>23</volume>:<fpage>416</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1097/MOH.0000000000000256</pub-id><pub-id pub-id-type="pmid">27101528</pub-id></mixed-citation>
</ref>
<ref id="B180">
<label>180.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>IC</given-names></name><name><surname>Wilson</surname><given-names>JE</given-names></name><name><surname>Schneider</surname><given-names>M</given-names></name><name><surname>Lich</surname><given-names>JD</given-names></name><name><surname>Roberts</surname><given-names>RA</given-names></name><name><surname>Arthur</surname><given-names>JC</given-names></name><etal></etal></person-group>. <article-title>NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-κB signaling</article-title>. <source/>Immunity (<year>2012</year>) <volume>36</volume>:<fpage>742</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2012.03.012</pub-id><pub-id pub-id-type="pmid">22503542</pub-id></mixed-citation>
</ref>
<ref id="B181">
<label>181.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malcomson</surname><given-names>FC</given-names></name><name><surname>Willis</surname><given-names>ND</given-names></name><name><surname>McCallum</surname><given-names>I</given-names></name><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Lagerwaard</surname><given-names>B</given-names></name><name><surname>Kelly</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Non-digestible carbohydrates supplementation increases miR-32 expression in the healthy human colorectal epithelium: a randomized controlled trial</article-title>. <source/>Mol Carcinog. (<year>2017</year>) <volume>56</volume>:<fpage>2104</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1002/mc.22666</pub-id><pub-id pub-id-type="pmid">28418082</pub-id></mixed-citation>
</ref>
<ref id="B182">
<label>182.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muro</surname><given-names>I</given-names></name><name><surname>Fang</surname><given-names>G</given-names></name><name><surname>Gardella</surname><given-names>KA</given-names></name><name><surname>Mahajan</surname><given-names>IM</given-names></name><name><surname>Wright</surname><given-names>CW</given-names></name></person-group>. <article-title>The TRAF3 adaptor protein drives proliferation of anaplastic large cell lymphoma cells by regulating multiple signaling pathways</article-title>. <source/>Cell Cycle (<year>2014</year>) <volume>13</volume>:<fpage>1918</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.4161/cc.28895</pub-id><pub-id pub-id-type="pmid">24739416</pub-id></mixed-citation>
</ref>
<ref id="B183">
<label>183.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>AC</given-names></name><name><surname>Kemp</surname><given-names>AJ</given-names></name><name><surname>Drabsch</surname><given-names>Y</given-names></name><name><surname>Behrends</surname><given-names>C</given-names></name><name><surname>Wilkinson</surname><given-names>S</given-names></name></person-group>. <article-title>Autophagy acts through TRAF3 and RELB to regulate gene expression via antagonism of SMAD proteins</article-title>. <source/>Nat Commun. (<year>2017</year>) <volume>8</volume>:<fpage>1537</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-017-00859-z</pub-id><pub-id pub-id-type="pmid">29146913</pub-id></mixed-citation>
</ref>
<ref id="B184">
<label>184.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>MC</given-names></name><name><surname>Hwang</surname><given-names>MJ</given-names></name><name><surname>Chou</surname><given-names>YC</given-names></name><name><surname>Chen</surname><given-names>WH</given-names></name><name><surname>Cheng</surname><given-names>G</given-names></name><name><surname>Nakano</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>The role of apoptosis signal-regulating kinase 1 in lymphotoxin-beta receptor-mediated cell death</article-title>. <source/>J Biol Chem. (<year>2003</year>) <volume>278</volume>:<fpage>16073</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M208661200</pub-id><pub-id pub-id-type="pmid">12566458</pub-id></mixed-citation>
</ref>
<ref id="B185">
<label>185.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Georgopoulos</surname><given-names>NT</given-names></name><name><surname>Steele</surname><given-names>LP</given-names></name><name><surname>Thomson</surname><given-names>MJ</given-names></name><name><surname>Selby</surname><given-names>PJ</given-names></name><name><surname>Southgate</surname><given-names>J</given-names></name><name><surname>Trejdosiewicz</surname><given-names>LK</given-names></name></person-group>. <article-title>A novel mechanism of CD40-induced apoptosis of carcinoma cells involving TRAF3 and JNK/AP-1 activation</article-title>. <source/>Cell Death Differ. (<year>2006</year>) <volume>13</volume>:<fpage>1789</fpage>–<lpage>801</lpage>. <pub-id pub-id-type="doi">10.1038/sj.cdd.4401859</pub-id><pub-id pub-id-type="pmid">16429118</pub-id></mixed-citation>
</ref>
<ref id="B186">
<label>186.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elmetwali</surname><given-names>T</given-names></name><name><surname>Young</surname><given-names>LS</given-names></name><name><surname>Palmer</surname><given-names>DH</given-names></name></person-group>. <article-title>CD40 ligand-induced carcinoma cell death: a balance between activation of TNFR-associated factor (TRAF) 3-dependent death signals and suppression of TRAF6-dependent survival signals</article-title>. <source/>J Immunol. (<year>2010</year>) <volume>184</volume>:<fpage>1111</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.0900528</pub-id><pub-id pub-id-type="pmid">20008286</pub-id></mixed-citation>
</ref>
<ref id="B187">
<label>187.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunnill</surname><given-names>CJ</given-names></name><name><surname>Ibraheem</surname><given-names>K</given-names></name><name><surname>Mohamed</surname><given-names>A</given-names></name><name><surname>Southgate</surname><given-names>J</given-names></name><name><surname>Georgopoulos</surname><given-names>NT</given-names></name></person-group>. <article-title>A redox state-dictated signalling pathway deciphers the malignant cell specificity of CD40-mediated apoptosis</article-title>. <source/>Oncogene (<year>2017</year>) <volume>36</volume>:<fpage>2515</fpage>–<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2016.401</pub-id><pub-id pub-id-type="pmid">27869172</pub-id></mixed-citation>
</ref>
<ref id="B188">
<label>188.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>W</given-names></name><name><surname>Kong</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Fu</surname><given-names>W</given-names></name><etal></etal></person-group>. <article-title>RIP2 promotes glioma cell growth by regulating TRAF3 and activating the NFkappaB and p38 signaling pathways</article-title>. <source/>Oncol Rep. (<year>2018</year>) <volume>39</volume>:<fpage>2915</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.3892/or.2018.6397</pub-id><pub-id pub-id-type="pmid">29693188</pub-id></mixed-citation>
</ref>
<ref id="B189">
<label>189.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciriello</surname><given-names>G</given-names></name><name><surname>Gatza</surname><given-names>ML</given-names></name><name><surname>Beck</surname><given-names>AH</given-names></name><name><surname>Wilkerson</surname><given-names>MD</given-names></name><name><surname>Rhie</surname><given-names>SK</given-names></name><name><surname>Pastore</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Comprehensive molecular portraits of invasive lobular breast cancer</article-title>. <source/>Cell (<year>2015</year>) <volume>163</volume>:<fpage>506</fpage>–<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2015.09.033</pub-id><pub-id pub-id-type="pmid">26451490</pub-id></mixed-citation>
</ref>
<ref id="B190">
<label>190.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Network</surname><given-names>TCGAR</given-names></name></person-group>
<article-title>Comprehensive molecular profiling of lung adenocarcinoma</article-title>. <source/>Nature (<year>2014</year>) <volume>511</volume>:<fpage>543</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1038/nature13385</pub-id><pub-id pub-id-type="pmid">25079552</pub-id></mixed-citation>
</ref>
<ref id="B191">
<label>191.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodis</surname><given-names>E</given-names></name><name><surname>Watson</surname><given-names>IR</given-names></name><name><surname>Kryukov</surname><given-names>GV</given-names></name><name><surname>Arold</surname><given-names>ST</given-names></name><name><surname>Imielinski</surname><given-names>M</given-names></name><name><surname>Theurillat</surname><given-names>JP</given-names></name><etal></etal></person-group>. <article-title>A landscape of driver mutations in melanoma</article-title>. <source/>Cell (<year>2012</year>) <volume>150</volume>:<fpage>251</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2012.06.024</pub-id><pub-id pub-id-type="pmid">22817889</pub-id></mixed-citation>
</ref>
<ref id="B192">
<label>192.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grasso</surname><given-names>CS</given-names></name><name><surname>Wu</surname><given-names>YM</given-names></name><name><surname>Robinson</surname><given-names>DR</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Dhanasekaran</surname><given-names>SM</given-names></name><name><surname>Khan</surname><given-names>AP</given-names></name><etal></etal></person-group>. <article-title>The mutational landscape of lethal castration-resistant prostate cancer</article-title>. <source/>Nature (<year>2012</year>) <volume>487</volume>:<fpage>239</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1038/nature11125</pub-id><pub-id pub-id-type="pmid">22722839</pub-id></mixed-citation>
</ref>
<ref id="B193">
<label>193.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kandoth</surname><given-names>C</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name><name><surname>Cherniack</surname><given-names>AD</given-names></name><name><surname>Akbani</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Integrated genomic characterization of endometrial carcinoma</article-title>. <source/>Nature (<year>2013</year>) <volume>497</volume>:<fpage>67</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1038/nature12113</pub-id><pub-id pub-id-type="pmid">23636398</pub-id></mixed-citation>
</ref>
<ref id="B194">
<label>194.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agrawal</surname><given-names>N</given-names></name><name><surname>Frederick</surname><given-names>MJ</given-names></name><name><surname>Pickering</surname><given-names>CR</given-names></name><name><surname>Bettegowda</surname><given-names>C</given-names></name><name><surname>Chang</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>RJ</given-names></name><etal></etal></person-group>. <article-title>Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1</article-title>. <source/>Science (<year>2011</year>) <volume>333</volume>:<fpage>1154</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1126/science.1206923</pub-id><pub-id pub-id-type="pmid">21798897</pub-id></mixed-citation>
</ref>
<ref id="B195">
<label>195.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pickering</surname><given-names>CR</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Yoo</surname><given-names>SY</given-names></name><name><surname>Bengtsson</surname><given-names>L</given-names></name><name><surname>Moorthy</surname><given-names>S</given-names></name><name><surname>Neskey</surname><given-names>DM</given-names></name><etal></etal></person-group>. <article-title>Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers</article-title>. <source/>Cancer Discov. (<year>2013</year>) <volume>3</volume>:<fpage>770</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0537</pub-id><pub-id pub-id-type="pmid">23619168</pub-id></mixed-citation>
</ref>
<ref id="B196">
<label>196.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bieche</surname><given-names>I</given-names></name><name><surname>Tomasetto</surname><given-names>C</given-names></name><name><surname>Regnier</surname><given-names>CH</given-names></name><name><surname>Moog-Lutz</surname><given-names>C</given-names></name><name><surname>Rio</surname><given-names>MC</given-names></name><name><surname>Lidereau</surname><given-names>R</given-names></name></person-group>. <article-title>Two distinct amplified regions at 17q11-q21 involved in human primary breast cancer</article-title>. <source/>Cancer Res. (<year>1996</year>) <volume>56</volume>:<fpage>3886</fpage>–<lpage>90</lpage>.<pub-id pub-id-type="pmid">8752152</pub-id></mixed-citation>
</ref>
<ref id="B197">
<label>197.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krajewska</surname><given-names>M</given-names></name><name><surname>Krajewski</surname><given-names>S</given-names></name><name><surname>Zapata</surname><given-names>JM</given-names></name><name><surname>Van</surname><given-names>Arsdale T</given-names></name><name><surname>Gascoyne</surname><given-names>RD</given-names></name><name><surname>Berern</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>TRAF-4 expression in epithelial progenitor cells</article-title>. Analysis in normal adult, fetal, and tumor tissues. <source/>Am J Pathol. (<year>1998</year>) <volume>152</volume>:<fpage>1549</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="pmid">9626059</pub-id></mixed-citation>
</ref>
<ref id="B198">
<label>198.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camilleri-Broet</surname><given-names>S</given-names></name><name><surname>Cremer</surname><given-names>I</given-names></name><name><surname>Marmey</surname><given-names>B</given-names></name><name><surname>Comperat</surname><given-names>E</given-names></name><name><surname>Viguie</surname><given-names>F</given-names></name><name><surname>Audouin</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>TRAF4 overexpression is a common characteristic of human carcinomas</article-title>. <source/>Oncogene (<year>2007</year>) <volume>26</volume>:<fpage>142</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1209762</pub-id><pub-id pub-id-type="pmid">16799635</pub-id></mixed-citation>
</ref>
<ref id="B199">
<label>199.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Peng</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>MH</given-names></name><name><surname>Lim</surname><given-names>D</given-names></name><name><surname>Zhu</surname><given-names>F</given-names></name><name><surname>Fu</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>TRAF4 is a critical molecule for Akt activation in lung cancer</article-title>. <source/>Cancer Res. (<year>2013</year>) <volume>73</volume>:<fpage>6938</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-0913</pub-id><pub-id pub-id-type="pmid">24154876</pub-id></mixed-citation>
</ref>
<ref id="B200">
<label>200.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Garcia</surname><given-names>de Vinuesa A</given-names></name><name><surname>de</surname><given-names>Kruijf EM</given-names></name><name><surname>Mesker</surname><given-names>WE</given-names></name><name><surname>Hui</surname><given-names>L</given-names></name><etal></etal></person-group>. <article-title>TRAF4 promotes TGF-β receptor signaling and drives breast cancer metastasis</article-title>. <source/>Mol Cell (<year>2013</year>) <volume>51</volume>:<fpage>559</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2013.07.014</pub-id><pub-id pub-id-type="pmid">23973329</pub-id></mixed-citation>
</ref>
<ref id="B201">
<label>201.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Han</surname><given-names>JJ</given-names></name></person-group>. <article-title>TRAF4 promotes the growth and invasion of colon cancer through the Wnt/β-catenin pathway</article-title>. <source/>Int J Clin Exp Pathol. (<year>2015</year>) <volume>8</volume>:<fpage>1419</fpage>–<lpage>26</lpage>.<pub-id pub-id-type="pmid">25973026</pub-id></mixed-citation>
</ref>
<ref id="B202">
<label>202.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Cai</surname><given-names>Q</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name></person-group>. <article-title>TRAF4 enhances osteosarcoma cell proliferation and invasion by Akt signaling pathway</article-title>. <source/>Oncol Res. (<year>2014</year>) <volume>22</volume>:<fpage>21</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.3727/096504014X14077751730351</pub-id><pub-id pub-id-type="pmid">25700355</pub-id></mixed-citation>
</ref>
<ref id="B203">
<label>203.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Zang</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Tan</surname><given-names>W</given-names></name><etal></etal></person-group>. <article-title>TRAF4 regulates migration, invasion, and epithelial-mesenchymal transition via PI3K/AKT signaling in hepatocellular carcinoma</article-title>. <source/>Oncol Res. (<year>2017</year>) <volume>25</volume>:<fpage>1329</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.3727/096504017X14876227286564</pub-id><pub-id pub-id-type="pmid">28256185</pub-id></mixed-citation>
</ref>
<ref id="B204">
<label>204.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Karri</surname><given-names>D</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Shao</surname><given-names>J</given-names></name><name><surname>Dasgupta</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>TRAF4-mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasis</article-title>. <source/>J Clin Invest. (<year>2018</year>) <volume>128</volume>:<fpage>3129</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1172/JCI96060</pub-id><pub-id pub-id-type="pmid">29715200</pub-id></mixed-citation>
</ref>
<ref id="B205">
<label>205.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kedinger</surname><given-names>V</given-names></name><name><surname>Rio</surname><given-names>MC</given-names></name></person-group>. <article-title>TRAF4, the unique family member</article-title>. <source/>Adv Exp Med Biol. (<year>2007</year>) <volume>597</volume>:<fpage>60</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1007/978-0-387-70630-6</pub-id>_5<pub-id pub-id-type="pmid">17633017</pub-id></mixed-citation>
</ref>
<ref id="B206">
<label>206.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Huan</surname><given-names>X</given-names></name><name><surname>Mei</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name></person-group>. <article-title>Down-regulation of TRAF4 targeting RSK4 inhibits proliferation, invasion and metastasis in breast cancer xenografts</article-title>. <source/>Biochem Biophys Res Commun. (<year>2018</year>) <volume>500</volume>:<fpage>810</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2018.04.164</pub-id><pub-id pub-id-type="pmid">29684350</pub-id></mixed-citation>
</ref>
<ref id="B207">
<label>207.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Jin</surname><given-names>C</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>LY</given-names></name><name><surname>Zhang</surname><given-names>YE</given-names></name></person-group>. <article-title>Ubiquitination of tumor necrosis factor receptor-associated factor 4 (TRAF4) by Smad ubiquitination regulatory factor 1 (Smurf1) regulates motility of breast epithelial and cancer cells</article-title>. <source/>J Biol Chem. (<year>2013</year>) <volume>288</volume>:<fpage>21784</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M113.472704</pub-id><pub-id pub-id-type="pmid">23760265</pub-id></mixed-citation>
</ref>
<ref id="B208">
<label>208.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>P</given-names></name><name><surname>Xia</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>RC</given-names></name><name><surname>Lonard</surname><given-names>DM</given-names></name><name><surname>Hung</surname><given-names>MC</given-names></name><name><surname>O'Malley</surname><given-names>BW</given-names></name></person-group>. <article-title>SRC-3 coactivator regulates cell resistance to cytotoxic stress via TRAF4-mediated p53 destabilization</article-title>. <source/>Genes Dev. (<year>2013</year>) <volume>27</volume>:<fpage>274</fpage>–<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1101/gad.203760.112</pub-id><pub-id pub-id-type="pmid">23388826</pub-id></mixed-citation>
</ref>
<ref id="B209">
<label>209.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Wen</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>E</given-names></name><etal></etal></person-group>. <article-title>TRAF2 regulates the cytoplasmic/nuclear distribution of TRAF4 and its biological function in breast cancer cells</article-title>. <source/>Biochem Biophys Res Commun. (<year>2013</year>) <volume>436</volume>:<fpage>344</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2013.05.107</pub-id><pub-id pub-id-type="pmid">23743189</pub-id></mixed-citation>
</ref>
<ref id="B210">
<label>210.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Shen</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name></person-group>. <article-title>TRAF4 enhances oral squamous cell carcinoma cell growth, invasion and migration by Wnt-β-catenin signaling pathway</article-title>. <source/>Int J Clin Exp Pathol. (<year>2015</year>) <volume>8</volume>:<fpage>11837</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="pmid">26617938</pub-id></mixed-citation>
</ref>
<ref id="B211">
<label>211.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Ren</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Diao</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>TRAF4 participates in Wnt/β-catenin signaling in breast cancer by upregulating β-catenin and mediating its translocation to the nucleus</article-title>. <source/>Mol Cell Biochem. (<year>2014</year>) <volume>395</volume>:<fpage>211</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/s11010-014-2127-y</pub-id><pub-id pub-id-type="pmid">24990246</pub-id></mixed-citation>
</ref>
<ref id="B212">
<label>212.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>HY</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>XL</given-names></name><name><surname>Wang</surname><given-names>AL</given-names></name><name><surname>Sun</surname><given-names>LL</given-names></name><etal></etal></person-group>. <article-title>Cytoplasmic TRAF4 contributes to the activation of p70s6k signaling pathway in breast cancer</article-title>. <source/>Oncotarget (<year>2015</year>) <volume>6</volume>:<fpage>4080</fpage>–<lpage>96</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.2977</pub-id><pub-id pub-id-type="pmid">25738361</pub-id></mixed-citation>
</ref>
<ref id="B213">
<label>213.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rousseau</surname><given-names>A</given-names></name><name><surname>McEwen</surname><given-names>AG</given-names></name><name><surname>Poussin-Courmontagne</surname><given-names>P</given-names></name><name><surname>Rognan</surname><given-names>D</given-names></name><name><surname>Nomine</surname><given-names>Y</given-names></name><name><surname>Rio</surname><given-names>MC</given-names></name><etal></etal></person-group>. <article-title>TRAF4 is a novel phosphoinositide-binding protein modulating tight junctions and favoring cell migration</article-title>. <source/>PLoS Biol. (<year>2013</year>) <volume>11</volume>:<fpage>e1001726</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pbio.1001726</pub-id><pub-id pub-id-type="pmid">24311986</pub-id></mixed-citation>
</ref>
<ref id="B214">
<label>214.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>D</given-names></name><name><surname>Van</surname><given-names>Allen EM</given-names></name><name><surname>Wu</surname><given-names>YM</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name><name><surname>Lonigro</surname><given-names>RJ</given-names></name><name><surname>Mosquera</surname><given-names>JM</given-names></name><etal></etal></person-group>. <article-title>Integrative clinical genomics of advanced prostate cancer</article-title>. <source/>Cell (<year>2015</year>) <volume>161</volume>:<fpage>1215</fpage>–<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2015.05.001</pub-id><pub-id pub-id-type="pmid">26000489</pub-id></mixed-citation>
</ref>
<ref id="B215">
<label>215.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morin</surname><given-names>RD</given-names></name><name><surname>Assouline</surname><given-names>S</given-names></name><name><surname>Alcaide</surname><given-names>M</given-names></name><name><surname>Mohajeri</surname><given-names>A</given-names></name><name><surname>Johnston</surname><given-names>RL</given-names></name><name><surname>Chong</surname><given-names>L</given-names></name><etal></etal></person-group>. <article-title>Genetic landscapes of relapsed and refractory diffuse large B-cell lymphomas</article-title>. <source/>Clin Cancer Res. (<year>2016</year>) <volume>22</volume>:<fpage>2290</fpage>–<lpage>300</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-2123</pub-id><pub-id pub-id-type="pmid">26647218</pub-id></mixed-citation>
</ref>
<ref id="B216">
<label>216.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruiz-Ballesteros</surname><given-names>E</given-names></name><name><surname>Mollejo</surname><given-names>M</given-names></name><name><surname>Rodriguez</surname><given-names>A</given-names></name><name><surname>Camacho</surname><given-names>FI</given-names></name><name><surname>Algara</surname><given-names>P</given-names></name><name><surname>Martinez</surname><given-names>N</given-names></name><etal></etal></person-group>. <article-title>Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis</article-title>. <source/>Blood (<year>2005</year>) <volume>106</volume>:<fpage>1831</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2004-10-3898</pub-id><pub-id pub-id-type="pmid">15914563</pub-id></mixed-citation>
</ref>
<ref id="B217">
<label>217.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weston</surname><given-names>VJ</given-names></name><name><surname>Austen</surname><given-names>B</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Marston</surname><given-names>E</given-names></name><name><surname>Alvi</surname><given-names>A</given-names></name><name><surname>Lawson</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Apoptotic resistance to ionizing radiation in pediatric B-precursor acute lymphoblastic leukemia frequently involves increased NF-κB survival pathway signaling</article-title>. <source/>Blood (<year>2004</year>) <volume>104</volume>:<fpage>1465</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2003-11-4039</pub-id><pub-id pub-id-type="pmid">15142883</pub-id></mixed-citation>
</ref>
<ref id="B218">
<label>218.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stunz</surname><given-names>LL</given-names></name><name><surname>Busch</surname><given-names>LK</given-names></name><name><surname>Munroe</surname><given-names>ME</given-names></name><name><surname>Sigmund</surname><given-names>CD</given-names></name><name><surname>Tygrett</surname><given-names>LT</given-names></name><name><surname>Waldschmidt</surname><given-names>TJ</given-names></name><etal></etal></person-group>. <article-title>Expression of the cytoplasmic tail of LMP1 in mice induces hyperactivation of B lymphocytes and disordered lymphoid architecture</article-title>. <source/>Immunity (<year>2004</year>) <volume>21</volume>:<fpage>255</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2004.07.008</pub-id><pub-id pub-id-type="pmid">15308105</pub-id></mixed-citation>
</ref>
<ref id="B219">
<label>219.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horie</surname><given-names>R</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Morishita</surname><given-names>Y</given-names></name><name><surname>Ito</surname><given-names>K</given-names></name><name><surname>Ishida</surname><given-names>T</given-names></name><name><surname>Kanegae</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells</article-title>. <source/>Oncogene (<year>2002</year>) <volume>21</volume>:<fpage>2493</fpage>–<lpage>503</lpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1205337</pub-id><pub-id pub-id-type="pmid">11971184</pub-id></mixed-citation>
</ref>
<ref id="B220">
<label>220.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horie</surname><given-names>R</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Ito</surname><given-names>K</given-names></name><name><surname>Morisita</surname><given-names>Y</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Ishida</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>Cytoplasmic aggregation of TRAF2 and TRAF5 proteins in the Hodgkin-Reed-Sternberg cells</article-title>. <source/>Am J Pathol. (<year>2002</year>) <volume>160</volume>:<fpage>1647</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/S0002-9440(10)61112-1</pub-id><pub-id pub-id-type="pmid">12000717</pub-id></mixed-citation>
</ref>
<ref id="B221">
<label>221.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horie</surname><given-names>R</given-names></name><name><surname>Gattei</surname><given-names>V</given-names></name><name><surname>Ito</surname><given-names>K</given-names></name><name><surname>Imajo-Ohmi</surname><given-names>S</given-names></name><name><surname>Tange</surname><given-names>T</given-names></name><name><surname>Miyauchi</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Frequent expression of the variant CD30 in human malignant myeloid and lymphoid neoplasms</article-title>. <source/>Am J Pathol. (<year>1999</year>) <volume>155</volume>:<fpage>2029</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="pmid">10595933</pub-id></mixed-citation>
</ref>
<ref id="B222">
<label>222.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>T</given-names></name><name><surname>Cheng</surname><given-names>C</given-names></name><name><surname>Ji</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><etal></etal></person-group>. <article-title>Numbl inhibits glioma cell migration and invasion by suppressing TRAF5-mediated NF-κB activation</article-title>. <source/>Mol Biol Cell (<year>2012</year>) <volume>23</volume>:<fpage>2635</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1091/mbc.E11-09-0805</pub-id><pub-id pub-id-type="pmid">22593207</pub-id></mixed-citation>
</ref>
<ref id="B223">
<label>223.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Wa</surname><given-names>Q</given-names></name><name><surname>Pan</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Downregulation of miR-141-3p promotes bone metastasis via activating NF-κB signaling in prostate cancer</article-title>. <source/>J Exp Clin Cancer Res. (<year>2017</year>) <volume>36</volume>:<fpage>173</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-017-0645-7</pub-id><pub-id pub-id-type="pmid">29202848</pub-id></mixed-citation>
</ref>
<ref id="B224">
<label>224.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Long</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>H</given-names></name></person-group>. <article-title>MiR-26b inhibits melanoma cell proliferation and enhances apoptosis by suppressing TRAF5-mediated MAPK activation</article-title>. <source/>Biochem Biophys Res Commun. (<year>2016</year>) <volume>471</volume>:<fpage>361</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2016.02.021</pub-id><pub-id pub-id-type="pmid">26872428</pub-id></mixed-citation>
</ref>
<ref id="B225">
<label>225.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lefebvre</surname><given-names>C</given-names></name><name><surname>Bachelot</surname><given-names>T</given-names></name><name><surname>Filleron</surname><given-names>T</given-names></name><name><surname>Pedrero</surname><given-names>M</given-names></name><name><surname>Campone</surname><given-names>M</given-names></name><name><surname>Soria</surname><given-names>JC</given-names></name><etal></etal></person-group>. <article-title>Mutational profile of metastatic breast cancers: a retrospective analysis</article-title>. <source/>PLoS Med. (<year>2016</year>) <volume>13</volume>:<fpage>e1002201</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pmed.1002201</pub-id><pub-id pub-id-type="pmid">28027327</pub-id></mixed-citation>
</ref>
<ref id="B226">
<label>226.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Network</surname><given-names>TCGAR</given-names></name></person-group>
<article-title>Comprehensive molecular characterization of urothelial bladder carcinoma</article-title>. <source/>Nature (<year>2014</year>) <volume>507</volume>:<fpage>315</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1038/nature12965</pub-id><pub-id pub-id-type="pmid">24476821</pub-id></mixed-citation>
</ref>
<ref id="B227">
<label>227.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Starczynowski</surname><given-names>DT</given-names></name><name><surname>Lockwood</surname><given-names>WW</given-names></name><name><surname>Delehouzee</surname><given-names>S</given-names></name><name><surname>Chari</surname><given-names>R</given-names></name><name><surname>Wegrzyn</surname><given-names>J</given-names></name><name><surname>Fuller</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>TRAF6 is an amplified oncogene bridging the RAS and NF-κB pathways in human lung cancer</article-title>. <source/>J Clin Invest. (<year>2011</year>) <volume>121</volume>:<fpage>4095</fpage>–<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1172/JCI58818</pub-id><pub-id pub-id-type="pmid">21911935</pub-id></mixed-citation>
</ref>
<ref id="B228">
<label>228.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Hebshi</surname><given-names>NN</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Nasher</surname><given-names>AT</given-names></name><name><surname>El-Setouhy</surname><given-names>M</given-names></name><name><surname>Alsanosi</surname><given-names>R</given-names></name><name><surname>Blancato</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Exome sequencing of oral squamous cell carcinoma in users of Arabian snuff reveals novel candidates for driver genes</article-title>. <source/>Int J Cancer (<year>2016</year>) <volume>139</volume>:<fpage>363</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.30068</pub-id><pub-id pub-id-type="pmid">26934577</pub-id></mixed-citation>
</ref>
<ref id="B229">
<label>229.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Peng</surname><given-names>B</given-names></name><name><surname>Kaufmann</surname><given-names>GF</given-names></name><etal></etal></person-group>. <article-title>Functional role of asparaginyl endopeptidase ubiquitination by TRAF6 in tumor invasion and metastasis</article-title>. <source/>J Natl Cancer Inst. (<year>2014</year>) <volume>106</volume>:<fpage>dju012</fpage>. <pub-id pub-id-type="doi">10.1093/jnci/dju012</pub-id><pub-id pub-id-type="pmid">24610907</pub-id></mixed-citation>
</ref>
<ref id="B230">
<label>230.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>JJ</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>JN</given-names></name><name><surname>Liang</surname><given-names>XN</given-names></name><name><surname>Luo</surname><given-names>YH</given-names></name><name><surname>Liu</surname><given-names>YR</given-names></name><etal></etal></person-group>. <article-title>Relationship between TRAF6 and deterioration of HCC: an immunohistochemical and <italic>in vitro</italic> study</article-title>. <source/>Cancer Cell Int. (<year>2016</year>) <volume>16</volume>:<fpage>76</fpage>. <pub-id pub-id-type="doi">10.1186/s12935-016-0352-z</pub-id><pub-id pub-id-type="pmid">27708550</pub-id></mixed-citation>
</ref>
<ref id="B231">
<label>231.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Fan</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Fang</surname><given-names>J</given-names></name></person-group>. <article-title>TRAF6 is upregulated in colon cancer and promotes proliferation of colon cancer cells</article-title>. <source/>Int J Biochem Cell Biol. (<year>2014</year>) <volume>53</volume>:<fpage>195</fpage>–<lpage>201</lpage>. <pub-id pub-id-type="doi">10.1016/j.biocel.2014.04.010</pub-id><pub-id pub-id-type="pmid">24755241</pub-id></mixed-citation>
</ref>
<ref id="B232">
<label>232.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Zhu</surname><given-names>Q</given-names></name><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>High TRAF6 expression is associated with esophageal carcinoma recurrence and prompts cancer cell invasion</article-title>. <source/>Oncol Res. (<year>2017</year>) <volume>25</volume>:<fpage>485</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.3727/096504016X14749340314441</pub-id><pub-id pub-id-type="pmid">27697099</pub-id></mixed-citation>
</ref>
<ref id="B233">
<label>233.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zeng</surname><given-names>W</given-names></name><name><surname>Su</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><etal></etal></person-group>. <article-title>TRAF6 regulates melanoma invasion and metastasis through ubiquitination of Basigin</article-title>. <source/>Oncotarget (<year>2016</year>) <volume>7</volume>:<fpage>7179</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.6886</pub-id><pub-id pub-id-type="pmid">26769849</pub-id></mixed-citation>
</ref>
<ref id="B234">
<label>234.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seshagiri</surname><given-names>S</given-names></name><name><surname>Stawiski</surname><given-names>EW</given-names></name><name><surname>Durinck</surname><given-names>S</given-names></name><name><surname>Modrusan</surname><given-names>Z</given-names></name><name><surname>Storm</surname><given-names>EE</given-names></name><name><surname>Conboy</surname><given-names>CB</given-names></name><etal></etal></person-group>. <article-title>Recurrent R-spondin fusions in colon cancer</article-title>. <source/>Nature (<year>2012</year>) <volume>488</volume>:<fpage>660</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1038/nature11282</pub-id><pub-id pub-id-type="pmid">22895193</pub-id></mixed-citation>
</ref>
<ref id="B235">
<label>235.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imielinski</surname><given-names>M</given-names></name><name><surname>Berger</surname><given-names>AH</given-names></name><name><surname>Hammerman</surname><given-names>PS</given-names></name><name><surname>Hernandez</surname><given-names>B</given-names></name><name><surname>Pugh</surname><given-names>TJ</given-names></name><name><surname>Hodis</surname><given-names>E</given-names></name><etal></etal></person-group>. <article-title>Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing</article-title>. <source/>Cell (<year>2012</year>) <volume>150</volume>:<fpage>1107</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2012.08.029</pub-id><pub-id pub-id-type="pmid">22980975</pub-id></mixed-citation>
</ref>
<ref id="B236">
<label>236.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Min</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Chun</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>KY</given-names></name></person-group>. <article-title>Inhibition of TRAF6 ubiquitin-ligase activity by PRDX1 leads to inhibition of NFKB activation and autophagy activation</article-title>. <source/>Autophagy (<year>2018</year>) <volume>14</volume>:<fpage>1347</fpage>–<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1080/15548627.2018.1474995</pub-id><pub-id pub-id-type="pmid">29929436</pub-id></mixed-citation>
</ref>
<ref id="B237">
<label>237.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Jiao</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Xiao</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>STX2 promotes colorectal cancer metastasis through a positive feedback loop that activates the NF-κB pathway</article-title>. <source/>Cell Death Dis. (<year>2018</year>) <volume>9</volume>:<fpage>664</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-018-0675-x</pub-id><pub-id pub-id-type="pmid">29855462</pub-id></mixed-citation>
</ref>
<ref id="B238">
<label>238.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>YC</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>GT</given-names></name><name><surname>Zhang</surname><given-names>WF</given-names></name><name><surname>Huang</surname><given-names>CF</given-names></name><etal></etal></person-group>. <article-title>TRAF6 regulates tumour metastasis through EMT and CSC phenotypes in head and neck squamous cell carcinoma</article-title>. <source/>J Cell Mol Med. (<year>2018</year>) <volume>22</volume>:<fpage>1337</fpage>–<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1111/jcmm.13439</pub-id><pub-id pub-id-type="pmid">29193723</pub-id></mixed-citation>
</ref>
<ref id="B239">
<label>239.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhan</surname><given-names>Z</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>XD</given-names></name><name><surname>Fan</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Autophagy facilitates TLR4- and TLR3-triggered migration and invasion of lung cancer cells through the promotion of TRAF6 ubiquitination</article-title>. <source/>Autophagy (<year>2014</year>) <volume>10</volume>:<fpage>257</fpage>–<lpage>68</lpage>. <pub-id pub-id-type="doi">10.4161/auto.27162</pub-id><pub-id pub-id-type="pmid">24321786</pub-id></mixed-citation>
</ref>
<ref id="B240">
<label>240.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sambandam</surname><given-names>Y</given-names></name><name><surname>Ethiraj</surname><given-names>P</given-names></name><name><surname>Hathaway-Schrader</surname><given-names>JD</given-names></name><name><surname>Novince</surname><given-names>CM</given-names></name><name><surname>Panneerselvam</surname><given-names>E</given-names></name><name><surname>Sundaram</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>Autoregulation of RANK ligand in oral squamous cell carcinoma tumor cells</article-title>. <source/>J Cell Physiol. (<year>2018</year>) <volume>233</volume>:<fpage>6125</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.26456</pub-id><pub-id pub-id-type="pmid">29323724</pub-id></mixed-citation>
</ref>
<ref id="B241">
<label>241.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Rhyasen</surname><given-names>G</given-names></name><name><surname>Bolanos</surname><given-names>L</given-names></name><name><surname>Rasch</surname><given-names>C</given-names></name><name><surname>Varney</surname><given-names>M</given-names></name><name><surname>Wunderlich</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1</article-title>. <source/>Blood (<year>2012</year>) <volume>120</volume>:<fpage>858</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2012-02-407999</pub-id><pub-id pub-id-type="pmid">22685174</pub-id></mixed-citation>
</ref>
<ref id="B242">
<label>242.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da</surname><given-names>Silva Almeida AC</given-names></name><name><surname>Abate</surname><given-names>F</given-names></name><name><surname>Khiabanian</surname><given-names>H</given-names></name><name><surname>Martinez-Escala</surname><given-names>E</given-names></name><name><surname>Guitart</surname><given-names>J</given-names></name><name><surname>Tensen</surname><given-names>CP</given-names></name><etal></etal></person-group>
<article-title>The mutational landscape of cutaneous T cell lymphoma and Sezary syndrome</article-title>. <source/>Nat Genet. (<year>2015</year>) <volume>47</volume>:<fpage>1465</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1038/ng.3442</pub-id><pub-id pub-id-type="pmid">26551667</pub-id></mixed-citation>
</ref>
<ref id="B243">
<label>243.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>YH</given-names></name><name><surname>Hung</surname><given-names>LY</given-names></name><name><surname>Chen</surname><given-names>RY</given-names></name><name><surname>Lai</surname><given-names>CH</given-names></name><name><surname>Chang</surname><given-names>KC</given-names></name></person-group>. <article-title>ON 01910</article-title>.Na inhibits growth of diffuse large B-cell lymphoma by cytoplasmic sequestration of sumoylated C-MYB/TRAF6 complex. <source/>Transl Res. (<year>2016</year>) <volume>175</volume>:<fpage>129</fpage>–<lpage>43</lpage>.e13. <pub-id pub-id-type="doi">10.1016/j.trsl.2016.04.001</pub-id><pub-id pub-id-type="pmid">27150054</pub-id></mixed-citation>
</ref>
<ref id="B244">
<label>244.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Sanchez</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>CS</given-names></name><name><surname>Lee</surname><given-names>T</given-names></name><name><surname>Soof</surname><given-names>CM</given-names></name><etal></etal></person-group>. <article-title>Combined TRAF6 targeting and proteasome blockade has anti-myeloma and anti-bone resorptive effects</article-title>. <source/>Mol Cancer Res. (<year>2017</year>) <volume>15</volume>:<fpage>598</fpage>–<lpage>609</lpage>. <pub-id pub-id-type="doi">10.1158/1541-7786.MCR-16-0293</pub-id><pub-id pub-id-type="pmid">28122920</pub-id></mixed-citation>
</ref>
<ref id="B245">
<label>245.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burger</surname><given-names>ML</given-names></name><name><surname>Xue</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Kang</surname><given-names>C</given-names></name><name><surname>Winoto</surname><given-names>A</given-names></name></person-group>. <article-title>Premalignant PTEN-deficient thymocytes activate microRNAs miR-146a and miR-146b as a cellular defense against malignant transformation</article-title>. <source/>Blood (<year>2014</year>) <volume>123</volume>:<fpage>4089</fpage>–<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2013-11-539411</pub-id><pub-id pub-id-type="pmid">24735967</pub-id></mixed-citation>
</ref>
<ref id="B246">
<label>246.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Younger</surname><given-names>K</given-names></name><name><surname>Gartenhaus</surname><given-names>R</given-names></name><name><surname>Joseph</surname><given-names>AM</given-names></name><name><surname>Hu</surname><given-names>F</given-names></name><name><surname>Baer</surname><given-names>MR</given-names></name><etal></etal></person-group>. <article-title>Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies</article-title>. <source/>J Clin Invest. (<year>2015</year>) <volume>125</volume>:<fpage>1081</fpage>–<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1172/JCI75821</pub-id><pub-id pub-id-type="pmid">25642772</pub-id></mixed-citation>
</ref>
<ref id="B247">
<label>247.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Network</surname><given-names>CGAR</given-names></name></person-group>
<article-title>Comprehensive genomic characterization defines human glioblastoma genes and core pathways</article-title>. <source/>Nature (<year>2008</year>) <volume>455</volume>:<fpage>1061</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/nature07385</pub-id><pub-id pub-id-type="pmid">18772890</pub-id></mixed-citation>
</ref>
<ref id="B248">
<label>248.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brennan</surname><given-names>CW</given-names></name><name><surname>Verhaak</surname><given-names>RG</given-names></name><name><surname>McKenna</surname><given-names>A</given-names></name><name><surname>Campos</surname><given-names>B</given-names></name><name><surname>Noushmehr</surname><given-names>H</given-names></name><name><surname>Salama</surname><given-names>SR</given-names></name><etal></etal></person-group>. <article-title>The somatic genomic landscape of glioblastoma</article-title>. <source/>Cell (<year>2013</year>) <volume>155</volume>:<fpage>462</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2013.09.034</pub-id><pub-id pub-id-type="pmid">24120142</pub-id></mixed-citation>
</ref>
<ref id="B249">
<label>249.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>CF</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>CY</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><name><surname>Jin</surname><given-names>G</given-names></name><etal></etal></person-group>. <article-title>TRAF6 restricts p53 mitochondrial translocation, apoptosis, and tumor suppression</article-title>. <source/>Mol Cell (<year>2016</year>) <volume>64</volume>:<fpage>803</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2016.10.002</pub-id><pub-id pub-id-type="pmid">27818144</pub-id></mixed-citation>
</ref>
<ref id="B250">
<label>250.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duran</surname><given-names>A</given-names></name><name><surname>Linares</surname><given-names>JF</given-names></name><name><surname>Galvez</surname><given-names>AS</given-names></name><name><surname>Wikenheiser</surname><given-names>K</given-names></name><name><surname>Flores</surname><given-names>JM</given-names></name><name><surname>Diaz-Meco</surname><given-names>MT</given-names></name><etal></etal></person-group>. <article-title>The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis</article-title>. <source/>Cancer Cell (<year>2008</year>) <volume>13</volume>:<fpage>343</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2008.02.001</pub-id><pub-id pub-id-type="pmid">18394557</pub-id></mixed-citation>
</ref>
<ref id="B251">
<label>251.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiu</surname><given-names>HW</given-names></name><name><surname>Lin</surname><given-names>SW</given-names></name><name><surname>Lin</surname><given-names>LC</given-names></name><name><surname>Hsu</surname><given-names>YH</given-names></name><name><surname>Lin</surname><given-names>YF</given-names></name><name><surname>Ho</surname><given-names>SY</given-names></name><etal></etal></person-group>. <article-title>Synergistic antitumor effects of radiation and proteasome inhibitor treatment in pancreatic cancer through the induction of autophagy and the downregulation of TRAF6</article-title>. <source/>Cancer Lett. (<year>2015</year>) <volume>365</volume>:<fpage>229</fpage>–<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2015.05.025</pub-id><pub-id pub-id-type="pmid">26052093</pub-id></mixed-citation>
</ref>
<ref id="B252">
<label>252.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>WL</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Chan</surname><given-names>CH</given-names></name><name><surname>Lee</surname><given-names>SW</given-names></name><name><surname>Campos</surname><given-names>AD</given-names></name><name><surname>Lamothe</surname><given-names>B</given-names></name><etal></etal></person-group>. <article-title>The E3 ligase TRAF6 regulates Akt ubiquitination and activation</article-title>. <source/>Science (<year>2009</year>) <volume>325</volume>:<fpage>1134</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1126/science.1175065</pub-id><pub-id pub-id-type="pmid">19713527</pub-id></mixed-citation>
</ref>
<ref id="B253">
<label>253.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>H</given-names></name><name><surname>Lopez</surname><given-names>GY</given-names></name><name><surname>Kim</surname><given-names>CK</given-names></name><name><surname>Alvarez</surname><given-names>A</given-names></name><name><surname>Duncan</surname><given-names>CG</given-names></name><name><surname>Nishikawa</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis</article-title>. <source/>J Clin Invest. (<year>2014</year>) <volume>124</volume>:<fpage>3741</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1172/JCI73093</pub-id><pub-id pub-id-type="pmid">25061874</pub-id></mixed-citation>
</ref>
<ref id="B254">
<label>254.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>YF</given-names></name><name><surname>Yu</surname><given-names>DJ</given-names></name><name><surname>Jiang</surname><given-names>CY</given-names></name><name><surname>Wang</surname><given-names>XJ</given-names></name><name><surname>Zhu</surname><given-names>YP</given-names></name><name><surname>Zhao</surname><given-names>RZ</given-names></name><etal></etal></person-group>. <article-title>TRAF6 regulates proliferation of stromal cells in the transition and peripheral zones of benign prostatic hyperplasia via Akt/mTOR signaling</article-title>. <source/>Prostate (<year>2018</year>) <volume>78</volume>:<fpage>193</fpage>–<lpage>201</lpage>. <pub-id pub-id-type="doi">10.1002/pros.23456</pub-id><pub-id pub-id-type="pmid">29171041</pub-id></mixed-citation>
</ref>
<ref id="B255">
<label>255.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>YH</given-names></name><name><surname>Wu</surname><given-names>WS</given-names></name><name><surname>Lin</surname><given-names>LC</given-names></name><name><surname>Liu</surname><given-names>CS</given-names></name><name><surname>Ho</surname><given-names>SY</given-names></name><name><surname>Wang</surname><given-names>BJ</given-names></name><etal></etal></person-group>. <article-title>Bortezomib enhances radiosensitivity in oral cancer through inducing autophagy-mediated TRAF6 oncoprotein degradation</article-title>. <source/>J Exp Clin Cancer Res. (<year>2018</year>) <volume>37</volume>:<fpage>91</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-018-0760-0</pub-id><pub-id pub-id-type="pmid">29703234</pub-id></mixed-citation>
</ref>
<ref id="B256">
<label>256.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>D</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Blonska</surname><given-names>M</given-names></name><name><surname>You</surname><given-names>MJ</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name></person-group>. <article-title>MALT1 is required for EGFR-induced NF-κB activation and contributes to EGFR-driven lung cancer progression</article-title>. <source/>Oncogene (<year>2016</year>) <volume>35</volume>:<fpage>919</fpage>–<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2015.146</pub-id><pub-id pub-id-type="pmid">25982276</pub-id></mixed-citation>
</ref>
<ref id="B257">
<label>257.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Xiao</surname><given-names>T</given-names></name><name><surname>Tang</surname><given-names>L</given-names></name><name><surname>Jia</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>TRAF6 regulates EGF-induced cell transformation and cSCC malignant phenotype through CD147/EGFR</article-title>. <source/>Oncogenesis (<year>2018</year>) <volume>7</volume>:<fpage>17</fpage>. <pub-id pub-id-type="doi">10.1038/s41389-018-0030-1</pub-id><pub-id pub-id-type="pmid">29463844</pub-id></mixed-citation>
</ref>
<ref id="B258">
<label>258.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rezaeian</surname><given-names>AH</given-names></name><name><surname>Li</surname><given-names>CF</given-names></name><name><surname>Wu</surname><given-names>CY</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Delacerda</surname><given-names>J</given-names></name><name><surname>You</surname><given-names>MJ</given-names></name><etal></etal></person-group>. <article-title>A hypoxia-responsive TRAF6-ATM-H2AX signalling axis promotes HIF1α activation, tumorigenesis and metastasis</article-title>. <source/>Nat Cell Biol. (<year>2017</year>) <volume>19</volume>:<fpage>38</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1038/ncb3445</pub-id><pub-id pub-id-type="pmid">27918549</pub-id></mixed-citation>
</ref>
<ref id="B259">
<label>259.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>XB</given-names></name><name><surname>Meng</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Fang</surname><given-names>J</given-names></name></person-group>. <article-title>TRAF6 upregulates expression of HIF-1α and promotes tumor angiogenesis</article-title>. <source/>Cancer Res. (<year>2013</year>) <volume>73</volume>:<fpage>4950</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-0370</pub-id><pub-id pub-id-type="pmid">23722539</pub-id></mixed-citation>
</ref>
<ref id="B260">
<label>260.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mu</surname><given-names>Y</given-names></name><name><surname>Sundar</surname><given-names>R</given-names></name><name><surname>Thakur</surname><given-names>N</given-names></name><name><surname>Ekman</surname><given-names>M</given-names></name><name><surname>Gudey</surname><given-names>SK</given-names></name><name><surname>Yakymovych</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>TRAF6 ubiquitinates TGFβ type I receptor to promote its cleavage and nuclear translocation in cancer</article-title>. <source/>Nat Commun. (<year>2011</year>) <volume>2</volume>:<fpage>330</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms1332</pub-id><pub-id pub-id-type="pmid">21629263</pub-id></mixed-citation>
</ref>
<ref id="B261">
<label>261.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sundar</surname><given-names>R</given-names></name><name><surname>Gudey</surname><given-names>SK</given-names></name><name><surname>Heldin</surname><given-names>CH</given-names></name><name><surname>Landstrom</surname><given-names>M</given-names></name></person-group>. <article-title>TRAF6 promotes TGFβ-induced invasion and cell-cycle regulation via Lys63-linked polyubiquitination of Lys178 in TGFβ type I receptor</article-title>. <source/>Cell Cycle (<year>2015</year>) <volume>14</volume>:<fpage>554</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.4161/15384101.2014.990302</pub-id><pub-id pub-id-type="pmid">25622187</pub-id></mixed-citation>
</ref>
<ref id="B262">
<label>262.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gudey</surname><given-names>SK</given-names></name><name><surname>Sundar</surname><given-names>R</given-names></name><name><surname>Mu</surname><given-names>Y</given-names></name><name><surname>Wallenius</surname><given-names>A</given-names></name><name><surname>Zang</surname><given-names>G</given-names></name><name><surname>Bergh</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>TRAF6 stimulates the tumor-promoting effects of TGFβ type I receptor through polyubiquitination and activation of presenilin 1</article-title>. <source/>Sci Signal. (<year>2014</year>) <volume>7</volume>:<fpage>ra2</fpage>. <pub-id pub-id-type="doi">10.1126/scisignal.2004207</pub-id><pub-id pub-id-type="pmid">24399296</pub-id></mixed-citation>
</ref>
<ref id="B263">
<label>263.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamidi</surname><given-names>A</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Thakur</surname><given-names>N</given-names></name><name><surname>Itoh</surname><given-names>S</given-names></name><name><surname>Marcusson</surname><given-names>A</given-names></name><name><surname>Bergh</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>TGF-β promotes PI3K-AKT signaling and prostate cancer cell migration through the TRAF6-mediated ubiquitylation of p85α</article-title>. <source/>Sci Signal. (<year>2017</year>) <volume>10</volume>:<fpage>eaal4186</fpage>. <pub-id pub-id-type="doi">10.1126/scisignal.aal4186</pub-id><pub-id pub-id-type="pmid">28676490</pub-id></mixed-citation>
</ref>
<ref id="B264">
<label>264.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linares</surname><given-names>JF</given-names></name><name><surname>Duran</surname><given-names>A</given-names></name><name><surname>Reina-Campos</surname><given-names>M</given-names></name><name><surname>Aza-Blanc</surname><given-names>P</given-names></name><name><surname>Campos</surname><given-names>A</given-names></name><name><surname>Moscat</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Amino acid activation of mTORC1 by a PB1-domain-driven kinase complex cascade</article-title>. <source/>Cell Rep. (<year>2015</year>) <volume>12</volume>:<fpage>1339</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2015.07.045</pub-id><pub-id pub-id-type="pmid">26279575</pub-id></mixed-citation>
</ref>
<ref id="B265">
<label>265.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Magyar</surname><given-names>CE</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Veena</surname><given-names>MS</given-names></name><name><surname>Srivatsan</surname><given-names>ES</given-names></name><etal></etal></person-group>. <article-title>Hyperactivated JNK is a therapeutic target in pVHL-deficient renal cell carcinoma</article-title>. <source/>Cancer Res. (<year>2013</year>) <volume>73</volume>:<fpage>1374</fpage>–<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-2362</pub-id><pub-id pub-id-type="pmid">23393199</pub-id></mixed-citation>
</ref>
<ref id="B266">
<label>266.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>X</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><etal></etal></person-group>
<article-title>Proteolytic release of the p75(NTR) intracellular domain by ADAM10 promotes metastasis and resistance to anoikis</article-title>. <source/>Cancer Res. (<year>2018</year>) <volume>78</volume>:<fpage>2262</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-2789</pub-id><pub-id pub-id-type="pmid">29437707</pub-id></mixed-citation>
</ref>
<ref id="B267">
<label>267.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Qin</surname><given-names>B</given-names></name><name><surname>Moyer</surname><given-names>AM</given-names></name><name><surname>Nowsheen</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine</article-title>. <source/>J Clin Invest. (<year>2018</year>) <volume>128</volume>:<fpage>2376</fpage>–<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1172/JCI97924</pub-id><pub-id pub-id-type="pmid">29708513</pub-id></mixed-citation>
</ref>
<ref id="B268">
<label>268.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhry</surname><given-names>SI</given-names></name><name><surname>Hooper</surname><given-names>S</given-names></name><name><surname>Nye</surname><given-names>E</given-names></name><name><surname>Williamson</surname><given-names>P</given-names></name><name><surname>Harrington</surname><given-names>K</given-names></name><name><surname>Sahai</surname><given-names>E</given-names></name></person-group>. <article-title>Autocrine IL-1β-TRAF6 signalling promotes squamous cell carcinoma invasion through paracrine TNFα signalling to carcinoma-associated fibroblasts</article-title>. <source/>Oncogene (<year>2013</year>) <volume>32</volume>:<fpage>747</fpage>–<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2012.91</pub-id><pub-id pub-id-type="pmid">22450746</pub-id></mixed-citation>
</ref>
<ref id="B269">
<label>269.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Barker</surname><given-names>B</given-names></name><name><surname>Bolanos</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Jerez</surname><given-names>A</given-names></name><name><surname>Makishima</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Myeloid malignancies with chromosome 5q deletions acquire a dependency on an intrachromosomal NF-κB gene network</article-title>. <source/>Cell Rep. (<year>2014</year>) <volume>8</volume>:<fpage>1328</fpage>–<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2014.07.062</pub-id><pub-id pub-id-type="pmid">25199827</pub-id></mixed-citation>
</ref>
<ref id="B270">
<label>270.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>WH</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>CG</given-names></name><etal></etal></person-group>. <article-title>FOXP3 Controls an miR-146/NF-κB negative feedback loop that inhibits apoptosis in breast cancer cells</article-title>. <source/>Cancer Res. (<year>2015</year>) <volume>75</volume>:<fpage>1703</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-2108</pub-id><pub-id pub-id-type="pmid">25712342</pub-id></mixed-citation>
</ref>
<ref id="B271">
<label>271.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Yi</surname><given-names>B</given-names></name><name><surname>Wei</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>WH</given-names></name><name><surname>Hart</surname><given-names>KM</given-names></name><name><surname>Chauhan</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>FOXP3-miR-146-NF-κB axis and therapy for precancerous lesions in prostate</article-title>. <source/>Cancer Res. (<year>2015</year>) <volume>75</volume>:<fpage>1714</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-2109</pub-id><pub-id pub-id-type="pmid">25712341</pub-id></mixed-citation>
</ref>
<ref id="B272">
<label>272.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Bo</surname><given-names>X</given-names></name><name><surname>Hou</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><etal></etal></person-group>. <article-title>MiR-146a suppresses hepatocellular carcinoma by downregulating TRAF6</article-title>. <source/>Am J Cancer Res. (<year>2016</year>) <volume>6</volume>:<fpage>2502</fpage>–<lpage>13</lpage>.<pub-id pub-id-type="pmid">27904767</pub-id></mixed-citation>
</ref>
<ref id="B273">
<label>273.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>miR-146b-5p functions as a tumor suppressor by targeting TRAF6 and predicts the prognosis of human gliomas</article-title>. <source/>Oncotarget (<year>2015</year>) <volume>6</volume>:<fpage>29129</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.4895</pub-id><pub-id pub-id-type="pmid">26320176</pub-id></mixed-citation>
</ref>
<ref id="B274">
<label>274.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Miao</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Down-regulation of miR-146b-5p by long noncoding RNA MALAT1 in hepatocellular carcinoma promotes cancer growth and metastasis</article-title>. <source/>Oncotarget (<year>2017</year>) <volume>8</volume>:<fpage>28683</fpage>–<lpage>95</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.15640</pub-id><pub-id pub-id-type="pmid">28404923</pub-id></mixed-citation>
</ref>
<ref id="B275">
<label>275.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiao</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>HL</given-names></name><name><surname>Li</surname><given-names>DD</given-names></name><name><surname>Yang</surname><given-names>KL</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><etal></etal></person-group>. <article-title>Regulation of glycolytic metabolism by autophagy in liver cancer involves selective autophagic degradation of HK2 (hexokinase 2)</article-title>. <source/>Autophagy (<year>2018</year>) <volume>14</volume>:<fpage>671</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1080/15548627.2017.1381804</pub-id><pub-id pub-id-type="pmid">28980855</pub-id></mixed-citation>
</ref>
<ref id="B276">
<label>276.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Izban</surname><given-names>MG</given-names></name><name><surname>Ballard</surname><given-names>BR</given-names></name><etal></etal></person-group>. <article-title>SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer</article-title>. <source/>Oncogene (<year>2017</year>) <volume>36</volume>:<fpage>1364</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2016.300</pub-id><pub-id pub-id-type="pmid">27869166</pub-id></mixed-citation>
</ref>
<ref id="B277">
<label>277.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Adhiambo</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><etal></etal></person-group>. <article-title>SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination</article-title>. <source/>Oncotarget (<year>2015</year>) <volume>6</volume>:<fpage>771</fpage>–<lpage>88</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.2718</pub-id><pub-id pub-id-type="pmid">25596733</pub-id></mixed-citation>
</ref>
<ref id="B278">
<label>278.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zapata</surname><given-names>JM</given-names></name><name><surname>Pawlowski</surname><given-names>K</given-names></name><name><surname>Haas</surname><given-names>E</given-names></name><name><surname>Ware</surname><given-names>CF</given-names></name><name><surname>Godzik</surname><given-names>A</given-names></name><name><surname>Reed</surname><given-names>JC</given-names></name></person-group>. <article-title>A diverse family of proteins containing tumor necrosis factor receptor-associated factor domains</article-title>. <source/>J Biol Chem. (<year>2001</year>) <volume>276</volume>:<fpage>24242</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M100354200</pub-id><pub-id pub-id-type="pmid">11279055</pub-id></mixed-citation>
</ref>
<ref id="B279">
<label>279.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zapata</surname><given-names>JM</given-names></name><name><surname>Martinez-Garcia</surname><given-names>V</given-names></name><name><surname>Lefebvre</surname><given-names>S</given-names></name></person-group>. <article-title>Phylogeny of the TRAF/MATH domain</article-title>. <source/>Adv Exp Med Biol. (<year>2007</year>) <volume>597</volume>:<fpage>1</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1007/978-0-387-70630-6_1</pub-id><pub-id pub-id-type="pmid">17633013</pub-id></mixed-citation>
</ref>
<ref id="B280">
<label>280.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Coleman</surname><given-names>I</given-names></name><name><surname>Morrissey</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>True</surname><given-names>LD</given-names></name><name><surname>Gulati</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer</article-title>. <source/>Nat Med. (<year>2016</year>) <volume>22</volume>:<fpage>369</fpage>–<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4053</pub-id><pub-id pub-id-type="pmid">26928463</pub-id></mixed-citation>
</ref>
<ref id="B281">
<label>281.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goode</surname><given-names>B</given-names></name><name><surname>Joseph</surname><given-names>NM</given-names></name><name><surname>Stevers</surname><given-names>M</given-names></name><name><surname>Van</surname><given-names>Ziffle J</given-names></name><name><surname>Onodera</surname><given-names>C</given-names></name><name><surname>Talevich</surname><given-names>E</given-names></name><etal></etal></person-group>. <article-title>Adenomatoid tumors of the male and female genital tract are defined by TRAF7 mutations that drive aberrant NF-kB pathway activation</article-title>. <source/>Mod Pathol. (<year>2018</year>) <volume>31</volume>:<fpage>660</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1038/modpathol.2017.153</pub-id><pub-id pub-id-type="pmid">29148537</pub-id></mixed-citation>
</ref>
<ref id="B282">
<label>282.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reuss</surname><given-names>DE</given-names></name><name><surname>Piro</surname><given-names>RM</given-names></name><name><surname>Jones</surname><given-names>DT</given-names></name><name><surname>Simon</surname><given-names>M</given-names></name><name><surname>Ketter</surname><given-names>R</given-names></name><name><surname>Kool</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations</article-title>. <source/>Acta Neuropathol. (<year>2013</year>) <volume>125</volume>:<fpage>351</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-013-1093-x</pub-id><pub-id pub-id-type="pmid">23404370</pub-id></mixed-citation>
</ref>
<ref id="B283">
<label>283.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>CJ</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Jentoft</surname><given-names>ME</given-names></name><name><surname>Mer</surname><given-names>G</given-names></name><name><surname>Spinner</surname><given-names>RJ</given-names></name><name><surname>Dyck</surname><given-names>PJ</given-names></name><etal></etal></person-group>. <article-title>Genomic analysis reveals frequent TRAF7 mutations in intraneural perineuriomas</article-title>. <source/>Ann Neurol. (<year>2017</year>) <volume>81</volume>:<fpage>316</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1002/ana.24854</pub-id><pub-id pub-id-type="pmid">28019650</pub-id></mixed-citation>
</ref>
<ref id="B284">
<label>284.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>VE</given-names></name><name><surname>Harmanci</surname><given-names>AS</given-names></name><name><surname>Bai</surname><given-names>H</given-names></name><name><surname>Youngblood</surname><given-names>MW</given-names></name><name><surname>Lee</surname><given-names>TI</given-names></name><name><surname>Baranoski</surname><given-names>JF</given-names></name><etal></etal></person-group>. <article-title>Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas</article-title>. <source/>Nat Genet. (<year>2016</year>) <volume>48</volume>:<fpage>1253</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/ng.3651</pub-id><pub-id pub-id-type="pmid">27548314</pub-id></mixed-citation>
</ref>
<ref id="B285">
<label>285.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>VE</given-names></name><name><surname>Erson-Omay</surname><given-names>EZ</given-names></name><name><surname>Serin</surname><given-names>A</given-names></name><name><surname>Yin</surname><given-names>J</given-names></name><name><surname>Cotney</surname><given-names>J</given-names></name><name><surname>Ozduman</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO</article-title>. <source/>Science (<year>2013</year>) <volume>339</volume>:<fpage>1077</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1126/science.1233009</pub-id><pub-id pub-id-type="pmid">23348505</pub-id></mixed-citation>
</ref>
<ref id="B286">
<label>286.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuzawa</surname><given-names>S</given-names></name><name><surname>Nishihara</surname><given-names>H</given-names></name><name><surname>Yamaguchi</surname><given-names>S</given-names></name><name><surname>Mohri</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>Clinical impact of targeted amplicon sequencing for meningioma as a practical clinical-sequencing system</article-title>. <source/>Mod Pathol. (<year>2016</year>) <volume>29</volume>:<fpage>708</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1038/modpathol.2016.81</pub-id><pub-id pub-id-type="pmid">27102344</pub-id></mixed-citation>
</ref>
<ref id="B287">
<label>287.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abedalthagafi</surname><given-names>M</given-names></name><name><surname>Bi</surname><given-names>WL</given-names></name><name><surname>Aizer</surname><given-names>AA</given-names></name><name><surname>Merrill</surname><given-names>PH</given-names></name><name><surname>Brewster</surname><given-names>R</given-names></name><name><surname>Agarwalla</surname><given-names>PK</given-names></name><etal></etal></person-group>. <article-title>Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma</article-title>. <source/>Neuro Oncol. (<year>2016</year>) <volume>18</volume>:<fpage>649</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1093/neuonc/nov316</pub-id><pub-id pub-id-type="pmid">26826201</pub-id></mixed-citation>
</ref>
<ref id="B288">
<label>288.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peyre</surname><given-names>M</given-names></name><name><surname>Gaillard</surname><given-names>S</given-names></name><name><surname>de</surname><given-names>Marcellus C</given-names></name><name><surname>Giry</surname><given-names>M</given-names></name><name><surname>Bielle</surname><given-names>F</given-names></name><name><surname>Villa</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Progestin-associated shift of meningioma mutational landscape</article-title>. <source/>Ann Oncol. (<year>2018</year>) <volume>29</volume>:<fpage>681</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1093/annonc/mdx763</pub-id><pub-id pub-id-type="pmid">29206892</pub-id></mixed-citation>
</ref>
<ref id="B289">
<label>289.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zotti</surname><given-names>T</given-names></name><name><surname>Scudiero</surname><given-names>I</given-names></name><name><surname>Vito</surname><given-names>P</given-names></name><name><surname>Stilo</surname><given-names>R</given-names></name></person-group>. <article-title>The emerging role of TRAF7 in tumor development</article-title>. <source/>J Cell Physiol. (<year>2017</year>) <volume>232</volume>:<fpage>1233</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.25676</pub-id><pub-id pub-id-type="pmid">27808423</pub-id></mixed-citation>
</ref>
<ref id="B290">
<label>290.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karsy</surname><given-names>M</given-names></name><name><surname>Azab</surname><given-names>MA</given-names></name><name><surname>Abou-Al-Shaar</surname><given-names>H</given-names></name><name><surname>Guan</surname><given-names>J</given-names></name><name><surname>Eli</surname><given-names>I</given-names></name><name><surname>Jensen</surname><given-names>RL</given-names></name><etal></etal></person-group>. <article-title>Clinical potential of meningioma genomic insights: a practical review for neurosurgeons</article-title>. <source/>Neurosurg Focus (<year>2018</year>) <volume>44</volume>:<fpage>E10</fpage>. <pub-id pub-id-type="doi">10.3171/2018.2.FOCUS1849</pub-id><pub-id pub-id-type="pmid">29852774</pub-id></mixed-citation>
</ref>
<ref id="B291">
<label>291.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apra</surname><given-names>C</given-names></name><name><surname>Peyre</surname><given-names>M</given-names></name><name><surname>Kalamarides</surname><given-names>M</given-names></name></person-group>. <article-title>Current treatment options for meningioma</article-title>. <source/>Expert Rev Neurother. (<year>2018</year>) <volume>18</volume>:<fpage>241</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1080/14737175.2018.1429920</pub-id><pub-id pub-id-type="pmid">29338455</pub-id></mixed-citation>
</ref>
<ref id="B292">
<label>292.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sneddon</surname><given-names>S</given-names></name><name><surname>Dick</surname><given-names>I</given-names></name><name><surname>Lee</surname><given-names>YCG</given-names></name><name><surname>Musk</surname><given-names>AWB</given-names></name><name><surname>Patch</surname><given-names>AM</given-names></name><name><surname>Pearson</surname><given-names>JV</given-names></name><etal></etal></person-group>. <article-title>Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations</article-title>. <source/>Lung Cancer (<year>2018</year>) <volume>119</volume>:<fpage>64</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1016/j.lungcan.2018.03.009</pub-id><pub-id pub-id-type="pmid">29656754</pub-id></mixed-citation>
</ref>
<ref id="B293">
<label>293.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bueno</surname><given-names>R</given-names></name><name><surname>Stawiski</surname><given-names>EW</given-names></name><name><surname>Goldstein</surname><given-names>LD</given-names></name><name><surname>Durinck</surname><given-names>S</given-names></name><name><surname>De</surname><given-names>Rienzo A</given-names></name><name><surname>Modrusan</surname><given-names>Z</given-names></name><etal></etal></person-group>. <article-title>Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations</article-title>. <source/>Nat Genet. (<year>2016</year>) <volume>48</volume>:<fpage>407</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1038/ng.3520</pub-id><pub-id pub-id-type="pmid">26928227</pub-id></mixed-citation>
</ref>
<ref id="B294">
<label>294.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuzawa</surname><given-names>S</given-names></name><name><surname>Nishihara</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>S</given-names></name></person-group>. <article-title>Genetic landscape of meningioma</article-title>. <source/>Brain Tumor Pathol. (<year>2016</year>) <volume>33</volume>:<fpage>237</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1007/s10014-016-0271-7</pub-id><pub-id pub-id-type="pmid">27624470</pub-id></mixed-citation>
</ref>
<ref id="B295">
<label>295.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peyre</surname><given-names>M</given-names></name><name><surname>Feuvret</surname><given-names>L</given-names></name><name><surname>Sanson</surname><given-names>M</given-names></name><name><surname>Navarro</surname><given-names>S</given-names></name><name><surname>Boch</surname><given-names>AL</given-names></name><name><surname>Loiseau</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Diffuse midline skull base meningiomas: identification of a rare and aggressive subgroup of meningiomas</article-title>. <source/>J Neurooncol. (<year>2017</year>) <volume>133</volume>:<fpage>633</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/s11060-017-2480-2</pub-id><pub-id pub-id-type="pmid">28536991</pub-id></mixed-citation>
</ref>
<ref id="B296">
<label>296.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fadlullah</surname><given-names>MZ</given-names></name><name><surname>Chiang</surname><given-names>IK</given-names></name><name><surname>Dionne</surname><given-names>KR</given-names></name><name><surname>Yee</surname><given-names>PS</given-names></name><name><surname>Gan</surname><given-names>CP</given-names></name><name><surname>Sam</surname><given-names>KK</given-names></name><etal></etal></person-group>. <article-title>Genetically-defined novel oral squamous cell carcinoma cell lines for the development of molecular therapies</article-title>. <source/>Oncotarget (<year>2016</year>) <volume>7</volume>:<fpage>27802</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.8533</pub-id><pub-id pub-id-type="pmid">27050151</pub-id></mixed-citation>
</ref>
<ref id="B297">
<label>297.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Jia</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>C</given-names></name><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><etal></etal></person-group>. <article-title>Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes</article-title>. <source/>Discov Med. (<year>2014</year>) <volume>18</volume>:<fpage>301</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="pmid">25549701</pub-id></mixed-citation>
</ref>
<ref id="B298">
<label>298.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>E</given-names></name><name><surname>Wu</surname><given-names>RC</given-names></name><name><surname>Guan</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses</article-title>. <source/>J Natl Cancer Inst. (<year>2012</year>) <volume>104</volume>:<fpage>1503</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1093/jnci/djs345</pub-id><pub-id pub-id-type="pmid">22923510</pub-id></mixed-citation>
</ref>
<ref id="B299">
<label>299.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizvi</surname><given-names>NA</given-names></name><name><surname>Hellmann</surname><given-names>MD</given-names></name><name><surname>Snyder</surname><given-names>A</given-names></name><name><surname>Kvistborg</surname><given-names>P</given-names></name><name><surname>Makarov</surname><given-names>V</given-names></name><name><surname>Havel</surname><given-names>JJ</given-names></name><etal></etal></person-group>. <article-title>Cancer immunology</article-title>. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. <source/>Science (<year>2015</year>) <volume>348</volume>:<fpage>124</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1126/science.aaa1348</pub-id><pub-id pub-id-type="pmid">25765070</pub-id></mixed-citation>
</ref>
<ref id="B300">
<label>300.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tokita</surname><given-names>MJ</given-names></name><name><surname>Chen</surname><given-names>CA</given-names></name><name><surname>Chitayat</surname><given-names>D</given-names></name><name><surname>Macnamara</surname><given-names>E</given-names></name><name><surname>Rosenfeld</surname><given-names>JA</given-names></name><name><surname>Hanchard</surname><given-names>N</given-names></name><etal></etal></person-group>. <article-title><italic>De novo</italic> missense variants in TRAF7 cause developmental delay, congenital anomalies, and dysmorphic features</article-title>. <source/>Am J Hum Genet. (<year>2018</year>) <volume>103</volume>:<fpage>154</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2018.06.005</pub-id><pub-id pub-id-type="pmid">29961569</pub-id></mixed-citation>
</ref>
<ref id="B301">
<label>301.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>W</given-names></name><name><surname>Bennett</surname><given-names>EJ</given-names></name><name><surname>Huttlin</surname><given-names>EL</given-names></name><name><surname>Guo</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Possemato</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Systematic and quantitative assessment of the ubiquitin-modified proteome</article-title>. <source/>Mol Cell (<year>2011</year>) <volume>44</volume>:<fpage>325</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2011.08.025</pub-id><pub-id pub-id-type="pmid">21906983</pub-id></mixed-citation>
</ref>
<ref id="B302">
<label>302.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>LG</given-names></name><name><surname>Li</surname><given-names>LY</given-names></name><name><surname>Shu</surname><given-names>HB</given-names></name></person-group>. <article-title>TRAF7 potentiates MEKK3-induced AP1 and CHOP activation and induces apoptosis</article-title>. <source/>J Biol Chem. (<year>2004</year>) <volume>279</volume>:<fpage>17278</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.C400063200</pub-id><pub-id pub-id-type="pmid">15001576</pub-id></mixed-citation>
</ref>
<ref id="B303">
<label>303.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouwmeester</surname><given-names>T</given-names></name><name><surname>Bauch</surname><given-names>A</given-names></name><name><surname>Ruffner</surname><given-names>H</given-names></name><name><surname>Angrand</surname><given-names>PO</given-names></name><name><surname>Bergamini</surname><given-names>G</given-names></name><name><surname>Croughton</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway</article-title>. <source/>Nat Cell Biol. (<year>2004</year>) <volume>6</volume>:<fpage>97</fpage>–<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1038/ncb1086</pub-id><pub-id pub-id-type="pmid">14743216</pub-id></mixed-citation>
</ref>
<ref id="B304">
<label>304.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krumm</surname><given-names>N</given-names></name><name><surname>Turner</surname><given-names>TN</given-names></name><name><surname>Baker</surname><given-names>C</given-names></name><name><surname>Vives</surname><given-names>L</given-names></name><name><surname>Mohajeri</surname><given-names>K</given-names></name><name><surname>Witherspoon</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>Excess of rare, inherited truncating mutations in autism</article-title>. <source/>Nat Genet. (<year>2015</year>) <volume>47</volume>:<fpage>582</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/ng.3303</pub-id><pub-id pub-id-type="pmid">25961944</pub-id></mixed-citation>
</ref>
<ref id="B305">
<label>305.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morita</surname><given-names>Y</given-names></name><name><surname>Kanei-Ishii</surname><given-names>C</given-names></name><name><surname>Nomura</surname><given-names>T</given-names></name><name><surname>Ishii</surname><given-names>S</given-names></name></person-group>. <article-title>TRAF7 sequesters c-Myb to the cytoplasm by stimulating its sumoylation</article-title>. <source/>Mol Biol Cell (<year>2005</year>) <volume>16</volume>:<fpage>5433</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1091/mbc.e05-08-0731</pub-id><pub-id pub-id-type="pmid">16162816</pub-id></mixed-citation>
</ref>
<ref id="B306">
<label>306.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fremin</surname><given-names>C</given-names></name><name><surname>Saba-El-Leil</surname><given-names>MK</given-names></name><name><surname>Levesque</surname><given-names>K</given-names></name><name><surname>Ang</surname><given-names>SL</given-names></name><name><surname>Meloche</surname><given-names>S</given-names></name></person-group>. <article-title>Functional redundancy of ERK1 and ERK2 MAP kinases during development</article-title>. <source/>Cell Rep. (<year>2015</year>) <volume>12</volume>:<fpage>913</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2015.07.011</pub-id><pub-id pub-id-type="pmid">26235619</pub-id></mixed-citation>
</ref>
<ref id="B307">
<label>307.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zotti</surname><given-names>T</given-names></name><name><surname>Vito</surname><given-names>P</given-names></name><name><surname>Stilo</surname><given-names>R</given-names></name></person-group>. <article-title>The seventh ring: exploring TRAF7 functions</article-title>. <source/>J Cell Physiol. (<year>2012</year>) <volume>227</volume>:<fpage>1280</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.24011</pub-id><pub-id pub-id-type="pmid">22105767</pub-id></mixed-citation>
</ref>
<ref id="B308">
<label>308.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scudiero</surname><given-names>I</given-names></name><name><surname>Zotti</surname><given-names>T</given-names></name><name><surname>Ferravante</surname><given-names>A</given-names></name><name><surname>Vessichelli</surname><given-names>M</given-names></name><name><surname>Reale</surname><given-names>C</given-names></name><name><surname>Masone</surname><given-names>MC</given-names></name><etal></etal></person-group>. <article-title>Tumor necrosis factor (TNF) receptor-associated factor 7 is required for TNFα-induced Jun NH2-terminal kinase activation and promotes cell death by regulating polyubiquitination and lysosomal degradation of c-FLIP protein</article-title>. <source/>J Biol Chem. (<year>2012</year>) <volume>287</volume>:<fpage>6053</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M111.300137</pub-id><pub-id pub-id-type="pmid">22219201</pub-id></mixed-citation>
</ref>
<ref id="B309">
<label>309.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zotti</surname><given-names>T</given-names></name><name><surname>Uva</surname><given-names>A</given-names></name><name><surname>Ferravante</surname><given-names>A</given-names></name><name><surname>Vessichelli</surname><given-names>M</given-names></name><name><surname>Scudiero</surname><given-names>I</given-names></name><name><surname>Ceccarelli</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>TRAF7 protein promotes Lys-29-linked polyubiquitination of IkappaB kinase (IKKgamma)/NF-kappaB essential modulator (NEMO) and p65/RelA protein and represses NF-kappaB activation</article-title>. <source/>J Biol Chem. (<year>2011</year>) <volume>286</volume>:<fpage>22924</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M110.215426</pub-id><pub-id pub-id-type="pmid">21518757</pub-id></mixed-citation>
</ref>
<ref id="B310">
<label>310.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsikitis</surname><given-names>M</given-names></name><name><surname>Acosta-Alvear</surname><given-names>D</given-names></name><name><surname>Blais</surname><given-names>A</given-names></name><name><surname>Campos</surname><given-names>EI</given-names></name><name><surname>Lane</surname><given-names>WS</given-names></name><name><surname>Sanchez</surname><given-names>I</given-names></name><etal></etal></person-group>. <article-title>Traf7, a MyoD1 transcriptional target, regulates nuclear factor-κB activity during myogenesis</article-title>. <source/>EMBO Rep. (<year>2010</year>) <volume>11</volume>:<fpage>969</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1038/embor.2010.154</pub-id><pub-id pub-id-type="pmid">20948544</pub-id></mixed-citation>
</ref>
<ref id="B311">
<label>311.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>H</given-names></name><name><surname>Jono</surname><given-names>H</given-names></name><name><surname>Kai</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>JD</given-names></name></person-group>. <article-title>The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7</article-title>. <source/>J Biol Chem. (<year>2005</year>) <volume>280</volume>:<fpage>41111</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M509526200</pub-id><pub-id pub-id-type="pmid">16230348</pub-id></mixed-citation>
</ref>
<ref id="B312">
<label>312.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Qu</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name></person-group>. <article-title>Downregulation of ubiquitin E3 ligase TNF receptor-associated factor 7 leads to stabilization of p53 in breast cancer</article-title>. <source/>Oncol Rep. (<year>2013</year>) <volume>29</volume>:<fpage>283</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.3892/or.2012.2121</pub-id><pub-id pub-id-type="pmid">23128672</pub-id></mixed-citation>
</ref>
<ref id="B313">
<label>313.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curtis</surname><given-names>C</given-names></name><name><surname>Shah</surname><given-names>SP</given-names></name><name><surname>Chin</surname><given-names>SF</given-names></name><name><surname>Turashvili</surname><given-names>G</given-names></name><name><surname>Rueda</surname><given-names>OM</given-names></name><name><surname>Dunning</surname><given-names>MJ</given-names></name><etal></etal></person-group>. <article-title>The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups</article-title>. <source/>Nature (<year>2012</year>) <volume>486</volume>:<fpage>346</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1038/nature10983</pub-id><pub-id pub-id-type="pmid">22522925</pub-id></mixed-citation>
</ref>
<ref id="B314">
<label>314.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>B</given-names></name><name><surname>Chin</surname><given-names>SF</given-names></name><name><surname>Rueda</surname><given-names>OM</given-names></name><name><surname>Vollan</surname><given-names>HK</given-names></name><name><surname>Provenzano</surname><given-names>E</given-names></name><name><surname>Bardwell</surname><given-names>HA</given-names></name><etal></etal></person-group>. <article-title>The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes</article-title>. <source/>Nat Commun. (<year>2016</year>) <volume>7</volume>:<fpage>11479</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms11479</pub-id><pub-id pub-id-type="pmid">27161491</pub-id></mixed-citation>
</ref>
<ref id="B315">
<label>315.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Network</surname><given-names>TCGAR</given-names></name></person-group>
<article-title>Integrated genomic characterization of oesophageal carcinoma</article-title>. <source/>Nature (<year>2017</year>) <volume>541</volume>:<fpage>169</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1038/nature20805</pub-id><pub-id pub-id-type="pmid">28052061</pub-id></mixed-citation>
</ref>
<ref id="B316">
<label>316.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>XK</given-names></name><name><surname>Yuan</surname><given-names>SL</given-names></name><name><surname>Tao</surname><given-names>HX</given-names></name><name><surname>Diao</surname><given-names>LP</given-names></name><name><surname>Wang</surname><given-names>YC</given-names></name><name><surname>Cao</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>The upregulation of TRAF1 induced by helicobacter pylori plays an antiapoptotic effect on the infected cells</article-title>. <source/>Helicobacter (<year>2016</year>) <volume>21</volume>:<fpage>554</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1111/hel.12311</pub-id><pub-id pub-id-type="pmid">27060717</pub-id></mixed-citation>
</ref>
<ref id="B317">
<label>317.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asano</surname><given-names>N</given-names></name><name><surname>Imatani</surname><given-names>A</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Fushiya</surname><given-names>J</given-names></name><name><surname>Kondo</surname><given-names>Y</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name><etal></etal></person-group>. <article-title>Cdx2 expression and intestinal metaplasia induced by <italic>H. pylori</italic> infection of gastric cells is regulated by NOD1-mediated innate immune responses</article-title>. <source/>Cancer Res. (<year>2016</year>) <volume>76</volume>:<fpage>1135</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-2272</pub-id><pub-id pub-id-type="pmid">26759244</pub-id></mixed-citation>
</ref>
<ref id="B318">
<label>318.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Asano</surname><given-names>N</given-names></name><name><surname>Fichtner-Feigl</surname><given-names>S</given-names></name><name><surname>Gorelick</surname><given-names>PL</given-names></name><name><surname>Tsuji</surname><given-names>Y</given-names></name><name><surname>Matsumoto</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>NOD1 contributes to mouse host defense against Helicobacter pylori via induction of type I IFN and activation of the ISGF3 signaling pathway</article-title>. <source/>J Clin Invest. (<year>2010</year>) <volume>120</volume>:<fpage>1645</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1172/JCI39481</pub-id><pub-id pub-id-type="pmid">20389019</pub-id></mixed-citation>
</ref>
<ref id="B319">
<label>319.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maeda</surname><given-names>S</given-names></name><name><surname>Yoshida</surname><given-names>H</given-names></name><name><surname>Ogura</surname><given-names>K</given-names></name><name><surname>Mitsuno</surname><given-names>Y</given-names></name><name><surname>Hirata</surname><given-names>Y</given-names></name><name><surname>Yamaji</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title><italic>H. pylori</italic> activates NF-κB through a signaling pathway involving IκB kinases, NF-κB-inducing kinase, TRAF2, and TRAF6 in gastric cancer cells</article-title>. <source/>Gastroenterology (<year>2000</year>) <volume>119</volume>:<fpage>97</fpage>–<lpage>108</lpage>. <pub-id pub-id-type="doi">10.1053/gast.2000.8540</pub-id><pub-id pub-id-type="pmid">10889159</pub-id></mixed-citation>
</ref>
<ref id="B320">
<label>320.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Jiang</surname><given-names>A</given-names></name><name><surname>Xia</surname><given-names>A</given-names></name><name><surname>Kong</surname><given-names>S</given-names></name><name><surname>Gong</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>MicroRNA-3178 ameliorates inflammation and gastric carcinogenesis promoted by Helicobacter pylori new toxin, Tip-α, by targeting TRAF3</article-title>. <source/>Helicobacter (<year>2017</year>) <volume>22</volume>:<fpage>e12348</fpage>. <pub-id pub-id-type="doi">10.1111/hel.12348</pub-id><pub-id pub-id-type="pmid">27493095</pub-id></mixed-citation>
</ref>
<ref id="B321">
<label>321.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenfeld</surname><given-names>H</given-names></name><name><surname>Takasaki</surname><given-names>K</given-names></name><name><surname>Walsh</surname><given-names>MJ</given-names></name><name><surname>Ersing</surname><given-names>I</given-names></name><name><surname>Bernhardt</surname><given-names>K</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>TRAF1 Coordinates polyubiquitin signaling to enhance epstein-barr virus LMP1-mediated growth and survival pathway activation</article-title>. <source/>PLoS Pathog. (<year>2015</year>) <volume>11</volume>:<fpage>e1004890</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1004890</pub-id><pub-id pub-id-type="pmid">25996949</pub-id></mixed-citation>
</ref>
<ref id="B322">
<label>322.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegler</surname><given-names>G</given-names></name><name><surname>Meyer</surname><given-names>B</given-names></name><name><surname>Dawson</surname><given-names>C</given-names></name><name><surname>Brachtel</surname><given-names>E</given-names></name><name><surname>Lennerz</surname><given-names>J</given-names></name><name><surname>Koch</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Expression of tumor necrosis factor receptor-associated factor 1 in nasopharyngeal carcinoma: possible upregulation by Epstein-Barr virus latent membrane protein 1</article-title>. <source/>Int J Cancer (<year>2004</year>) <volume>112</volume>:<fpage>265</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.20367</pub-id><pub-id pub-id-type="pmid">15352039</pub-id></mixed-citation>
</ref>
<ref id="B323">
<label>323.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kung</surname><given-names>CP</given-names></name><name><surname>Raab-Traub</surname><given-names>N</given-names></name></person-group>. <article-title>Epstein-Barr virus latent membrane protein 1 modulates distinctive NF-κB pathways through C-terminus-activating region 1 to regulate epidermal growth factor receptor expression</article-title>. <source/>J Virol. (<year>2010</year>) <volume>84</volume>:<fpage>6605</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00344-10</pub-id><pub-id pub-id-type="pmid">20410275</pub-id></mixed-citation>
</ref>
<ref id="B324">
<label>324.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schnetzke</surname><given-names>U</given-names></name><name><surname>Fischer</surname><given-names>M</given-names></name><name><surname>Spies-Weisshart</surname><given-names>B</given-names></name><name><surname>Zirm</surname><given-names>E</given-names></name><name><surname>Hochhaus</surname><given-names>A</given-names></name><name><surname>Muller</surname><given-names>JP</given-names></name><etal></etal></person-group>. <article-title>The E3 ubiquitin ligase TRAF2 can contribute to TNF-α resistance in FLT3-ITD-positive AML cells</article-title>. <source/>Leuk Res. (<year>2013</year>) <volume>37</volume>:<fpage>1557</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/j.leukres.2013.08.004</pub-id><pub-id pub-id-type="pmid">23998902</pub-id></mixed-citation>
</ref>
<ref id="B325">
<label>325.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirakata</surname><given-names>M</given-names></name><name><surname>Imadome</surname><given-names>KI</given-names></name><name><surname>Okazaki</surname><given-names>K</given-names></name><name><surname>Hirai</surname><given-names>K</given-names></name></person-group>. <article-title>Activation of TRAF5 and TRAF6 signal cascades negatively regulates the latent replication origin of Epstein-Barr virus through p38 mitogen-activated protein kinase</article-title>. <source/>J Virol. (<year>2001</year>) <volume>75</volume>:<fpage>5059</fpage>–<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.75.11.5059-5068.2001</pub-id><pub-id pub-id-type="pmid">11333886</pub-id></mixed-citation>
</ref>
<ref id="B326">
<label>326.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guasparri</surname><given-names>I</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Cesarman</surname><given-names>E</given-names></name></person-group>. <article-title>The KSHV oncoprotein vFLIP contains a TRAF-interacting motif and requires TRAF2 and TRAF3 for signalling</article-title>. <source/>EMBO Rep. (<year>2006</year>) <volume>7</volume>:<fpage>114</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/sj.embor.7400580</pub-id><pub-id pub-id-type="pmid">16311516</pub-id></mixed-citation>
</ref>
<ref id="B327">
<label>327.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumari</surname><given-names>P</given-names></name><name><surname>Saha</surname><given-names>I</given-names></name><name><surname>Narayanan</surname><given-names>A</given-names></name><name><surname>Narayanan</surname><given-names>S</given-names></name><name><surname>Takaoka</surname><given-names>A</given-names></name><name><surname>Kumar</surname><given-names>NS</given-names></name><etal></etal></person-group>. <article-title>Essential role of HCMV deubiquitinase in promoting oncogenesis by targeting anti-viral innate immune signaling pathways</article-title>. <source/>Cell Death Dis. (<year>2017</year>) <volume>8</volume>:<fpage>e3078</fpage>. <pub-id pub-id-type="doi">10.1038/cddis.2017.461</pub-id><pub-id pub-id-type="pmid">28981114</pub-id></mixed-citation>
</ref>
<ref id="B328">
<label>328.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>H</given-names></name><name><surname>Spath</surname><given-names>SS</given-names></name><name><surname>Clavijo</surname><given-names>PE</given-names></name><etal></etal></person-group>
<article-title>Attenuated TRAF3 fosters alternative activation of NF-κB and reduced expression of anti-viral interferon, TP53, and RB to promote HPV-positive head and neck cancers</article-title>. <source/>Cancer Res. (<year>2018</year>) <volume>78</volume>:<fpage>4613</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-0642</pub-id><pub-id pub-id-type="pmid">29921694</pub-id></mixed-citation>
</ref>
<ref id="B329">
<label>329.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>H</given-names></name><name><surname>Kato</surname><given-names>N</given-names></name><name><surname>Shiratori</surname><given-names>Y</given-names></name><name><surname>Otsuka</surname><given-names>M</given-names></name><name><surname>Maeda</surname><given-names>S</given-names></name><name><surname>Kato</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Hepatitis C virus core protein activates nuclear factor kappa B-dependent signaling through tumor necrosis factor receptor-associated factor</article-title>. <source/>J Biol Chem. (<year>2001</year>) <volume>276</volume>:<fpage>16399</fpage>–<lpage>405</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M006671200</pub-id><pub-id pub-id-type="pmid">11278312</pub-id></mixed-citation>
</ref>
<ref id="B330">
<label>330.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>KA</given-names></name><name><surname>Abbas</surname><given-names>W</given-names></name><name><surname>Varin</surname><given-names>A</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Di</surname><given-names>Martino V</given-names></name><name><surname>Dichamp</surname><given-names>I</given-names></name><etal></etal></person-group>. <article-title>HIV-1 Nef interacts with HCV Core, recruits TRAF2, TRAF5 and TRAF6, and stimulates HIV-1 replication in macrophages</article-title>. <source/>J Innate Immun. (<year>2013</year>) <volume>5</volume>:<fpage>639</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1159/000350517</pub-id><pub-id pub-id-type="pmid">23774506</pub-id></mixed-citation>
</ref>
<ref id="B331">
<label>331.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diani</surname><given-names>E</given-names></name><name><surname>Avesani</surname><given-names>F</given-names></name><name><surname>Bergamo</surname><given-names>E</given-names></name><name><surname>Cremonese</surname><given-names>G</given-names></name><name><surname>Bertazzoni</surname><given-names>U</given-names></name><name><surname>Romanelli</surname><given-names>MG</given-names></name></person-group>. <article-title>HTLV-1 Tax protein recruitment into IKKepsilon and TBK1 kinase complexes enhances IFN-I expression</article-title>. <source/>Virology (<year>2015</year>) <volume>476</volume>:<fpage>92</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2014.12.005</pub-id><pub-id pub-id-type="pmid">25531185</pub-id></mixed-citation>
</ref>
<ref id="B332">
<label>332.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>YB</given-names></name><name><surname>Harhaj</surname><given-names>EW</given-names></name></person-group>. <article-title>HTLV-1 tax stabilizes MCL-1 via TRAF6-dependent K63-linked polyubiquitination to promote cell survival and transformation</article-title>. <source/>PLoS Pathog. (<year>2014</year>) <volume>10</volume>:<fpage>e1004458</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1004458</pub-id><pub-id pub-id-type="pmid">25340740</pub-id></mixed-citation>
</ref>
<ref id="B333">
<label>333.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boulabiar</surname><given-names>M</given-names></name><name><surname>Boubaker</surname><given-names>S</given-names></name><name><surname>Favre</surname><given-names>M</given-names></name><name><surname>Demeret</surname><given-names>C</given-names></name></person-group>. <article-title>Keratinocyte sensitization to tumour necrosis factor-induced nuclear factor kappa B activation by the E2 regulatory protein of human papillomaviruses</article-title>. <source/>J Gen Virol. (<year>2011</year>) <volume>92</volume>(<issue>Pt 10</issue>):<fpage>2422</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1099/vir.0.032466-0</pub-id><pub-id pub-id-type="pmid">21715600</pub-id></mixed-citation>
</ref>
<ref id="B334">
<label>334.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellanger</surname><given-names>S</given-names></name><name><surname>Tan</surname><given-names>CL</given-names></name><name><surname>Xue</surname><given-names>YZ</given-names></name><name><surname>Teissier</surname><given-names>S</given-names></name><name><surname>Thierry</surname><given-names>F</given-names></name></person-group>. <article-title>Tumor suppressor or oncogene? A critical role of the human papillomavirus (HPV) E2 protein in cervical cancer progression</article-title>. <source/>Am J Cancer Res. (<year>2011</year>) <volume>1</volume>:<fpage>373</fpage>–<lpage>89</lpage>.<pub-id pub-id-type="pmid">21968515</pub-id></mixed-citation>
</ref>
<ref id="B335">
<label>335.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLaughlin-Drubin</surname><given-names>ME</given-names></name><name><surname>Munger</surname><given-names>K</given-names></name></person-group>. <article-title>Viruses associated with human cancer</article-title>. <source/>Biochim Biophys Acta (<year>2008</year>) <volume>1782</volume>:<fpage>127</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2007.12.005</pub-id><pub-id pub-id-type="pmid">18201576</pub-id></mixed-citation>
</ref>
<ref id="B336">
<label>336.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morales-Sanchez</surname><given-names>A</given-names></name><name><surname>Fuentes-Panana</surname><given-names>EM</given-names></name></person-group>. <article-title>Human viruses and cancer</article-title>. <source/>Viruses (<year>2014</year>) <volume>6</volume>:<fpage>4047</fpage>–<lpage>79</lpage>. <pub-id pub-id-type="doi">10.3390/v6104047</pub-id><pub-id pub-id-type="pmid">25341666</pub-id></mixed-citation>
</ref>
<ref id="B337">
<label>337.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slotwinski</surname><given-names>R</given-names></name><name><surname>Slotwinska</surname><given-names>SM</given-names></name></person-group>. <article-title>Dysregulation of signaling pathways associated with innate antibacterial immunity in patients with pancreatic cancer</article-title>. <source/>Cent Eur J Immunol (<year>2016</year>) <volume>41</volume>:<fpage>404</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.5114/ceji.2016.65140</pub-id><pub-id pub-id-type="pmid">28450804</pub-id></mixed-citation>
</ref>
<ref id="B338">
<label>338.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Chun</surname><given-names>J</given-names></name><name><surname>Kang</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>G</given-names></name><etal></etal></person-group>. <article-title>TRAF4 promotes lung cancer aggressiveness by modulating tumor microenvironment in normal fibroblasts</article-title>. <source/>Sci Rep. (<year>2017</year>) <volume>7</volume>:<fpage>8923</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-09447-z</pub-id><pub-id pub-id-type="pmid">28827764</pub-id></mixed-citation>
</ref>
<ref id="B339">
<label>339.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theodoraki</surname><given-names>MN</given-names></name><name><surname>Yerneni</surname><given-names>S</given-names></name><name><surname>Sarkar</surname><given-names>SN</given-names></name><name><surname>Orr</surname><given-names>B</given-names></name><name><surname>Muthuswamy</surname><given-names>R</given-names></name><name><surname>Voyten</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Helicase-driven activation of NFκB-COX2 mediates the immunosuppressive component of dsRNA-driven inflammation in the human tumor microenvironment</article-title>. <source/>Cancer Res. (<year>2018</year>) <volume>78</volume>:<fpage>4292</fpage>–<lpage>302</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-3985</pub-id><pub-id pub-id-type="pmid">29853604</pub-id></mixed-citation>
</ref>
<ref id="B340">
<label>340.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snell</surname><given-names>LM</given-names></name><name><surname>Lin</surname><given-names>GH</given-names></name><name><surname>McPherson</surname><given-names>AJ</given-names></name><name><surname>Moraes</surname><given-names>TJ</given-names></name><name><surname>Watts</surname><given-names>TH</given-names></name></person-group>. <article-title>T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy</article-title>. <source/>Immunol Rev. (<year>2011</year>) <volume>244</volume>:<fpage>197</fpage>–<lpage>217</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-065X.2011.01063.x</pub-id><pub-id pub-id-type="pmid">22017440</pub-id></mixed-citation>
</ref>
<ref id="B341">
<label>341.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Xue</surname><given-names>G</given-names></name><name><surname>Bi</surname><given-names>E</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Th9 cells represent a unique subset of CD4(+) T cells endowed with the ability to eradicate advanced tumors</article-title>. <source/>Cancer Cell (<year>2018</year>) <volume>33</volume>:<fpage>1048</fpage>–<lpage>60.e7</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccell.2018.05.004</pub-id><pub-id pub-id-type="pmid">29894691</pub-id></mixed-citation>
</ref>
<ref id="B342">
<label>342.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Dang</surname><given-names>L</given-names></name><name><surname>Liang</surname><given-names>C</given-names></name><name><surname>Guo</surname><given-names>B</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Osteoclastic miR-214 targets TRAF3 to contribute to osteolytic bone metastasis of breast cancer</article-title>. <source/>Sci Rep. (<year>2017</year>) <volume>7</volume>:<fpage>40487</fpage>. <pub-id pub-id-type="doi">10.1038/srep40487</pub-id><pub-id pub-id-type="pmid">28071724</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>